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Preface 
I would lilce to take this oportunity to make several notes regarding the presentaion of 
my thesis. First, it is important to riote that my thesis is presented much in the same tlow 
as steroidogenesis. Since I worked on two distinctive projects, it was decided to present 
these works individually under the common theme of molecular ~odeling, headed by the 
StAR protein and followed by the P4S0cl 7. This was intended to represent the overall 
steroidogenesis pathway such that P4SOc7 bas no role in steroidogenesis if StAR cannot 
transfer cholesterol inside mitochondria. Yet, the most part of my studies was spent on 
the analysis of the P4SOc 17, which originated all this work. Second, a1l the articles are 
presented as exact copies of those sent for review in the specitied journals. This results in 
a slight discrepancy in terms of the overall format, but should not distress the reader to a 
great extent. And tinally, 1 participated in the composition of a review article after the 




Au fil des années, beaucoup de travail a été accompli pour comprendre les 
mécanismes gouvernant le métabolisme des stéroïdes. Malheureusement, plusieurs 
maladies stéroîdogéniques existent et sont directement reliées à la. dysfonction des 
enzymes responsables du métabolisme des stéroïdes. En particu!!er, l'hyperplasie lipoïde 
surrénalienne congénitale a été attribuée à la protéine <<.steroidogenic acute regulatory» 
(StAR) portant des mutations qui inhibent sa fonction primaire; StAR est responsable du 
transport du cholestérol dans les mitochondries permettant la première étape 
stéroîdogénique enzymatique, transformant le cholestérol en pregnénolone. Plusieurs 
mutations de la StAR ont été caractérisées dans le but de comprendre le mode d'action de 
cette protéine sur le transport du cholestérol dans la mitochondrie. Cependant, à date nous 
sommes toujours incapables d'en comprendre le mécanisme exact. Nous avons donc 
entrepris des démarches pour clarifier le mécanisme d'action de la StAR en utilisant des 
techniques à la fine pointe de la technologie, telle que la modélisation moléculaire. 
Nous avons développé un modèle StAR basé sur les données cristallographiques de la 
protéine MLN64 humaine. Nous démontrons par notre modèle que StAR possède une 
cavité hydrophobe et non un tunnel tel qu'observé pour la molécule MLN64. Cette cavité 
a une surface de 783.9 A2, assez large pour maintenir une molécule de cholestérol. De 
plus, nous avons identifié un pont salin unique dans cette cavité, responsable de la liaison 
du cholestérol via une molécule d'eau; ceci suggère que le cholestérol se lie à l'intérieur 
de la StAR. En considérant que des cavités à l'intérieur des protéines déstabilisent les 
structures des protéines natives, et que la cavité de StAR doit s'ouvrir pour être accessible 
au cholestérol, nous avons exploré la possibilité que StAR existe sous forme 
xvii 
probablement associée au vieillissement. Or, il est important d'élucider le mécanisme 
d'action du P4S0cl 7 pour comprendre son contrôle différentiel lors du vieillissement. 
Nous démontrons que trois mutants, T202N, D240N, et D407H, modulent l'activité du 
P4SOc 17 de manières différentes dépendant de leurs effets structuraux .. Ceci supporte le 
concept que le P4SOc 17 est contrôlé par des facteurs post traductionnels qui modifieraient 
aussi sa structure, tel que la phosphorylation. Notre modèle du P450cl 7 de hamster révèle 
une structure légèrement différente de celle du modèle du P450cl 7 humain, ce qui n'est 
pas surprenant puisqu'ils possèdent des d'activités différentes. Dans ce contexte notre 
modèle est utilisable pour l'étude du mécanisme d'action du P450cl 7. 
En couplant la modélisation moléculaire et la mutagénèse dirigée, nous avons donc 
créé des systèmes testables in silico nous permettant d'obtenir d'importantes informations 
et de suggérer de nouveaux mécanismes d'action. 
1 
1. Introduction: 
1.1. The Adrenal Gland: 
1.1.J. History and Histology: The initial description of the adrenal gland seems to 
have been in 1563 by Eustachius as the "glandulae renis inCW1!,bentes". Unfortunately, 
bis results were only published in 1714, as edited by Lancisius (Eustachius, 1774). The 
adrenal gland was then shown to be separated into two distinct zones due to dift'erential 
staining in 1856 by Vulpian (Vulpian, 1856}; these zones are the cortex and the medulla, 
basically representing two glands in one. Although both zones are important for normal 
physiological function, only the cortex is of interest for this presentation. Ten years after 
the discovery of the cortex and medulla, the cortex was then subdivided into three layers 
termed zonae glomerulosa, /asciculata and reticularis (Arnold, 1866) each of which 
secretes a particular steroid subfamily due to distinct expression of steroidogenic 
enzymes (see "The Steroidogenesis Pathway" below). 
Regrettably, associating function to the adrenal gland remained unclear for a long 
period of tiJne since the discovery of the adrenal gland. In 1849, Addison first published 
the results of abnormal adrenal glands in three deceased patients with anemia (Addison, 
1849), J>ut it wasn't until 1855 that he described chronic adrenal insufficientcy (Addison, 
1855), now referred to as Addison's disease. The year after, Brown-Séquard 
demonstrated that adrenal glands were essential for life as bilateral adrenalectomy on 
various animal species caused death (Brown-Séquard, 1856). Since, many disorders have 
been characterized descn"bing different adrenal function deficiencies. In particular, 
Cushing descn"bed a disease involving excessive and prolonged secretion of 
3 
lnfcrior pluenic vein 
l 
!nfcrior vcna cava Abdominal 11011a 
Fig. 1. Location of the adrenal glands. Of particular interest, both adrenal 
glands are properly supplied with blood (not distinctly shown in this diagram) 
and each adrenal gland is directly attached to a principal vein; the right 
adrenal vein empties into the inferior vena cava and the left adrenal gland into 
the renal vein. This "connectivity" is required for appropriate release of 












Fig. 2. Adrenal gland zones. a) The adrenal gland is composed of two 
distinct zones: the cortex and the medulla representing approximately 85% 
and 15% of the total adrenal gland weight respectively. Bach zone is 
responsible for the secretion of a particular hormone (Griffin and Ojeda, 
1992). Histological cuts of the hamster (b) and human ( c) adrenal glands also 
demonstrate the subdivision of the cortex in zones called zonae glomerulosa, 
fasciculata and reticularis (Dulbecco, 1991 ). 
4 
5 
1.2. Hormonal Steroids: 
1.2.J. History: Cbolesterol, the mother of ail steroids, was apparently first discovered 
in gallstones in 1763 (DeFourcroy, 1789). Tbereafter, ail compounds discovered with the 
basic cyclopentanoperbydropbenanthrene structure (Fig. 3) were tenned steroids (also 
known as hormonal steroids). Estrogen was structurally detined in 1932, followed by 
progesterone in 1934, testosterone in 1935, and aldosterone in 1953. Today, hundreds of 
steroids produced from various steroidogenic tissues bave been identified contributing to 
their field of study, termed endocrinology. 
1.2.2. Classification and Nomenclature: The adrenal steroids can be classified into two 
distinct groups according to their structures: androstanes and pregnanes. A 
cyclopentanoperbydrophenanthrene core with two additional methyl groups attached at 
positions 13 and 10 (carbons respectively numbered 18 and 19) are androstanes, wbile 
pregnanes are androstanes with an additional ethyl group at position 17 (respectively 
carbons 20 and 21). Although, adrenal steroids can also be classified according to thefr 
secretion patterns and biological functions: mineralocorticoids, glucocorticoids, and 
androgens. Basically, mineralocorticoids are steroids secreted from the zona glomerulosa 
wbose primary fonction is to regulate plasma ion bomeostasis and ultimately lead to 
plasma volume and tension regulation. Glucorticoids on the other band, are mainly 
secreted from the zona fasciculata and generally perceived as stress mediators broadly 
implicated in a variety of biological responses. Tbese include increased gluconeogenesis, 
relaxation of blood vessels in the vicinity of skeletal muscle, and decreased immunity 
response. In contrast, androgens are secreted from the zona reticularis and serve as 
precursors to sexual hormones. All these steroids are derived from cbolesterol and their 
6 
nomenclature follows either of two possibilities: nomenclature established by the 
International Union of Pure and Applied Chemistry (IUP AC) (International Union of 
Pure and Applied Chemistry, 1972 - also at http://www.chem.qmw.ac.uk/iupac/steroid/) 
or trivial names based on biological properties (some examples given in Table l); for 






Fig. 3. Cyclopentanoperhydrophenanthrene. Basic structural 
core for all steroids. Rings are labelled A-D while each carbon is 
numbered. 










Pregn-4-ene-l l Jl,2l-cliol-3,18,20-trione 
Androst-4-ene-3,17-dione 







1.3. The Adrenal Steroldogenic Pathway: 
The adrenal steroidogenic pathway consists of many steroidogenic enzymes 
responsible for the metabolism of cholesterol to various hormonal steroids. Figure 4 
depicts the classical steroidogenic pathway in the adrenal gland. One has to keep in mind 
that the adrenal steroidogenic pathway is different in species, dependent on the 
expression of the steroidogenic enzymes. Here, a general perception of the adrenal 
steroidogenic pathway is introduced and as such, makes no distinction of species-specific 
steroidogenesis. This will be discussed later. 
Cytochromes P4SO make up the· majority of adrenal steroidogenic enzymes. These 
enzymes contain a single heme prosthetic group (Fig. S), which the maximum absorbance 
is displaced from 420 nm to 450 nm when reduced and bound to carbon monoxide 
(Nebert and Gonzalez, 1987), effectively and efficiently differentiating them from other 
heme-bound proteins. These enzymes mostly consist of approximately 500 amino acids 
and with electrons provided by NADPH, can reduce atmospheric oxygen in the following 
manner: 
NADPH+H·+~+R-H P45o • R-OH+H20+NADp+ 
R=Steroid 
Most P4SO's are of hepatic origin responsible for the catabolism of a huge number of 
toxins, medication, and polluents (Nebert and Gonzalez, 1987). Since only a few hundred 
P4SO's are available for this catabolism, it is not surprising that the P450's have evolved 
to accommodate and be reactive to more than one substrate. This applies to ail adrenal 
P450's that recognize more than one substrate and have more than one catalytic activity. 
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In adrenal gland cells, two types of P450's exist: mitochondrial and microsomal. 
These are evidently characterized by their location, but also by their electron transport 
mechanisms. Mitochondrial P450's require adrenodoxin and adrenodoxin reductase in 
order to complete the reduction reaction (Fig. 6). In mitochondria, the electron transport 
system is located in the inner mitochondrial membrane, facing the matrix. Adrenodoxin 
reductase oxidizes NADPH and adrenodoxin serves as an electron shuttle, transporting 
one electron at a time from adronodoxin reductase to the target acceptor P450. 
Microsomal P450's on the other band, directly obtain their electrons sequentially from 
the NADPH reductase located on the cytosolic side of the endoplasmic reticulum 
membrane (Fig. 6). 
Before any steriodogenesis can occur, cholesterol first bas to be localized in the 
steroidogenic tissue. There are two sources of cholesterol: circulating plasma lipoproteins 
and de novo synthesis. Circulating lipoproteins provide the majority of the cholesterol 
(-80%) utilized for steroidogenesis (Boité et al., 1967; Borkowski et al., 1967; Gwynne 
and Strauss, III, 1982). Particularily, low-density lipoproteins are endocytosed through 
coated pits, degraded by lysozymes, and the esterified cholesterol is stored in lipid 
droplets until utilisation (Fig. 7). High-density lipoproteins also transfer cholesterol to 
steroidogenic tissue, although through a non-degradation pathway using the scavenger, 
class B, type 1 receptor (SR-81) (Williams et al., 2000). Endogenous sources of 
cholesterol require synthesis from acetate; the rate-limiting step of cholesterol synthesis is 
the conversion of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate 
though the HMG-CoA reductase (Gibson and Paker, 1987). Before utilisation, lipid 
droplet esterified cholesterol has to be desterified though the activity of cholesterol 
10 
esterase, and transported to the mitochondria outer membrane via various possible 
candidates (Sviridov, 1999). Once at the mitochondrial outer mitochondria membrane, 
the hydrophobie cholesterol necessitates a transport mechanism to cross the 
mitochondrial hydrophilic intermembrane space; thi~ transport mechanism has been 
identified as the steroidogenic acute regulatory protein (StAR). 
Cholesterol l P450scc fi P450c17 #P450c17 fi 
Pregnenolone 17-Hydroxypregnenolone Dehydroepiandrosterone l 3p-HSD l 3P-HSD l 3P-~SD 
~P450c17 ÙP450c17 ~ 
Progesterone 
~~1 




11-Deoxycorticosterone 11-Deoxycortisol Cortisol l P450aldc 
);kP45~1do #P~aldo # 
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Fig. 5. Herne prosthetic group for the 
P450 enzymes. The heme prosthetic 
group for the family of P450 enzymes is 
of type b, characterized by a propionate 
and methyl group on the A and D rings, 
and a methyl and ethene group on the B 
and C rings. 
Adr. reductase Adrenodoxin P450 
lnner mitochondrial membrane 
P450-Reductase P450 
Endoplasmic reticulum membrane 
Fig. 6. Models for the electron transport system of mitochondrial 
and microsomal P450's. Adr. Reductase, adenodroxin reductase; St, 
Steroid (Hanukoglu, 1992). 
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Fig. 7. Cholesterol supply to endocrine cells by low-density lipoproteins 
(LDL). LDL from the blood flow is endocytosed through clatherin-coated 
pits, degraded by lysosomes, and the cholesterol is stored in lipid droplets 
until utilisation (V oet and Voet, 1990), 
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1.3.1. Steroidogenic Acute Regulatory Protein (StAR): It bas long been believed that 
the rate-limiting step in steroidogenesis was the conversion of cbolesterol to 
pregnenolone by the protein P450 side-cbain cleavage (P450scc) in view of the fact that it 
is the first enzyme-dependent step in steroidogenesis (Farkasb et al., 1986). Relatively 
recently, it bas been demonstrated that the true rate-limiting step in steroidogenesis is the 
protein-dependent transfer of cbolesterol to the matrix side of the inner mitochondrial 
membrane where P450scc is located (Epstein and Orme-Johnson, 199lb; Privalle et al., 
1983). Basically, cyclobeximide-inhibition of de novo protein synthesis inhibited both 
steroidogenesis and the transfer of cholesterol inside mitochondria, although the identity 
of the protein responsible for such a task remained a mystery for many years. The 
discovery of StAR by Clark, B.J. and collaborators (Clark et al., 1994) in the MA-10 
mouse Leydig tumor cell line, identitied the best candidate for the protein responsible for 
the adrenocorticotropin hormone (ACTH - see below) stimulated steroidogenesis 
described by Orme-Johnson and colleagues (Alberta et al., 1989; Epstein and Orme-
Johnson, 199la; Epstein and Orme-Johnson, 199lb; Hartigan et al., 1995;Pon et al., 
1986; Pon and Orme-Johnson, 1988). Many experimental results support StAR's 
implication in the protein-dependent transfer of cholesterol inside mitocbondria, but the 
most bolstering result is the StAR knock-out mouse (Caron et al., 1997) displaying lipoid 
congenital hyperplasia (LCAH - see below). Mutational analyses of StAR also 
demonstrated that a dysfunctional StAR was responsible for the defective steroidogenesis 
in patients with LCAH (Bose et al., 1996; Bose et al., 1997; Fujieda et al., 1997; Lin et 
al., 1995; Nakae et al., 1997; Tee et al., 1995). Yet, the exact mecbanism of StAR in the 
transfer of cbolesterol inside mitochondria is controversial. 
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Tbree mechanisms for StAR action have been proposed: 1) desorption (Stocco and 
Clark, 1996), 2) molten glubule acting on the outer mitochondrial membrane (Bose et al., 
1999), and 3) intermembrane shuttle (Tsujishita and Hurley, 2000). Several key 
observations are in support of these contradicting mechanisms. First, StAR has a 
mitochondrial leader peptide targeting it to mitochondria and mediating its entry. The 
desorption model (Stocco and Clark, 1996) suggests that as StAR enters mitochondria via 
its targeting leader peptide, contact sites are created between the outer and inner 
mitochondria membranes, effectively ablating the intermembrane space, and thus 
allowing large amounts of cholesterol to flow from the outer to inner mitochondrial 
membrane. The greatest downfall of·this mechanism is the fact that it bas been shown 
that StAR lacking the first 46 amino acids (lacking the mitochondrial targeting peptide) 
can still transfer cholesterol inside mitochondria (Arakane et al., 1996; Arakane et al., 
1998). Second, loss of StAR tertiary structure without loss of secondary structure was 
observed at low pH (3.5-4.0), suggesting that a molten globular fonn is important for 
StAR fonction (Bose et al., 1999). Talcen together with the observation that the N-
terminally cleaved StAR can still function, these authors suggest that StAR functions as a 
molten globule remaining in contact with the cytosol side of the outer mitochondria 
membrane. Although it has been shown that an active electrochemical force is necessary 
for the transfer of cholesterol inside mitochondria (King et al., 1999), an acidic 
environment immediately adjacent to the outer mitochondrial membrane in vivo is 
speculative and bas not been demonstrated to exist. Finally, the crystal structure 
determination of the human MLN64, a protein believed to replace StAR in tissues lacking 
StAR such as the placenta, showed the presence of a hydrophobie tunnel large enough to 
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accommodate one cholesterol molecule resembling other sterol carrier proteins 
(Tsujishita and Hurley, 2000). In addition, the tunnel openings are not large enough to 
allow passage of the cholesterol molecule, suggesting that StAR shuttles one cholesterol 
molecule at a time between the mitochondrial membranes. Unfortunately, this model 
cannot support the observed rapid cholesterol transfer mechanism inside mitochondria 
(Artemenko et al., 2001) or the fact that StAR still functions without its mitochondrial 
leader peptide. It is clear that not one mechanism can account for the true functionality of 
StAR and thus the idea of an amalgamated mechanism is growing (Stocco, 2000). 
Regrettably, crytallization of StAR bas been unsuccessful, and the closest approximation 
of the actual StAR structure and mechanism is the crystallized MLN64. Moreover, StAR 
bas been shown to exist as a phosphoprotein and the implication of this phosphorylation 
in its mechanism remains unclear. 
Indeed, StAR phosphorylation was reported well in advance of the identification of 
StAR as the main constituent responsible for the protein-mediated mitochondrial 
cholesterol transfer (Alberta et al., 1989; Epstein and Orme-Johnson, 199la; Epstein and 
Orme-Johnson, 199lb; Pon et al., 1986; Pon and Orme-Johnson, 1986; Pon and Orme-
Johnson, 1988), and mutational analyses of StAR's serine 195 reduced its 32P 
incorporation and activity by 50% ex vivo (Arakane et al., 1997). Although StAR bas 
been shown to have several forms in two-dimensional SDS-PAGE (Arakane et al., 1997; 
Epstein and Orme-Johnson, 199la; LeHoux et al., 1999; Pon et al., 1986; Pon and Orme-
Johnson, 1988), no systematic phosphorylation/function analyses have been undertaken 
to explain such observations, and no almagamated mechanism bas been methodically 
verified. 
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1.3.2.Cytochrome P45017a-Hydroxylase/17,20-Lyase (P450cl7): Once pregnenolone 
has been formed in mitochondria, it can then be converted into any other steroid tbrough 
metabolism by many different enzymes. In fact, pregenenolone is located at the apex of a 
major divergence in the steroidogenic pathway (Fig. 4). P450c17 is a bifunctional 
endoplasmic reticulum membrane-bound enzyme, displaying two activites in a single . 
active site (Nakajin et al., 1981; Zuber et al., 1986). The first activity is 17a-
hydroxylation, adding a hydroxyl group at carbon 17 of the 
cyclopentanoperhydrophenantbrene core. The second activity, 17,20-lyase, uses the l 7a-
hydroxylated products previously formed and cleaves the carbon 17 to carbon 20 bond 
leading to the formation of androstanes. Not only is the P450c 17 complex enough with 
the utilisation of a single active site for two distinct activites, but two sets of substrates 
can also bind and be reactive in the P450c 17. Therefore, four different substrates can bind 
and be reactive in the P450cl 7: pregnenolone, progesterone, l 7a-hydroxypregnenolone 
and 17a-hydroxyprogesterone (Fig. 4). 
In adrenal glands, P450cl 7 is usually expressed in the zonae fasciculata and 
reticularis, and never in the zona glomerulosa ensuing in the observed patterns of steroid 
secretion (Fig. 2 vs Fig. 4). Moreover, P450c17 expression and reactivity are species-
specific (see the section entitled "The Hamster as a Model'') and may not even be 
expressed in the adrenal glands. Without the expression of P450cl 7, pregnenolone is 
eventually converted into corticosterone and mineralocorticoids. In the case where 
P450cl 7 is expressed, separation of both activites leads to the production of either 
glucocorticoids or androgens. Due to the complexity of the P450cl7 system with species-
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specific steroid production, much work is being undertaken to understand the differential 
functional control of the P450cl 7 in steroidogenesis. 
In order to have a fully functional P450cl 7, four elements must be present: proper 
P450cl 7 binding to the endoplasmic reticulum membrane, heme binding, substrate 
binding, and electron transfer from NADPH to P450cl7. If any one or more of these 
processes are dysfunctional, impaired P450cl 7 may result in various clinical symptoms 
including hypertension, ambiguous genital formation in males, and lack of progression 
into puberty for females (Auchus, 2001). 
Although pregnenolone is produced in mitochondria and the P450c 17 is bound to the 
endoplasmic reticulum, pregnenolone can still attain the P450cl 7. As a matter of fact, 
cleavage of cholesterol's hydrophobie side chain by P450scc confers and additional polar 
group to pregnenolone allowing it to be readily soluable in hydrophilic solvent; the 
cyclopentanoperhydrophenanthrene ring still maintains the hydrophobie character of 
steroids allowing the steroids to diffuse across membranes. 
1.3.3. Other Steroidogenic Enzymes: Obviously, many enzymes are necessary for the 
production of all the adrenal steroids (Fig. 4) and are not of particular interest for this 
thesis. Thus, only a brief description of their activites is presented here. These enzymes 
can be divided into two groups: mitochondrial and microsomal. Along with P450cl 7, the 
3(3-hydroxysteroid dehydrogenase (3(3-HSD) and the cytochrome P450 21-hydroxylase 
(P450c21) are located in the endoplasmic reticulum. 3(3-HSD is nota P450 enzyme and is 
expressed in all three zones of the adrenal cortex (Dupont et al., 1990); various isoforms 
of 3(3-HSD have been identified in a panoply of tissues for a variety of species, including 
the hamster (Rogerson et al., 1998). In the adrenal, 3P-HSD is responsible for the 
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conversion of 3(3-hydroxy-5-ene steroids into 3-keto-4-ene steroids. Therefore, 
pregnenolone, l 7a-hydroxypregnenolone and DHEA are ail substrates for 3JJ-HSD and 
are converted into progesterone, l 7a-hydroxyprogesterone, and androstenedione 
respectively (Fig. 4). 
The microsomal P450c21 is responsible for the hydroxylation.at carbon 21 of the alkyl 
group of pregnanes, essential for the synthesis of mineralocortiocoids and 
glucocorticoids. This enzyme is expressed in ail three zones of the adrenal cortex 
(Ishimura and Fujita, 1997) and mediates the conversion of progesterone to 11-
deoxycorticosterone and the conversion of 17a-hydroxyprogesterone to 11-deoxycortisol 
(Fig. 4). Being microsomal, the P450c21 uses the same electron transport system as the 
P450cl 7 (Fig. 6). 
The remaining steroidogenic enzymes presented here are the mitochondrial 
cytochromes P4SO 11(3-hydroxylase (P450cl 1) and P4SO aldosterone synthase 
(P450aldo ). Both these enzymes are located on the matrix side of the inner mitochondrial 
membranes and use the same electron transport mechanism as P450scc. Due to their high 
homology (>90% in humans), it was believed for a considerable time that these enzymes 
were in fact only one protein and caused much debate on "its" düîerential activity 
regulation in the zona glomeru/osa versus the zonae fascicu/ata and reticu/aris. As shown 
in Fig. 4, both the P450cl 1 and the P450aldo display 11(3-hydroxylation, but the 
P450aldo bas additional 18-hydroxylation and 18-oxidation activities to synthesize 
aldosterone. What then, was the determining factor allowing 18-hydroxylation and 18-
oxidation for the corticosterone pathway while inhibiting these activities in the cortisol 
pathway? It was discovered over time that in actuality, two enzymes were present; the 
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P450cl l was expressed in the zonae fascicu/ata and reticu/aris while the P450aldo was 
only expressed in the zona glomerulosa explaining the differential activity profiles. 
1.4. Deftclencies in Steroidogenic Enzymes: 
1.4.1. Congenital Adrenal Hyperplasia (CAH): The term "congenital adrenal 
, 
hyperplasia" refers to genetic defects hindering cortisol biosynthesis (Ortb and Kovacs, 
1998). Therefore, any steroidogenic enzyme involved in the production of cortisol from 
cholesterol can be implicated in this syndrome, including the P450scc, 3J3-HSD, 
P450cl 7, and P450c2 l (Fig. 4.). According to the dysfunctional enzyme present, since no 
cortisol is produced, there loss of negative feedback inhibition of ACTH production (see 
Regulation of Steroidogenic Enzyme Expression below) and accumulation of precursor 
steroids directing various symptoms (Orth and Kovacs, 1998). For example, loss of 
P450cl 7 activity causes accumulation of aldosterone and intermediate steroids clinically 
presenting hypertension, hypokalemia, and hypogonadonism (Fig. 8). 
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Fig. 8. Congenital Adrenal Hyperplasia manifested by loss of P450cl 7 activity. 
Same representation as in Fig_ 4 showing the classic steroidogenic pathway in adrenal 
glands, although with a dysfunctional P450cl 7. Accumulated steroids are represented by 
larger arrows and bold names. Inhibited P450cl 7 activity is represented by small grey 
arrows, and grey steroid structures and names. 
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1.4.2. Lipoid Congenital Adrenal Hyperplasia (LCAH): Lipoid CAH is a fatal fonn of 
CAH, characterized by a severe adrenal insufficiency and cholesterol accumulation in 
adrenal glands and gonads; LCAH is manifested by failure to thrive, vomiting, diarrhea, 
hyponatrimia, and hypokalemia during the prenatal period (Orth and Kovacs, 1998). It 
was believed that LCAH was due to a dysfunctional P450scc as it is the steroidogenic 
enzyme responsible for the initial conversion of cholesterol to pregnenolone (Fig. 4), 
although since the discovery of StAR, ail LCAH cases have been attnbuted to a 
dysfunctional mutant StAR (Miller, 1997) and is best described by a two-hit model. This 
model bypothesizes initial loss of steroidogenesis due to the dysfunctional StAR, 
followed by complete loss of steroidogenesis due to loss of cellular fonction by the 
accumulation of cholesterol in lipid droplets (Fig. 9). 
Fig. 9. Lipoid Congenital Adrenal Hyperplasia. A) Normal conditions. B) 
Initial loss of steroidogenesis by a dysfunctional StAR. C) Complete loss of 
cellular function and steroidogeneis due to accumulation of cholesterol esters 
in lipid drop lets (Bose et al., 1996). 
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1.5. Regulation of Adrenal Steroidogenic Enzyme Expression: 
1.5.1. Adrenocorticotropin Hormone (ACTH): It bas been known for a considerable 
time that there exists a tight association of the hypothalamus, pituitary, and adrenal 
glands (Fig. 1 O); this is called the hypothalamus-pituitary-adrenal axis (HP A). In the 
1930's, the existence of a functional pituitary-adrenal axis was documented (Smith, 
1930), followed by the demonstration of a negative feedback regulation of the 
adrenocorticotropic effect of the pituitary gland by adrenal extracts (lngle and Kendall, 
1937). In the decade following 1956, the adrenocorticotropin hormone was identified and 
its structure determined (Graf et al., 1971). The major factor responsible for the secretion 
of pituitary ACTH is the corticotropin releasing hormone (CRH) from the hypothalamus; 
it was characterized in 1981 (Yale et al., 1981). Also of importance, the hypothalamus 
arginine vassopressin (A VP) can stimulate pituitary ACTH secretion, although it mostly 
potentiates the action of CRH in vivo and in vitro (DeBold et al., 1984). Basically, 
neurological responses such as the circadian rhythm and stress, stimulate CRH and A VP 
secretion from the hypothalamus. CRH and A VP then stimulate the secretion of the 
ACTH from the pituitary, which stimulates cortisol secretion from the adrenal glands. 
Cortisol then negatively regulates both the hypopthalamus and pituitary hormone 
secretions (Fig. 10). 
ACTH is produced by the peptidic cleavage of pro-opiomelanocortin (POMC). Upon 
stimulation, POMC is expressed in the pituitary gland where it is processed into various 
peptidic species (Fig. 11) according to the location of the POMC; the anterior lobe 
processing is responsible for the release of ACTH from POMC. ACTH is a 39 amino acid 
peptide that binds to the melanocortin-2 receptor on the surface of adrenal cells 
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(Mountjoy et al., 1992). This binding leads to the formation of cAMP by adenylyl 
cyclase, ultimately leading to the activation of cAMP-dependent protein kinase (PKA) 
phosphorylating various proteins for a variety of functions (Gill, 1976). ACTH response 
can be divided into two categories, acute and chronic (Simpson and Waterman, 1983; 
Simpson and Waterman, 1988). The acute response is characterized by the rapid 
conversion of cholesterol into pregnenolone (the first step in steroidogenesis - Fig. 4), 
mediated through the rapid transport of cholesterol to the inner mitochondrial membrane 
where the P450scc resides (Lin et al., 1995). The chronic effect on the other band, 
involves increased synthesis of most of the steroidogenic enzymes including the P450c 17 
(Simpson and Waterman, 1983; Simpson and Waterman, 1988). ACTH also increases 
circulating aldosterone levels, however this is of minor effect (Conaglen et al., 1984; 
Williams and Dluhy, 1983); aldosterone synthesis is mostly regulated by the renin-
angiotensin system (RAS). 
Glucocorticoids, such as cortisol, inln"bit both the ACTH secretion as well as POMC 
expression (Lundblad and Roberts, 1988). Also, glucocorticoids decrease CRH and A VP 
levels, although to a lesser extent (Davis et al., 1986; Itoi et al., 1987). Moreover, as 
though it wasn't enough, glucocorticoids block the stimulatory effect of CRH on the 
expression of POMC (Eberwine et al., 1987) and the secretion of ACTH (Oki et al., 
1991 ), as well as inhibit CRH receptor expression in the anterior pituitary (Holmes et al., 
1987; Luo et al., 1995). In the rat, the negative glucocorticoid feedback mechanism 
consists of two distinct steps (Keller-Wood and Dallman, 1984): a fast feedback in the 
order of seconds to minutes proportional to the rate of glucocorticoid concentration 
increase, and a latent feedback in the order of hours to days relative to the absolute 
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concentration of glucocorticoids in plasma. The secretion of ACTH. is balted tirst, 
followed by the reduction in ACTH synthesis due to reduced CRH dependent POMC 
expression (Eberwine et al., 1987). 
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Fig. 10. The Hypothalamus-Pituitary-
Adrenal Axis. N eurological eff ectors 
stimulate the secretion of corticotropin 
releasing hormone (CRH) and arginine 
vassopressm (VP) from the 
hypothalamus, which in turn stimulate 
pituitary adenocorticotropin hormone 
(ACTH) secretion. ACTH then 
stimulates cortisol production in the 
adrenal glands, which negatively 
regulates both the hypothalamus and the 
pituitary glands (Arnold, 1998). 
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Fig. 11. Structure of the Pro-opimelanocortin (POMC) gene and protein. 
Once stimulated, the POMC gene expresses the POMC protein which is then 
proteotically cleaved according toits location in the pituitary. In this example, 
POMC is cleaved into the NH2-terminal peptide, joining peptide (J Peptide), 
adenocorticotropin hormone and P-lipotropin in the pituitary anterior lobe 
(Orth and Kovacs, 1998). 
29 
1.5.2. Renin-Angiotensin System (RAS): The RAS is composed of many factors 
resulting in the production of angiotensin Il {Ali), the most abundant biologically active 
angiotensin species in plasma, responsible for maintaining plasma volume and tension 
(Fig. 12). Renin is an enzyme synthesized in the kidneys, responsible for the conversion 
of angiotensinogen to angiotensin I (AI) (Gibbons et al., 1984). AI is then rapidly 
converted to AII by the angiotensin converting enzyme (ACE) in the lung and other 
tissues including the adrenal gland. Ali can then be cleaved to angiotensin m (Am) by 
the peptidic cleavage of the N-terminal aspartate; both Ali and AIII stimulate the 
production of aldosterone similarly in the adrenal gland, although Ali is more potent as a 
vasopressor (Blair-West et al., 1980;Gibbons et al., 1984). 
Renin is the limiting factor in this system; renin secretion is regulated by blood 
pressure, sodium concentration in the renal tubular fluid, and by renal sympathetic nerve 
activity (Gibbons et al., 1984). Renin levels are increased by factors that decrease renal 
blood flow. For example, hemorrhaging, dehydration, and sait restriction decrease renin 
secretion. On the flip side, factors that increase the blood pressure, such as high sait 
intake, decrease renine secretion. Moreover, Ali inhibits the secretion of renin by a short-
feedback loop (Williams and Dluhy, 1983). 
Ali mediates its effects on the adrenal gland through specific cell-surface receptors 
coupled to guanosine triphosphate-binding proteins (G-proteins). Although much work 
bas been accomplished in this area, only a brief description will be given here. Two major 
types of the Ali receptors have been identified in various tissues of species, mediating a 
variety ofresponses; these receptors are appropriately termed type 1and2 (ATl and AT2 
respectively). Binding of Ali on its receptor in the adrenal gland triggers the activation of 
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phospholypase C responsible for the hydrolysis of phosphatidylinositol-4,S-bisphosphate 
(PIP2) to inositol 1,4,5-triphosphate (IP3) and 1,2-diacylglycerol (DAO). DAO and IP3 
are both implicated in the mediation of signal through the protein kinase C (PKC) 
pathway leading to various cellular responses. In the case of the adrenal cortex, this 
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Fig. 12. The Renin-Angiotensin 
System. Renin from the liver converts 
the angiotensinogen (renin substrate) in 
angiotensin 1 (Al). In lungs, AI is 
converted to angiotensin II (Ali) by 
angiotensin converting enzyme (ACE). 
Ali can then regulate plasma volume and 
pressure by stimulating vasoconstriction 
and the production of aldosterone in the 
adrenal glands, responsible for the 
minerai homeostasis of plasma. Ali can 
be converted to angiotensin III (AIII) by 
aminopeptidase (AP) (Orth and Kovacs, 
1998). 
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1.6. The Hamster as a Model: 
1.6./. Steroidogenesis: ln order to understand human endocrinology, a variety of 
animais have been utilized as models. Yet, not ail biological systems are appropriate to 
relate biological responses to hnmans. Small laboratory animais, including the rat, mouse 
and guinea pig, have been used in relation to human endocrinology. Unfortunately, these 
models are not always desireable due to their steroidogenic enzyme expression and/or 
activity profiles (particularly for P450cl 7). We have chosen the hamster as a model to 
study human endocrinology for a variety of reasons. The two most convincing reasons 
are: 1) the hamster expresses adrenal P450cl 7 that resembles more like the human 
P450cl7 activity profile than the other laboratory animais (Brière et al., 1997; Cloutier et 
al., 1995; Cloutier et al., 1997; LeHoux et al., 1992), and 2) the hamster uses cortisol as 
its major glucocorticoid like hnmans (LeHoux et al., 1992; LeHoux and Lefebvre, 1980). 
1.6.2. StAR: Since the discovery of the mouse StAR in MA-10 Leydig tumor cell line, 
StAR has been cloned Crom human, horse, pig, sheep, cow, rat, mouse, chicken, frog, and 
raibow and brook trout. We have cloned the cDNA of the hamster StAR and bave shown 
that the transcribed protein has 284 amino acids (Fleury et al., 1998), one less than that of 
human StAR; the human and hamster StAR are 86% homologous. We have also shown 
that administrattion of ACTH to hamsters provoked and increase in adrenal StAR content 
within one hour in vivo (Fleury et al., 1998). 
1.6.3. P450cl 7: ln hnmans, the adrenal P450cl 7 l 7a.-hydroxylates both pregnenolone 
and progesterone, but DHEA is the preferred final product over androstenedione (AD) 
(Chung et al., 1987; Lin et al., 1993). The rat and mouse do not express P450cl 7 in the 
adrenal glands (Fevold et al., 1989; Namiki et al., 1988; van Weerden et al., 1992; 
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Youngblood and Payne, 1992), and the gonadal P450cl7 preferentially produces AD. 
The guinea pig on the other band, does express adrenal P450cl 7 and although it l 7a-
hydroxylates both pregnenolone and progesterone, AD is the preferred final product 
(Provencher et al., 1992; Tremblay et al., 1994). We have previously isolated the hamster 
adrenal P450cl 7 cDNA and have compared the activity profile of the hamster P450cl 7 . 
enzyme to tbat of the human P450cl 7. 
We have demonstrated that the hamster adrenal l 7a-hydroxylates both pregnenolone 
and progesteone, and produces both DHEA and AD in adrenal cell suspensions, 
microsomal preparations, and transiently transfected COS-1 cells with the hamster 
adrenal P450cl 7 cDNA (Cloutier et al., 1995; Cloutier et al., 1997). Furthermore, we 
have immunolocalized the hamster P450c 17 in the zonae fasciculata and reticularis of 
hamster adrenals (Brière et al., 1997), and we have shown that the hamster adrenal 
P450cl 7 mRNA is positively regulated by ACTH (LeHoux et al., 1992). 
1. 7. SpecUlc Objectives: 
1.7.1. Understanding StAR: Unfortunately, adrenal dysfuction is a reality. Since the 
first discovery of adrenal insufticiency by Addison in 1855, much effort bas been put in 
research to understand the structural/functional relationship of the adrenal gland and a11 
its machinery. Dysfonction of practically any adrenal steroidogenic enzyme results in 
CAH, presenting various symptoms outside of the adrenal gland morphology, even death. 
LCAH, the most severe type of CAH7 is a direct consequence of a genetically 
dysfunctional StAR abolishing a11 steroidogenesis with accumulation of cholesterol in 
lipid droplets in adrenocortical cells, prohibiting normal cellular function. Since the 
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discovery of StAR in 1994, several mechanisms for its action in cholesterol transfer 
inside mitochondria have been suggested but none can explain ail experimental evidence 
reported to date and cause much debate. We therefore hypothesized that the actual 
mechanism of the StAR-dependent cholesterol transfer inside mitochondria was a unified 
portrayal of these views. With advances in technology, new experimental methods . 
enlighten the deepest recesses of the misunderstood. Hence, we explored the possibility 
that molecular modeling could shed light on the true StAR mechanism of action. Our 
specific objectives were: 
i. To obtain a realistic molecular model of StAR based on 
the recently crystallized human MLN64 protein having 
similar properties to the human StAR; 
ii. To utilize the StAR molecular model to explain rational 
site-directed mutagenesis, particularly those targeting 
potential phosphorylation sites; and, 
iii. To clarify contradicting experimental results, proposing 
a new mechanism for the StAR-dependent transfer of 
cholesterol inside mitochondria. 
Here, we show that the rational use of homology modeling, coupled to rational 
mutagenesis can resolve contradicting experimental evidence and we propose a novel 
mechanism for StAR action. 
1.7.2. Understanding P450cl7: Molecular modeling is not restrained to sheding light 
on dysfunctional systems. During the lifespan of man, many developmental stages such 
as adrenarche, puberty, and aging are surpassed. Throughout these developmental stages, 
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secretion patterns of the adrenal steroids change due to their differential regulation, 
particularly for the production of DHEA. DHEA is the most abundant steroid in man 
(Chung et al., 1987; Lin et al., 1993). It is converted to a sulfated fonn, DHEA sulphate 
(DHEAS), in the zona reticularis of the human adrenal cortex by a sulphotransferase 
fittingly termed DHEA sulphotransferase (Kennerson et al., 1983). Adding this sulphate 
group to the 3J3-hydroxyl group of DHEA stabilizes DHEA for transport in the blood 
tlow. In peripheral tissues, DHEAS is hydrolyzed locally by a sulfatase in order to 
liberate the active form DHEA (Fig. 13) (Wolf and Kirschbaum, 1999). In man, 99% of 
the circulating DHEA is in the stable DHEAS form (Zumoff et al., 1980), leaving l % for 
bioactivity. This miniscule portion bas been shown to be metabolically active in aging 
(Morales et al., 1994), breast cancer (Bulbrook et al., 1971), hypertension in rats 








Fig. 13. Conversion of DHEA to DHEAS. In adrenal glands, 
DHEA is sulphated by a sulfotransferase at the functional hydroxyl 
group on carbon 3, stabilizing DHEA for transport in the blood flow. 
In periferal tissues, DHEAS in then converted back to the active 
fonn DHEA by a sulfatase. 
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Interestingly, the secretion pattern ofDHEAS with age and gender changes drastically 
(Fig. 14). Indeed, plasma DHEAS levels are low at birth and begin to rise prior sexual 
matuation and continue to rise well into the early twenties, only to decrease therafter 
approximately 10% for every decade (Migeon et al., 1957; Orentreich et al., 1984; 
Regelson et al., 1994; Regelson and Kalimi, 1994); the increase of DHEAS is termed 
adrenarche. Moreover, cortisol production in man remains unchanged with aging. The 
fluctuation in DHEA(S) can be attributable to any steroidogenic enzyme directly or 
indirectly implicated in the production of DHEA. Predominantly, it is conceivable that a 
decrease in 3J3-HSD and/or P450c21 could lead to augmentation of DHEA production 
due to increased precursor availability for the P450c 17; CAH due to dysfuctional 
P450c21 causes accumulation of DHEA (White et al., 1987). It was discovered that 3P-
HSD expression does decrease in the zona reticularis only, simultaneous to observed 
adrenarche (Gell et al., 1998). On the other band, tbis research showed tbat the adultzona 
reticularis also bas a decreased 3J3-HSD expression, which cannot explain the observed 
loss ofDHEA production with aging (starting around 25 years old-Fig. 14). This same 
investigation revealed that P450c2 l expression does not change significantly with age 
under normal circumstances. This is reasonable since the production of cortisol does not 
change with time in man. Finally, the human P450cl7 bas been shown to be 
phosphorylated on serine and threonine (Zhang et al., 1995) and that this phosphorylation 
can regulate the l 7cx-hydroxylase/l 7,20-lyase activity ratio (Biason-Lauber et al., 2000a; 
Miller, 1999). 
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It seems therefore, that the adrenal P450cl 7 is differentially regulated with time in the 
zona reticularis; this is the adrenocortical zone responsible for the secretion of DHEA(S) 
in man. Since the hamster is an attractive model to study DHEA production with respect 
to man, yet still presenting a different activity profile, we hypothesized that elements 
conferring basal activity distinction between the human and hamster P450cl 7 was 
directly linked to the amino acid sequences of these forms. Again, our objectives 
consisted of using molecular modeling to study the structure/function relationship of the 
hamster P450cl 7 and explain the activity profiles of the hamster and human P450cl 7s. 
Specifically, our objectives were: 
t. To identify potentially regulating amino acids in the hamster 
P450cl 7 protein conferring its specific activity profile using 
rational site-directed mutagenesis; 
11. To obtain a rational model of the hamster P450cl 7 based on 
the coordinates of the human P450cl 7 structure; 
iü. To utilize the hamster P450cl 7 model to account for the site-
directed mutagenesis results; 
iv. To clarify the substrate selectivity of the hamster P450cl7 
versus the human P450cl 7; and, 
v. To propose a mechanism for substrate selectivity and uptake 
conferring the observed activity profile of the hamster 
P450cl7. 
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Briefly, we show that the validated hamster P450c 17 model can account for the 
rational site-directed mutagenesis results altering the hamster P450c 1 7 activity profile, 
and that substrate selection appears to be important early in substrate uptake inside the 
hamster P450cl7. The P450cl7 structures have three key features: 1) amino acids 
responsible to maintain core elements and structural integrity of the protein; 2) amino 
acids responsible for the heme binding, redox partner ineteractions, and catalysis; and 3) 
amino acids responsible for substrate selectivity and uptake. Moreover, any amino acid 
can participate in one or more of these fonctions, regulating P450cl 7 activity. Finally, 
substrate selectivity and intake requires three distinct steps: 1) recognition of the substrate 
at the accessible surface of the putative substrate entrance; 2) entrance of the substrate 
into the active site directed by key hydrogen bonding to particular amino acids in the 
active site; and 3) rotation of the substrate inside the active site to position the substrates 
optimally for catalysis. 
We have thus developed testable models of two key enzymes in the hamster 
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ABSTRACT 
The steroidogenic acute regulatory protein (StAR) is the major entrance for 
cholesterol in mitochondria under acute stimulation. Under such circumstances, 
dysfunctional StAR activity can ultimately lead to llpoid congenital adrenal 
hyperplasia (LCAH). A complete understanding of the StAR's molecular structure 
and mechanism is essential to comprehend LCAH. Thus far, there is no mechanistic 
model that can explain experimental results at the molecular level. This is partly due 
to the Jack of the molecular structure of StAR. The closest approximation to the 
StAR molecular structure is the human MLN64 which has a simllar activity to 
StAR, bas a highly homologous primary structure and for which an X-Ray 
structure is lmown. In this context, we have modeled the structure of StAR through 
standard homology modeling procedures based on the MLN64 structure. Our StAR 
model shows the presence of a hydrophobie cavity of 783.9 A1 in surface, large 
enough to fit one molecule of cholesteroL ln addition, we have identifted a unique 
charged pair as in MLN64, llning the surface of the cavity and which could play a 
key role in the binding of cholesterol through the formation of an H-Bond with the 
its OH moiety. This suggests that the cholesterol-binding site of StAR is located 
inside this cavity. Taking into account that internai cavities are destabillzing to 
native protein structures and that the lining of the cavity bas to become accessible in 
order to allow cholesterol binding, we have explored the possibillty that S~ could 
exist in eqUrubrium with partially unfolded states. Using a structure-based 
thermodynamics approacb, we show that partially folded states (with an unfolded 
C-terminal a-belix, and an open cavity) can be significantly populated at 
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equllibrium and therefore allow cholesterol binding. These results are supported by 
recent experiments that show a loss of StAR helical character upon binding of an 
analogue of cbolesterol. Moreover, we show that the replacement of the resldues 
involved in the cbarged-pair located in the binding site, results in the loss of StAR 
actlvlty supportlng a key role for these resldues. Taken together, our results are 
applicable to both a StAR functlonlng in the mitochondrial intermembrane space as 
well as outside mitocbondria. 
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Until recently, it was believed that the rate-limiting step in steroid hormone synthesis 
was the conversion of cholesterol into pregnenolone by the cytochrome P450 side-chain 
cleavage (P450scc) enzyme in the inner membrane ofmitochondria (Farkash et al. 1986). 
However, it was discovered that the true rate-limiting step in steroidogenesis is the 
transfer of cholesterol from the outer mitochondrial membrane, through the aqueous 
intermembrane space, to the inner mitochondrial membrane where the P450scc resides 
(Brownie et al. 1972; Crivello and Jefcoate 1980; Privalle et al. 1983; Simpson et al. 
1978). 
As potential cholesterol transferring proteins, the best candidate to date is the 
Steroidogenic Acute Regulatory protein (StAR) first cloned and cbaracterized in the MA-
10 mouse Leydig tumor cell line by Clark, BJ et al. (Clark et al. 1994). Effectively, these 
authors were the first to identify StAR as being the same 30-kDa protein originally 
described by Orme-Johnson and colleagues (Alberta et al. 1989; Epstein and Orme-
Johnson 1991a; Epstein and Orme-Johnson 199lb; Hartigan et al. 1995; Pon et al. 1986; 
Pon and Orme-Johnson 1988), responsible for adrenocorticotropin hormone (ACTH) 
stimulated steroidogenesis. The involvement of StAR in cholesterol translocation is 
supported through a number of experimental results, the most obvious being the StAR 
knockout mice (Caron et al. 1997) displaying lipoid congenital adrenal hyperplasia 
(LCAH). Patients with LCAH cannot synthesize adequate amounts of steroids and are 
characterized by cholesterol accumulation in the adrenal glands and gonads. This 
potentially lethal condition is now commonly attn"buted to a dysfunctional StAR, most 
importantly in the critical C-terminal region as demonstrated by StAR mutants (Bose et 
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al. 1996; Lin et al. 1995). In hwnans, StAR is expressed in adrenal glands, gonads, and 
brain, and consists of 285 amino acids (Sugawara et al. 1995) separated into two 
functional domains: 1) the mitochondrial import sequence responsible for its localization 
in mitochondria, and 2) the StAR lipid transfer (START) domain (Ponting et al. 1999; 
Ponting and Aravind 1999) responsible for the transfer of cholesterol into the inner 
membrane of mitochondria. 
START demains have been discovered and characterized for a large variety of 
proteins with different fonctions (Homma and Emori 1995; Masucci et al. 1996; Ponting 
et al. 1999; Ponting and Aravind 1999; Raya et al. 1999). Of these, the human MLN64 
protein may have a similar fonction as the human StAR in the placenta, brain, and non-
steroidogenic tissues for the formation of steroids and bile acids (Bieche et al. 1996; 
Moog-Lutz et al. 1997; Watari et al. 1997). The structure ofMLN64 was recently solved 
by X-Ray crystallography and revealed several interesting features (Tsujishita and Hurley 
2000). More importantly, the cholestcrol binding site is best described as a hydrophobie 
tunnel fonned predominantly from a U-shaped unclosed (3-barrel topped by the parallel 
C-terminal a-helix. The tunnel completely traverses the entire MLN64 and has been 
suggested to work as an intermembrane shuttle (Tsujishita and Hurley 2000), although 
the exact mechanism by which StAR mediates cholesterol transfer is still a subject of 
intensive research. Several mechanisms have been suggested for the action of cholesterol 
transfer by StAR.. These include desorption, the implication of a molten globule state and 
the intennembrane shuttle (Stocco 2000; Stocco 2001; Stocco and Clark 1996). 
Desorption requires that the inner and outer mitochondrial membranes come into 
contact as StAR is imported into the mitochondrial matrix by its mitochondrial targeting 
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sequence (Kallen et al. 1998). Then, high volumes of cholesterol can be transferred from 
the cholesterol-rich outer membrane to the cholesterol-depleted inner membrane. This 
mechanism does account ·for localization of mitochondrial imported proteins at contact 
points (Pon et al. 1989; Schwaiger et al. 1987; Stocco and Clark 1996), the rapid 
cholesterol transfer requiring little StAR, and the quick degradation of StAR by 
mitochondria (Clark et al. 1994; Stocco and Clark 1996). It does not however, account 
for the fact that StAR can still function without its N-terminal import sequence (Arakane 
et al. 1996; Arakane et al. 1998). As for the molten globule (Bose et al. 2002; 
Christensen et al. 2001), it was shown that StAR looses tertiary structure at low pH (3.5-
4.0) while retaining secondary structures, suggesting that partially folded states of StAR 
are significantly populated at low pH and even at pH values closer to neutrality 
(Christensen et al. 2001). ln the latter study, the authors suggest tbat this "molten 
globular state" is important for StAR function outside mitochondria (Bose et al. 2002). 
This model is in agreement with the observation that an active electrochemical force is 
required for the transfer of cholesterol (King et al. 1999) but the in vivo local acidic 
environment still remains to be proven. Finally, the intermembrane shuttle states that 
StAR acts as a sterol carrier, migrating between mitochondrial membranes (Tsujishita 
and Hurley 2000). The molecular mechanism and structural requirement for the carrier 
role of StAR is still elusive. On the other band, it appears that the structure of MLN64 
may reveal key features to understand the mode of cholesterol transport by StAR. The X-
Ray structure of MLN64 (Tsujishita and Hurley 2000) depicts a hydrophobie tunnel 
characterized by P-strands forming the tloor and sidewalls, topped by a C-terminal œ-
helix and two loops. lnside the tunnel, there is opening of the cavity such that one 
49 
cholesterol molecule may fit. On the other band, the tunnel openings are not large enough 
to allow a cholesterol molecule to pass through StAR. Tsujishita & Hurley (Tsujishita 
and Hurley 2000) suggest that transient conformational changes of the loops and/or the 
C-tenninal a-helix allow cholesterol access to the hydrophobie tunnel, supported by the 
recent crystallization of the phosphatidyldylinositol transfer protein a (PITPa) open 
'• 
conformation (Schouten et al. 2002); PITPa is involved in the regulation of lipid and 
vesicular trafficking and in lipid-mediated signal transduction pathways (Cockcroft 1999; 
Cunningham et al. 1995). lmportantly, in support of the C-terminal a-helix transient 
conformational changes, it bas been recently observed that there is loss of helical content 
in StAR upon binding of a cholesterol chromophoric analogue, NBD-cholesterol 
(Petrescu et al. 2001 ). 
Following the observation that the C-terminal region of StAR is important for proper 
StAR activity (Bose et al. 1996; Lin et al. 1995), that the C-tenninal region is suggested 
to transiently change conformations for cholesterol binding (Tsujishita and Hurley 2000), 
that loss of StAR helical structure is obtained upon binding of a cholesterol analogue 
(Petrescu et al. 2001 ), that molten globular states of StAR are possible (Bose et al. 1999; 
Christensen et al. 2001), and that the C-terminal a-helix in MLN64 entirely covers the 
putative cholesterol binding site, we investigated the possible implication of various 
conformational states of.this C-terminal a-helix in the binding of cholesterol to StAR 
through molecular modeling. 
We show that the hamster StAR model bas a hydrophobie cavity instead of a tunnel. 
This cavity is proposed to be the driving force for the unfolding of the C-terminal a-helix 
revealing the cholesterol binding site. We calculate through structure-based 
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thermodynamics (Freire 1993);(Lavigne et al. 2000) that this partially folded state could 
be significantly populated and that cholesterol favorably binda to it. We also observe that 
once cholesterol has bound to StAR, adjacent loops to the opened StAR binding site 
(loop 01 and the loop between ~-strands 1 and 2) effectively inhibit the C-terminal a-
helix reformation, supporting the observed loss of a-helical structure upon cholesterol . 
binding to StAR thus allowing a rapid cholesterol transfer inside mitochondria. Finally, 
we show a peculiar sait-bridge in the binding site plays a key role in cholesterol binding. 
This is supported by new mutagenesis results showing that cholesterol transfer can be 
abolish by removal of this sait-bridge. 
Taken together, these results suggest a rapid unfolded StAR mechanism for the 
transfer of cholesterol from the outer to the inner mitochondial membranes, driven by the 
transmembrane cholesterol gradient; our calculations are applicable to both a StAR 
functioning in the mitochondrial intermebrane space or in the cytosol in proximity of 
mitochondria. Thus, we propose a plausible common ground for the intermembrane 
shuttle and molten globule mechanisms. 
MATERIALS AND MEmODS 
Modellng Methodology 
Ali calculations were performed on an SGI Octane 2 workstation and the Insightll 
(2000) suite of programs (Homology, Discover, Biopolymer, and Builder) to obtain ail 
models. The amino acid sequences for the hamster and human StAR were obtained from 
Genbank (Accession Numbers AAB06763 and NP_000340 respectively) and aligned to 
the extracted amino acid sequence of MLN64 by a ClustalW algorithm (Thompson et al. 
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1994), and manually adjusted in Homology. The amino acid side cbains of the hamster 
and human StAR were replaced in the MLN64 coordinate file (PDB ID number 1EM2.). 
The minimimtion calculations were performed in the absence of Coulombic potential, 
cross terms and morse potentials. The consistent valence forcefield (CVFF (Dauber-
Osguthorpe et al. 1988)) was used for all calculations. Essentially, the minimization was 
completed in four steps: l) fixed heavy (all but hydrogens) atoms, 2) fixed backbone 
atoms with tethered heavy atoms, 3) tethered backbone atoms, and 4) no atoms tixed. 
Each step was performed as follows: 1) steepest descent for l 000 iterations or until the 
maximum derivative is less than 0.001 kcaVA, followed by 2) conjugate gradient for 
l 000 iterations or until the maximum derivative is less than 0.001 kcaV A. 
To define the cavity, we filled it with water; water molecules were discovered in the 
MNL64 crystal (Tsujishita and Hurley 2000). First, a 50 A solvent layer was added to the 
StAR models, upon which the cavity was placed "over'' the water molecules. Ail the 
water molecules outside the cavity volume were removed, keeping only the water 
molecules that fit in the cavity. These water molecules were visually identified by 
comparing the molecular surfaces of the water molecules as well as the cavity. 
For binding studies, a cholesterol molecule was created using the Builder module in 
the Insightll suite. The initial planar structure was minimiz.ed using steepest decent for 
1000 iterations or until the maximum derivative is less than 0.001 kcal/A, fixing nothing 
and using no Coulombic potential, cross terms and morse potentials. After, the 
cholesterol molecule was manually and visually placed inside the StAR cavity, as 
previously suggested (Tsujishita and Hurley 2000). Due to the shape of StAR's cavity, 
placement of cholesterol was unambiguous. The structures were then minimfaed as 
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mentioned above. The cholesterol free native hamster and human models have been 
deposited in the PDB and have PDB ID numbers llLJ and lIMG respectively. 
Free Energy Calculations 
In order to calculate the Gibb's free energy difference (AG) between the native and 
' 
partially unfolded states of StAR, we have used an approach called structure-based 
thermodynamics (Freire 1993) as implemented in the computer program STC (Lavigne et 
al. 2000). This approach has been shown to allow for the identification of partially folded 
(unfolded) states of proteins in equilibrium with their native states and to allow for the 
prediction of binding free energy of ligands to proteins (Baker and Murphy 1998; Hilser 
and Freire 1997). 
Briefly, we manually unfolded the C-terminal a-helix of the hamster StAR model 
using the Biopolymer module of the Insightll suite. As a model for the unfolded state, we 
bave used an extended conformation ('I/ and+ =180°). Then, the changes in accessible 
surface area (MSA) between the ''unfolded states" and the native state were calculated 
using the CALC_ASA module of STC (Lavigne et al. 2000) and separated into polar (N 
and 0 atoms) and non-polar (C and S atoms). Using the calculated MSA and empirical 
fonctions relating changes in heat capacity (ACp), enthalpy (Ml}, entropy (âS) per unit of 
MSA, AG between the different states were calculated using the THERMO module of 
STC (Lavigne et al. 2000). Note that no changes in the protonation states were 
considered. We also explored loop movement above the opened StAR cavity using this 
same methodology. Finally, the binding constant between cholesterol and the partially 
unfolded state was calculated as described elsewhere (Lavigne et al. 2000). 
53 
Rendering 
Ail the model graphical images were created using either Insightll for molecular 
surfaces or Ribbons 3.0 for ribbon diagrams. 
Materials for Slte-Directed Mutagenesis 
Ali restriction and modifying enzymes were purchased from New England Biolabs 
(Mississauga, ON, Canada). The expression vector pcDNA3.1Myc-His, Lipofectamine 
and oligonucleotides were purchased from lnvitrogen Canada lnc. (Burlington, ON, 
Canada). Ali vectors were amplified in XLl Blue E coli competent cells (Stratagene, La 
Jolla, CA), and purified on Qiagen anion-exchange columns (Qiagen, Chatsworth, CA). 
TPA and (Bu)2-cAMP (cAMP) were obtained from Sigma-Aldrich (St-Louis, MO). 
Hamster StAR Mutagenesis by PCR 
Brietly, two series of PCR amplifications were obtained using the following 
conditions: Hot start of S min at 94°C (without DNA polymerase) followed by a touch 
down of 2°C from 94°C/70°C/72°C to 94°C/S0°C/72°C, completed with 30 cycles of 
94°C/50°C/72°C and a final 72°C elongation of 15 min. The first series consists of 
amplifying hamster StAR cDNA in two different reactions. 1) A wild type (WT) 
upstream (sense) oligonucleotide to the downstream mutant (antisense) oligonucleotide at 
the site of interest for mutagenesis and 2) a mutant sense oligonucleotide from the site of 
interest for mutagenesis to a WT antisense oligonucleotide. The second series consists of 
pooling both PCRs previously obtained, purified by agarose gel electrophoresis, and 
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amplifying using WT 5' and 3' oligonucleotides. WT-StAR and ail mutants were cloned 
into pcDNA3.1Myc-His using unique EcoRI and HindITJ. restriction sites, and entirely 
sequenced between these restriction sites using T7 sequencing kit from Amersham 
Pharmacia Biotech (Baie d'Urfé, QC Canada), amplified, and purified on Qiagen anion-
exchange columns. 
Hamster StAR Expression 
Either WT or mutated StAR was transiently transfected into monkey kidney COS-1 
cells (American Type Culture Collection, Rockville, MD) using the lipofectamine 
method. Twenty-four hours before transfection the cells were harvested with pancreatin-
EDTA solution (lnvitrogen Canada Inc., Burlington, ON, Canada) and plated at an initial 
density of 3.S x 105 cells per 10 cm2 well in 6-well plates. Cells were cultured in DMEM 
supplemented with 10% fetal bovine serum (FBS), 5.96 g/L HEPES, 2.2 g/L NaHC03, 1 
mM L-glutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin sulphate. DMEM 
containing no fetal bovine serum and no antibiotics was used for transfections. Each 
transfection assay received 1 µg of DNA (500 ng/ml F2 construct (Harikrishna et al. 
1993) containing cytochrome P450scc/adrenodoxin reductase/adrenodoxin and 500 ng/ml 
of pcDNA3.l + pcDNA3.l-StAR) and 10 µg/ml lipofectamine. Twenty two hours after 
transfection cells were rinsed with PBS. Cells were then incubated for 24 hours in 
DMEM without phenol red containing 10% dextran-coated charcoal-treated FBS and 
antibiotics without or with stimulation agents. Media were kept for pregnenolone 
determination and cells for immunoblotting analyses. 
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Measurement of the Hamster StAR Activity 
In this study, StAR activity is defined as the quantity of pregnenolone formed by 
transfected COS-1 cells ûi co-transfection experiments using F2 (Harikrishna et al. 1993) 
and StAR plasmids. Pregnenolone was analyzed by radioimmunoassay (ICN 
Pharmaceuticals, Diagnostics Division, Orangeburg, NY). This conversion of cholesterol 
into pregnenolone is directly related to the rate of cholesterol transfer by StAR to 
P4S0scc in the inner mitochondrial membrane. 
lmmunoblotting Analysis 
Sodium-dodecyl sulphate polyacrylamide gel electrophoresis (SDS-P AGE) were 
performed with 20 µg of soluble proteins on a 12% gel and analyzed by immunoblotting 
(LeHoux et al. 1992) using a rabbit polyclonal anti-mouse StAR antibody (kindly given 
by Dr. Dale Buchanan Hales, Department of Physiology and Biophysics, University of 
Illinois at Chicago, Chicago, IL) as previously described (LeHoux et al. 1996). This 
immunoglobulin was raised against a GST-fusion protein from a mouse StAR cDNA 
from a 208-1467 bp fragment (Clark et al. 1997). Cells were scraped and directly 
harvested in hot (100°C) Laemmli buffer. Ail samples were then passed through a 26 
gauge needle, then boiled for 10 min and finally centrifuged at 12000 x g for 2 min. 
Soluble proteins were determined on the supematant using the Bio-Rad Protein Assay 
Dye Reagent (Bio-Rad Laboratories, Ltd. Mississauga, ON, Canada). 
Immunoreactive proteins were detected using ECL-PLUS light emitting reagents 
(Amersham Pharmacia Biotech UK Ltd., Amersham Place, Little Chalfont, 
Buckinghamshire, UK). Autoradiograms were observed by exposing the blots to Kodax 
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X-Omat XK films. The results were also visualized and quantified on the optical imager 
STORM 860 using ImageQuant software version 5.0 (Molecular Dynamics, Sunnyvale, 
CA). 
Statistical Analyses 
Differences between experimental groups were analyzed by ANOVA followed by 
Dunnett's test, using the SigmaStat program for Windows (SPSS Science, Chicago, IL). 
RESULTS 
Overall Structure of Molecular Models 
In order to undertake theoretical molecular modeling of proteins, a suitable alignment 
between a protein of known three-dimensional structure with the target protein must be 
obtained. In this case, the alignment of the human MLN64 with the hamster and human 
StAR proteins is depicted in Fig. 1 and shows a suitable identity of approximately 34% 
between the sequence of the hamsterlhuman StAR and MLN64. Following the 
unambiguousness of the alignment, the amino acid residues of the hamster and human 
StAR proteins were substituted in the l\fLN64 coordinate file and the potential energy of 
the model was minimized appropriately (see MATERIALS AND METHODS). The 
stereochemical quality of the models were checked with the program PROCHECK 
(Laskowski et al. 1993) and was found to be excellent. 
As expected, the theoretical models for the hamster and human StAR greatly 
resembled the crystalline structure of the human :MLN64 (Tsujishita and Hurley 2000). 
As demonstrated in Fig. 2 ( only hamster model shown), the prominent feature to the 
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hamster StAR model is the U-shaped unclosed P-strand barrel, topped by the parallel C-
terminal a-helix. Altogether, the structure is composed of 4 a-helices and 9 twisted anti-
parallel P-strands like the MLN64. Although, the most significant change in the overall 
structure of the StAR model as compared to the human MLN64 crystal, is a cholesterol 
binding site in the shape of an oval cavity matching the size an<! structure of cholesterol 
(Fig. 3A - cholesterol not shown); in :MLN64, the cholesterol binding site is ''tunnel-like" 
(Tsujishita and Hurley 2000). Amidst the mostly hydrophobie environment of the cavity, 
there are two charged amino acid residues (Glul68-Argl87, hamster numbering) forming 
a sait bridge (Fig. 3B) as described previously in MLN64 (Tsujishita and Hurley 2000). 
STC Calculations 
To get insight into the cholesterol transfer mechanism into the mitochondria, we 
attempted to calculate the change in free energy of various conformations of the hamster 
StAR model. STC is one of the very few methods applicable to model partially folded 
states that has been validated by others (Baker and Murphy 1998; Freire 1993; Hilser and 
Freire 1997; Lavigne et al. 2000). We therefore utilized STC to calculate the change in 
free energy of the various conformational states of our StAR model and to calculate a 
theoretical dissociation constant O'd). 
Free Energy of Cavity Formation 
Bearing in mind that the binding site of StAR bas to become accessible and that 
cavities inside globular proteins destabilize the native state of proteins (Creighton 1993), 
we have calculated the &G for cavity formation using STC. Moreover, the water 
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moleeules discovered in the MLN64 erystal contribute to the destabilization of the 
hydrophobie cavity. In order to calculate the AG, we manually caleulated the ASA inside 
the binding site of the StAR eavity. Briefly, ail atoms directly adjacent the water 
moleeules in the solvated model of the hamster StA.R were visually identified. After, the 
hamster StA.R model was "eut" parallel to the oval binding site (Fig. 3C) and each piece . 
was subjected to ASA calculations separately. MSA between the "eut state" and the 
native state was taken to be the solvated ASA (MSAnp = 627.8 A2 and MSApol = 
156.1 A2) inside the hydrated cavity. This translates into a AG of destabilization (cavity 
formation) of approximately 12 kcaVmol. 
Partial Unfolding of StAR 
It is elear that StAR with a closed binding site would have to open to allow cholesterol 
inside. Supporting evidence for s1ructural changes during cholesterol binding to StAR, 
and cholesterol transfer inside mitochondria include: 1) the C-terminal region of StAR is 
important for proper StA.R activity (Bose et al. 1996; Lin et al. 1995); 2) the C-terminal 
region as well as the loops spatially adjacent to this region, are believed to transiently 
change conformations for cholesterol binding (Tsujishita and Hurley 2000); 3) molten 
globular states of StAR are possible (Bose et al. 1999); and 4) the C-terminal a-helix of 
our StAR model entirely covers the putative cholesterol binding site as for the MLN64 
crystal (Tsujishita and Hurley 2000) and should be free for movement. Yet, the most 
convincing discovery supporting StAR conformational changes for proper StAR activity 
is the loss of StAR helical structure upon the binding of a cholesterol analogue in StAR 
(Petrescu et al. 2001). We therefore conceptualized the opening of the binding site 
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primarily by the movement of the C-terminal a-helix covering the U-shaped unclosed (J-
barrel such as could happen in a molten globule state, driven by the âG of destabilization 
caused by the hydrophobie cavity hydration as calculated above. In order to test this 
hypothesis, we modeled different conformations of the C-terminal a-helix of the hamster 
StAR model. In absence of cholesterol, three key conformatio~ were considered: A) 
native, B) opened: C-terminal a-helix still folded but remove Crom the binding site, and 
C) partially unfolded: C-terminal a-helix unfolded but with the rest of the molecule 
native. The free energy change for ail the steps are indicated in Fig. 4 (A, B, and C 
respectively). Note that we have subtracted the âG for cavity formation Crom calculated 
âG change between state A and B; indeed, the destabilization of the native state by the 
cavity bas to be taken into account The net free energy change between the native state 
(A) and the partially unfolded state (C) is +2.61 kcal/mol. To a first approximation, i.e. 




we can estimate a significant relative population of approximately 2% for this partially 
unfolded conformation. Note that state B is less stable than state C, mosdy due to the cost 
in conformational entropy for maintaining the helical conformation of the C-terminal a-
helix without tertiary interactions. 
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Binding of Cholesterol to the Partially Unfolded State 
Next, we bave calculated the dG of binding cholesterol to the partially unfolded state 
of StAR using STC as described elsewhere (Lavigne et al. 2000), and found a relatively 
weak ~of 9.44 x10·5 M (Fig. 4, C to D). Once cholesterol binds to the partially unfolded 
state of the hamster StAR protein, the free energy of the complex drops below the free . 
energy of the native state ( corrected for the cost of cavity formation). Since is was 
discovered that there is loss of helical character upon cholesterol binding (Petrescu et al. 
2001 ), we simulated movement of the loops adjacent the cholesterol binding site Ooop 
Q 1 and loop between P-strands 1 and 2) such as to inhibit the C-terminal a-helix 
reformation. These loops are the only structures available for movement in the vicinity of 
the C-terminal a-helix, as mentioned previously (Tsujishita and Hurley 2000), that could 
aid in maintaining it in the unfolded state; Fig. S (D to E) depicts the movement of these 
loops and represent a partially refolded state of StAR. 
Trapping Cholesterol lnside the Cavity of the StAR Protein 
Although it was observed that there is loss of helical structure upon binding of 
cholesterol inside (Petrescu et al. 2001), it is still conceivable that the C-terminal a-helix 
refolds on top of the bound cholesterol. We thus simulated the refolding of the C-terminal 
a-helix, trapping cholesterol inside StAR (Fig. 6, D to F to G). A dG for a closing 
reaction of the folded C-terminal a-helix trapping the cholesterol inside was calculated 
(conformation A to G) to be -17.91 kcaVmol. As one can see, there is a dramatic 
stabilization of the complex. As discussed below we propose that this reaction could be 
involved in the shut-off of the transfer. 
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Cholesterol Bindiilg Site 
As mentioned above, the cholesterol bincling site of the hamster StAR model took the 
shape of a hydrophobie cavity and not a hydrophobie tunnel (Fig. 3). We thus 
investigated the possibility that water molecules could change the binding site 
conformation since water molecules were discovered inside the MLN64 crystal 
(Tsujishita and Hurley 2000). The model was then solvated in the binding site as well as 
surrouncling the protein as described in MA TERIALS AND METHODS. After 
minimization, the overall structure of the model and the cholesterol bind site did not alter. 
A cholesterol molecule was then inserted in the hamster StAR models and minimized 
accordingly. In the minimized complex, the 3J3-0H group of cholesterol localized 
adjacent to the sait bridge formed by Glul68-Arg187 as we expected (Fig. 7). As seen, 
the 3J3-0H group was localized < 6 A away, which is a sufficient distance for one water 
molecule to bridge the 3J3-0H of cholesterol and the sait bridge through hydrogen 
bonding. 
Mutant Activity Alterations 
The sait bridge mutants of the hamster StAR were expressed in COS-1 cells and 
veritied for activity alterations. In both cases, when either of the amino acids involved in 
the formation of the sait bridge were changed for a hydrophobie residues of similar 
volume (i.e.: Glul68Leu, and Argl87Met), total loss of StAR activity was obtained in the 
absence of cAMP-stimulation as compared to the mock transfections (Fig. SA). Under 
cAMP-stimulation, an increase in StAR activity was obtained but never higher than the 
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non-stimulated wild type indicating a critical role for this sait bridge in the StAR-
mediated transfer of cholesterol. 
Mutant SDS-PAGE Analysis 
Whole cell extracts from the mutant hamster StAR-expressing COS-1 cells were 
analyzed by SDS-PAGE (Fig. SB). Under non-stimulated conditions, wild type and 
mutant hamster StAR is expressed in similar proportions as seen by the ensemble of three 
experiments (Fig. SC). Under cAMP-stimulation, protein concentrations were markedly 
increased, similarly for ail preparations. The contrai empty vector pcDNAJ .1 did not 
produce detectable StAR protein but a basal StAR-independent cholesterol transfer into 
mitochondria was obtained (Bose et al. 1996). Unexpectedly, different migratory patterns 
were obtained for the hamster StAR mutant Glul68Leu (El68L) preparations, which 
remain unexplained. 
DISCUSSION 
Molecular Modeling and Mutagenesis 
As expected, the structure of the hamster and human StAR models greatly resemble 
the human MLN64 crystal structure. The most surprising structural difference compared 
to the MLN64 crystal structure was the loss of the hydrophobie tunnel replaeed by a 
hydrophobie cavity in our StAR models, matehing the overall structure of cholesterol. 
The cavity can be imagined as the driving force allowing StAR to open, exposing the 
binding site to incoming cholesterol molecules. Indeed, trapping water molecules inside 
this hydrophobie cavity, as those co-crystallized in the MLN64 (Tsujishita and Hurley 
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2000), greatly costs to StAR stability. According to our structure-based thermodynamic 
calculations, tbis hydration destabilizes StAR by approximately 12 keaVmol, driving the 
unfolding of the C-tenninal cx-helix in solution. With a net differenee of 2.61 kcaVmol 
between the original empty folded state and the open unfolded state of StAR, we can 
expect approx. 2% of the StAR population to be in partially unfolded state . . 
The sait bridge inside the cavity can be coneeptualized as having two major functions: 
1) allowing cholesterol to bind in the proper orientation inside the well defined cavity, 
and 2) maintaining minima) StAR folding for optimal cholesterol binding. The tirst 
function is elearly demonstrated through cholesterol doeking analyses in the presence of 
one water molecule. After ail, the sait bridge is located opposite the moveable C-terminal 
cx-helix at the bottom of the hydrophobie pocket, where it will not move and to which the 
31}-0H group of cholesterol can interact as it binds to StAR. 
Although molten globular states are possible for StAR, a minimal structure must be 
maintained to mediate StAR function. Therefore, the sait bridge can be visualized as a 
key component to maintain StAR in a conformation such that cholesterol will bind. This 
is supported by our mutational analyses of the sait bridge, as well as the presenee of a 
peptidase-resistant domain in the human StAR, which includes tbis sait bridge (Bose et 
al. 1999). ln the case where the sait bridge is replaced by hydrophobie residues of similar 
volume (hamster E168L-R187M}, total loss of StAR-dependent cholesterol transfer into 
mitochondria is obtained as compared to the mock transfections. This is most likely due 
to non-specitie interactions of the hydrophobie amino acids and thus eould lead to 
improper StAR folding altogether (Bose et al. 1996); the residual cholesterol transfer 
inside mitochondria is StAR-independent (Bose et al. 1996). 
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Serine 185 was thought to be a potential phosphorylation site and was thus changed 
into an alanine that cannot be phosphorylated; total loss of StAR-dependent cholesterol 
transfer was also obtained (Fleury et al., unpublished results). To further test the 
hypothesis that Sl8S is indeed phosphorylated, we mutated Sl8S into aspartate and 
glutamate mimicking phosphorylation, and no gain in StAR activity was obtained. The 
only recuperation of StAR activity was obtained with the mutant S 18SC, where cysteine 
greatly resembles serine both in volume and hydrophilicity but still cannot be 
phosphorylated. Moreover, 20-PAGE analyses of the Sl85A mutant did not reveal any 
differences to wild type StAR. This clearly indicates that SISS is notphosphorylated and 
its control on StAR activity comes from structural alterations. Upon a closer look, SISS is 
located directly beneath the sait bridge, inaccessible to solvent. It thus becomes clear that 
not only the sait bridge is important, but also its immediate environment leading to its 
proper positioning. Therefore in summary, removal of the sait bridge by mutagenesis can 
not only reduce cholesterol affinity to the StAR binding site due to loss of orientation, but 
could also result in improper folding of StAR altogether as demonstrated for the human 
StAR mutant El69G (Bose et al. 1998). 
Cholesterol Translocation 
The major reason for modeling StAR is to visualize its environment, hopefully leading 
to an understanding of the cholesterol translocation into mitochondria. Now, two 
mechanisms are widely accepted: the molten globule, and the intennembrane shuttle. 
Here, we demonstrate the possibility of structural changes in the hamster StAR supported 
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by theoretical molecular thermodynamics, in accordance with either of these 
mechanisms. 
As one looks at the energy profile of the proposed states of StAR (Fig. 9), two 
possible mechanisms become clear to account for either the intermembrane shuttle or the 
molten globular states acting outside mitochondria (Fig. 10). First, if in the mitochondrial 
intermembrane space, StAR is mainly in the native state (Fig. 9, A) in equihbrium with 
approximately 2% in the partially unfolded state (Fig. 9, C). Upon stimulation (i.e.: 
cAMP), cholesterol is mobilized to the outer mitochondrial membrane, increasing the 
chemical potential between the inner and outer mitochondrial membr~es (Jefcoate et al. 
1987). This increased chemical gradient should be sufficient to increase the amount of 
cholesterol bound StAR, shifting the equilibrium between native and partially unfolded 
StAR states, towards the partially unfolded state (Fig. lOC). This is because the 
cholesterol bound partially unfolded StAR is more stable than empty native StAR (Fig. 9, 
C vs 9, A). Upon cholesterol binding, StAR partially closes through the movement of the 
loops (loop '21 and the loop between P-strands 1 and 2 - Fig. SE) and maintains the 
observed loss of helical structure upon cholesterol binding (Petrescu et al. 2001). This 
partially "refolded" state (E) then rotationally translates on itself (Fig. 10, step Ill), now 
positioning the opened cholesterol-bound cavity towards the inner mitochondrial 
membrane to allow cholesterol to be transferred. Once flipped, StAR releases the 
cholesterol in the inner mitochondrial membrane and returns to the outer mitochondrial 
where it can bind another cholesterol molecule for transfer (Fig. 10, D). In the event that 
the cholesterol gradient across the mitochondrial membranes is insufficient to drive the 
transfer of cholesterol inside mitochondria, refolding of the C-terminal a-helix competes 
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with the release of cholesterol and the recycling of StAR. In other words, if the release of 
cholesterol is disfavored due to a lowered chemical gradient, cholesterol remains bound 
to StAR long enough due to no net cholesterol transfer inside mitochondria. This allows 
enough time for the C-terminal a-helix to refold on top of cholesterol; it is widely 
accepted that refolding of a helix is much slower than transient movement of loops in 
sol vent. Y et, it is impossible at the moment to estimate the differences in energy 
threshold between the refolding of the C-terminal a-helix and the recycling of StAR to 
the native state after cholesterol release (Fig. 5, steps 4a vs 4b, and Fig. 10, steps Va and 
Vb ). In virtue of the large stabilization of the closed C-terminal a-helix on top of the 
bound cholesterol in StAR (Fig. 9, G), this step can be visualized as a rapid shut off 
mechanism halting StAR function, as it is irreversible. Even though these various StAR 
states can be located throughout the mitochondrial intermembrane, this mechanism will 
only function if in close proximity of "contact sites". In support of this, the complete 
human StAR bas been located in the intermembrane space and the inner mitochondrial 
membrane facing the intermembrane space by immunoelectron microscopy (King et al. 
1995), and at mitochondrial contact sites by immunoblotting (Cherradi et al. 1997). 
Since our STC calculations have been performed in an aqueous solvent, these StAR 
partially unfolded states are also applicable to StAR in the cytosol (Bose et al. 2002). In 
this case, StAR functions similarly to that of the intermembrane mechanism with the 
exception that StAR does not rotationally translate upon itself. On the other band, it 
would seem that StAR needs another unidentified factor to transfer cholesterol inside 
mitochondria as it does not enter mitochondria itself other than to be degraded. Recently, 
it has been shown that the peripheral benzodiazepine receptor (PBR) is located 
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preferentially at approx. 70 A from StAR on the mitochondrial cytosolic surface (West et 
al. 2001 ), suggestive of a close interaction for cholesterol transfer inside mitochondria. 
Therefore, cytosolic StAR mediates cholesterol transfer inside mitochondria by 
"shuttling,, cholesterol from the cholesterol rich outer mitochondrial membrane to 
another factor (i.e.: PBR) for subsequent cholesterol transfer inside mitochondria (Fig. 
11); this mechanism may still be dependant on the cholesterol gradient across the outer 
and inner mitochondrial membranes. In this case moreover, it is not inconceivable that 
cholesterol may be fed to StAR directly from the cytosol cholesterol carriers, such as the 
sterol carrier protein-2 (SCP-2) (Gallegos et al. 2001). 
The Pros and Cons 
The largest downfall from our mechanism is the fact that the first 65 amino acids are 
unaccounted; this N-terminal region is presently surrounded by controversy. On one 
hand, it permits cholesterol transfer in the desorption mechanism (Kallen et al. 1998). On 
the other hand, it has absolutely nothing to do with cholesterol transfer (Arakane et al. 
1996; Arakane et al. 1998; Tsujishita and Hurley 2000). Yet not too long ago, it was 
demonstrated by 20-PAGE and 2-phased analyses of cholesterol metabolism, that newly 
synthesized complete StAR is rapidly processed to the N-teminally cleaved StAR, the 
form that mediates cholesterol access to P450scc (Artemenko et al. 2001). 
Combining the observation that removal of the first 46 N-terminal amino acids only 
slightly affected protein concentrations and not StAR activity (Fleury et al., unpublished 
results), that N-terminally cleaved StAR is the active form of StAR mediating cholesterol 
access to P450scc (Artemenko et al. 2001), and that through modeling we canjustify the 
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existence of molten globular StAR states, further support our mechanism. Therefore, in 
the case of the intermembrane shuttle, an import sequence independent internalization of 
StAR into the mitochondrial intermembrane space is necessary and could be possible 
(Derman et al. 1993). In the event where StAR fonctions outside mitochondria, StAR 
interactions with mitochondrial proteins are key for proper StAR fonction and still remain 
to be clearly identified. 
Petrescu et al. (Petrescu et al. 2001) have recently observed four novel characteristic of 
StAR lacking the first 62 amino acids: 1) NBD-cholesterol bound at two distinct sites, 2) 
loss of StAR a-helical structure when bound with NBD-cholesterol, 3) an average Kcs 
near 32 nM for both binding sites, and 4) NBD-cholesterol binds inside the StAR 
''tunnel". First, the authors suggest that there is room inside the "tunnel" for two NBD-
cholesterol molecules. Following our modeling, the replacement of the tunnel by the 
cavity restrains its volume to only permit one cholesterol molecule. In addition, this is 
contradictory to previous results showing molar cholesterol binding to the human 
MLN64 and StAR (Tsujishita and Hurley 2000). Therefore the second "cholesterol" 
binding site seems to be an artifact from the intrinsic polar properties ofNBD-cholesterol 
chromophoric side-chain. 
Second, a nanomolar Kct is unlikely for StAR. Although this strong association of 
"cholesterol" to StAR could explain the dissociation of cholesterol from the outer 
mitochondrial membrane as Petrescu et al. (Petrescu et al. 2001) suggested, it cannot 
explain how cholesterol is released to the inner mitochondrial membrane. Furthermore, 
such strong interactions are against a rapid cholesterol transfer, as they would slow down 
StAR efficiency. On the other band, a Kct in the micromolar proportions, such as our 
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theoretical calculated Kct - 95 µM validated by STC, supports a rapid release of 
cholesterol by StAR. 
Our STC calculations can account for several key points in the StAR-dependent 
cholesterol mechanism. First, the N-terminal mitochondrial sequence is not required for 
cholesterol transfer (Arakane et al. 1996; Arakane et al. 1998) either inside the 
intemembrane space or outside mitochondrial in the cytosol. Second, a signiticant 
population of molten globular StAR is possible (Bose et al. 1999; Christensen et al. 
2001) under normal conditions for both mechanisms. Third, the hydrophobie tunnel is 
inexistent but rather replaced by a hydrophobie pocket that opens through the molten 
globule; according to the MLN64 crystal, it was argued that the openings were too small 
to allow cholesterol to pass though the hydrophobie tunnel (Tsujishita and Hurley 2000). 
Forth, the intermembrane shuttle becomes extremely rapid for the transfer of a great 
amount of cholesterol in a short period of time (Artemenko et al. 2001) through StAR 
partially unfolded states. Fifth, there is loss of StAR helical structure upon "cholesterol" 
binding (Petrescu et al. 2001 ). Sixth, the C-terminal region of StAR is critical for StAR 
activity (Bose et al. 1996; Lin et al. 1995). Finally, shutting off StAR-dependent 
cholesterol transfer inside mitochondria by irreversibly trapping cholesterol inside StAR 
is in agreement with the dependence of cholesterol transfer on newly synthesized StAR 
(Artemenko et al. 2001). Finally, our proposed StAR unfolding is entirely consistent with 
similar C-terminal movement and unfolding of PITPa, discovered by crystallization, to 
allow substrate binding (Schouten et al. 2002). 
In conclusion, we were able to enlarge our understanding of the elusive StAR-
dependent cholesterol transfer into mitochondria through molecular modeling and 
70 
structure-based thermodynamics. This is supported by our experimental and validated 
computational (Freire 1993) results presented here, and those of others (Lin et al. 1995). 
lt is now possible to envision a global mechanism accounting for previously contradicting 
results. 
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FIGURE LEGENDS 
FIGURE 1. Alignment of the hamster and human StAR, and human MLN64 amino acid 
sequences used for homology modeling. 
FIGURE 2. Ribbon diagram of the final hamster StAR model. The same overall structure 
was obtained for the human StAR and is therefore not shown. Helices in red, strands in 
blue, and loops in yellow. There is "fog" in the image for depth perception. Ail structural 
elements have been labeled according to the human :MLN64 crystal structure. 
FIGURE 3. Hamster StAR model cholesterol binding site. A, Ribbon diagram of the 
hamster StAR with a solvated binding site. The solvent is represented as Connolly 
surface dots with the water molecules as black sticks. The black and gray areas show 
where the model bas been "opened" to allow surface area calculations of the cholesterol 
binding site. In black, the major feature is the C-terminal a-helix which tops the binding 
site; in gray, the major feature is the U-shaped J3-barrel fonning the bottom of the binding 
site, along with the majority of the remaining amino acids. B, Connolly surface 
representation of the "opened" hamster StAR model, as depicted from A. Left, U-shaped 
~-barrel as seen from above the cholesterol binding site. Right, C-terminal a-helix seen 
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from below (as though in the cholesterol binding site). Color scheme: hydrophobie atoms 
in gray, potentially polar atoms in yellow, and charged atoms in red (oxygens) and blue 
(nitrogens). The cholesterol binding site sait bridge is circled in orange. C, S11ne 
representation as in B except everything in white but the atoms directly in contact to the 
cholesterol binding site in black. 
FIGURE 4. Molecular mechanism of cholesterol binding in StAR. The cholesterol binding 
site of StAR is opened through two movements of the C-terminal a-helix (dark gray) 
from the original folded conformation (A): step 1) opened (B): completely removed from 
the cholesterol binding site, and step 2) partially unfolded (C): ail of the a-helical 
structure of the C-terminal a-helix is lost. Once open, cholesterol can bind to StAR (D) 
as indicated in step 3; a theoretical Kcs of 94.4 µM was calculated with STC. StAR is 
represented as a ribbons diagram while cholesterol is depicted as van der Waals radii. 
StAR is white with the C-terminal a-helix dark gray, and cholesterol dark gray. AG is the 
change in Gibb 's free energy in kcal/mol. 
FIGURE S. Representation of loop mobility upon cholesterol binding to StAR. Cholesterol 
binding was simulated in the partially unfolded StAR (Fig. 4, D); after cholesterol 
binding, the loops immediately adjacent to the unfolded C-terminal a-helix (loop 01 and 
the loop between P-strands 1 and 2) cover the bound cholesterol {E), inhibiting the 
refolding of the C-terminal a-helix. D; partially unfolded StAR (same as in Fig. 4, D), E; 
partially refolded StAR with loops "closed". Main StAR structure drawn as white nbbons 
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with the exception of the moveable loops in dark gray; cholesterol represented as van der 
Waals radii, also in dark gray. ~Gis the change in Gibb's free energy in kcal/mol. 
FIGURE 6. Cholesterol solvation by StAR. Closure of the cholesterol bound StAR active 
site can take either of two pathways: 1) closure of the loops adjacent the open binding site . 
(loop 01 and the loop between P-strands 1 and 2), resulting in a partially refolded state 
where C-terminal a-helix refolding is inhibited (step 4a, D to E to G); and 2) C-terminal 
a-helix refolding in the opposite direction of Fig. 4, resulting in the trapping of 
cholesterol inside StAR (steps 4b and S, D to F to G). The color code is the same as for 
Fig. 6 with the exception of the closed loop partially folded cholesterol bound StAR (F) 
colored dark gray, distinguishing it from the partially unfolded cholesterol bound StAR 
(D). 
FIGURE 7. Cholesterol binding inside StAR. Surface diagram of the StAR U-shaped P-
barrel with representation of cholesterol as sticks without hydrogens. One water molecule 
is depicted as a thick stick, allowing hydrogen bonding of the cholesterol's 3P-OH with 
Argl87. The color scheme is the same as in Fig. 3B: hydrophobie atoms in gray, · 
potentially polar atoms in yellow, and charged atoms in red (oxygens) and blue 
(nitrogens). 
FIGURE 8. Altered StAR activity of sait bridge mutants. COS-1 cells co-transfected with 
F2 and different StAR-pcDNA3.l plasmids were incubated without (Ctr) and with (Bu)l-
cAMP (cAMP) for 24 hours. A) Relative StAR activity compared to Ctr-WT; values are 
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the mean of three different experiments. B) After electrophoresis and transfer on 
membranes, proteins were revealed using a mouse anti-StAR antibody: results are from 
three different homogenate preparations. C) Quantification of the protein bands obtained 
in B. *p < 0.05 compared to their own control value; tp < 0.05 compared to Ctr-WT. 
FIGURE 9. Profile of the change in free Gibb' s energy. Graphical representation of the 
results obtained in Figs. 4 and 6; the letters represent the same conformations as in these 
figures. Under normal conditions, StAR is in equilibrium between to the native and 
partially unfolded states (A vs C). Approx. 2% of the StAR population is expected to be 
in the partially unfolded state. Note that the opened state B should not be existent other 
than to go change from the native to partially unfolded state and vice versa (A to C and C 
to A). Upon cholesterol binding, the cholesterol bound partially unfolded StAR is slightly 
more stable than the native state (D vs A, respectively) therefore shlfting the equilibrium 
of the population of StAR to the partially unfolded state. Half of the partially unfolded 
cholesterol bound StAR population bas the loops closed on top of the cholesterol (E; 
population° = populationE). The partially refolded StAR (E) can tben return to the 
partially unfolded empty StAR (C) if cholesterol is released, or irreversibly trap 
cholesterol inside StAR's cholesterol binding site if cholesterol is not released (G). In the 
latter case, the transient refolded C-terminal a-helix with the open binding site (F) is not 
believe to exist other than to allow the transition from the partially unfolded to native 
cholesterol bound StAR. Threshold activation between conformational states are arbitrary 
and do not represent experimental data. AG is the change in Gibb's free energy 
sequentially obtained from Figs. 4 and 6. 
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FIGURE 10. Proposed StAR mechanism in the mitochondrial intermembrane space. 
Cholesterol is transferred into mitochondria through the flipping of StAR from the outer 
mitochondrial membrane (OMM) to the inner mitochondrial membrane (IMM). In the 
intennembrane space at contact sites, the cholesterol deprived native StAR opens and 
Unfolds through the movement of the C-terminal a.-helix (step I, A to C). Close to the 
cholesterol rich OMM, maybe even interacting with it, cholesterol binds to the exposed 
StAR binding site and the loops adjacent the binding site (loop '21 and the loop between 
13-strands 1 and 2) close, covering cholesterol (step II, C to E). The StAR-cholesterol 
complex then tlips on itself to release cholesterol in the IMM after the loops open to 
expose cholesterol (steps m and IV, E to D). If cholesterol is released in the IMM, then it 
can be recycled back to the native/partially unfolded state equilibrium for transport of 
another cholesterol molecule (step Va, D to C). In the event where no cholesterol gradient 
exists to drive the transport of cholesterol inside the IMM, the C-terminal a-helix of the 
partially unfolded cholesterol-bound StAR can then refold on top of cholesterol, 
irreversibly trapping cholesterol inside StAR (step Yb, D to G) and shutting off StAR 
function; equilibrium between the native and partially unfolded state of StAR is re-
established (step I, A to C). The structures, their colors, and their labels are identical to 
Figs. 4 and 6 for consistency. 
FIGURE 11. Proposed StAR mechanism in the cytosol. Cholesterol enters mitochondria 
through the concerted action of a cytosolic StAR with an unidentified factor (?). In this 
case, StAR unfolding is identical to the case where StAR is located in the mitochondrial 
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intermembrane space (Fig. 10), with the exception that StAR now shuttles cholesterol 
from the cholesterol-rich outer mitochondrial membrane to the unidentified 
mitochondrial factor. StAR supposedly remains outside mitochondria until it is marked 
for degradation inside mitochondria. For consistency, the structures, their colors, and 
their labels are identical to Figs. 4, 6, and 10. OMM: outer mitochondrial membrane; 
Tht:IM: inner mitochondrial membrane. 
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FIG 1 
Hum MLN64 230 269 
Ham StAR 66 105 
Hum StAR 67 106 
Hum MLN64 270 309 
Ham StAR 106 145 
Hum StAR 107 146 
Hum MLN64 310 349 
Ham StAR 146 185 
Hum StAR 147 186 
Hum MLN64 350 389 
Ham StAR 186 225 
Hum StAR 187 226 
Hum MLN64 390 429 
Ham StAR 226 265 
Hum StAR 227 266 
Hum MLN64 430 443 
Ham StAR 266 SS 279 
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Phosphorylation and Function of the Hamster Adrenal Steroidogenic Acute 
Regulatory Protein. [Journal Article) Submitted to The Journal of Biological 
Chemistry 1012001 - To be revised. 
Contribution: My greatest contribution in this paper was the molecular modeling analysis of the 
putative phophorylation sites, actively participating in the decision of which mutants to test, and 
their analyses. 
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The steroidogenic acute regulatory protein (StAR) undergoes post-translational changes 
that modify its activity, defined as the quantity of pregnenolone synthesized in co-
transfection experiments of COS-1 cells using F2 (P450scc-adrenodo:lin reductase-
adrenodoxin) and StAR plasmids. Eleven putative phosphorylation sites were mutated in . 
the hamster StAR. Decreases of 30%, 81 o/o and 95% in basal activity were found only for 
the mutants S13A, S185A and S194A respectively. The (Bu)2-cAMP stimulated activities of 
the mutants S185A and S194A were 40% and 89% lower than other preparations. Control 
and (Bu)2-cAMP stimulated activities of the S194A mutant were significantly lower than 
those of the S194A/Sl3A and S194A/Sl85A double mutants. The 2D-PAGE migration 
patterns of stimulated preparations revealed many low pl StAR specfes, presumably 
phosphorylated, in WT, S13A and S185A, but absent in S194A preparations. Substitution 
of 8185 by D or E residues to mimic phosphorylation resulted in decreased activity, and 
since the quantity of expressed StAR was simllar between preparations, we can conclude 
that S185 is not a site of phosphorylation. According to a 3D-model of StAR, 8194 is 
located at the exterior of the molecule and accessible to kinases, whereas S18S is hidden 
inside the protein and not accessible to kinases. However, S18S is located near a saline 
bridge that may be involved in the mechanism of cholesterol binding since it is the only 
hydrophilic component of the cholesterol-binding site. This suggests that mutation of S18S 
alters the binding site environment, changing its affinity for cholesterol and consequently 
decreasing StAR activity. 
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The rate limiting step of steroidogenesis is the delivery of cholesterol to the matrix side of 
inner mitochondria membrane where resides the cholesterol side-chain cleavage cytochrome 
P4SO (P450scc)1, the enzyme catalyzing the transformation of cholesterol to pregnenolone (1). 
The transfer of cholesterol into mitochondria across the inter-membrane aqueous space and 
steroidogenesis are both inhibited by the protein synthesis inhibitor cycloheximide (2;3). 
In lipoid congenital adrenal hyperplasia, mutations in the steroidogenic acute regulatory 
protein (StAR) gene were shown to be responsible for defective steroidogenesis (4-9). In vitro, 
the expression of StAR was shown to induce steroidogenesis without hormonal stimulation (1 ). 
Furthermore, impaired steroidogenesis and lipid accumulation in steroidogenic tissues was 
obtained in StAR gene nullizygous mice produced by homologous recombination with identical 
phenotYJ>e (10). This genetic and biochemical evidence bas indicted StAR as a key molecule in 
regulating cholesterol transfer across the mitochondria membrane and consequently in 
controlling the transformation of cholesterol to pregnenolone. 
Up to now three models have been proposed to describe the mechanism of action of StAR on 
the cholesterol entry into mitochondria. One model suggests cholesterol desorption from the 
outer side of the outer membrane to the inner membrane (11 ). The second model proposes that 
StAR is active as a molten globule (12). In the third model, cholesterol is transferred via an 
intermembrane shuttle mechanism (13). 
Two main factors are regulating steroidogenesis in the adrenal cortex, adrenocorticotropin 
hormone (ACTH) and angiotensin Il (Ail), both regulating steroid formation at the site of 
transformation of cholesterol to pregnenolone (14). We have demonstrated that ACTH 
administration (15-17) and sodium restriction (18) in vivo affected the formation of different 
species of StAR in rat (16-18) and hamster (1 S) adrenals. 
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The labeling of phosphoproteins upon ACTH and gonadotropin treatment of steroidogenic 
cells were reported well before their identification as StAR (2;19-25) and recently using 35S-
methionine or 32P-orthophosphate, Arakane et al. (26) showed that ACTH and Ali affected the 
labeling of 30 kDa phosphoproteins in steroidogenic cells. Moreover, using COS-1 cells to 
express human StAR, a mutation of a potential site for protein kinase A-mediated 
phosphorylation at serine 195 to alanine (Sl95A) reduced 32P incorporation from labeled ATP to 
StAR. The capacity of that mutant to induce pregnenolone production was reduced by 50%, 
indicating the importance of phosphorylation as part of the mechanism of action of this protein to 
control steroidogenesis. Up to now, the remaining capacity of transfected COS-1 cells by the 
S l 95A to synthesize pregnenolone has not been attributed to other phosphorylation sites and no 
systematic studies have been completed to cover this aspect. 
Since the first report on the mouse StAR cDNA (1), StAR cDNA were cloned from twelve 
other animal species including the hamster (15). By alignment analysis of the amino acid 
sequences of ail these StARs, we have found that eleven putative phosphorylation sites were 
conserved among most animal species. In order to determine if these putative phosphorylation 
sites were part of the mode of action of StAR, we have mutated these eleven conserved 
sequences in the hamster StAR and studied their effect on pregnenolone synthesis in transfected 
COS 1 cells. 
EXPERIMENTAL PROCEDURES 
Materials-All restriction and modifying enzymes were purchased from New England Biolabs 
(Mississauga, ON, Canada). The expression vector pcDNA3.1Myc-His, Lipofectamine and 
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oligonucleotides were purchased from Invitrogen Canada Inc. (Burlington, ON, Canada). All 
vectors were amplified in XLl Blue E. coti competent cells (Stratagene, La Jolla, CA), and 
purified on anion-exchange columns (Qiagen, Chatsworth, CA). TP A and (Bu)2-cAMP were 
obtained from Sigma-Aldrich (St-Louis, MO). 
Hamster StAR mutagenesis by PCR-The hamster StAR cDNA was isolated and cloned as 
previously described (lS). StAR sequences of man (27), horse (28), pig (29), sheep (30), cow 
(31), rat (32), mouse (1), hamster (15), chicken (33), frog (33), zebra fish (33), rainbow trout 
(34) and brook trout (35) were obtained from Genbank and aligned by Clustal method using 
Lasergene software from DNASTAR Inc. Madison WI. Putative phosphorylation sites were 
determined using PhosphoBase v2.0, a database of phosphorylation sites provided by Center for 
Biological Sequence Analysis at the Technical University of Denmark 
(http://www.cbs.dtu.dk/databases/PhosphoBase). Site-directed mutagenesis was performed by 
PCR (36). Brietly, two series of PCR amplifications were obtained using the following 
conditions: Hot start of S min at 94°C (without DNA polymerase) followed by a touch down of 
2°C from 94°C/70°C/72°C to 94°C/S0°C/72°C, completed with 30 cycles of 94°C/S0°C/72°C and 
a final 72°C elongation of 15 min. The first series consists of amplifying hamster StAR cDNA in 
two differentreactions. 1) A wild type (WT) upstream (sense) oligonucleotide to the downstream 
mutant (antisense) oligonucleotide at the site of interest for mutagenesis and 2) a mutant sense 
oligonucleotide from the site of interest for mutagenesis to a WT antisense oligonucleotide. The 
second series consists of pooling both PCRs previously obtained, purified by agarose gel 
electrophoresis, and amplifying using WT 5' and 3' oligonucleotides. WT-StAR and all mutants 
were cloned into pcDNA3.1Myc-His using unique Eco RI and Hind m restriction sites, and 
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entirely sequenced between these restriction sites using T7 sequencing kit Crom Amersham 
Phannacia Biotech (Baie d'Urfé, QC Canada), amplified, and purified on Qiagen anion-
exchange columns. 
Hamster StAR expression-Either WT or mutated StAR was transieJ).tly transfected into monkey 
kidney COS-1 cells (American Type Culture Collection, Rockville, MD) using the lipofectamine 
method. Twenty-four hours before transfection, the cells were harvested witb. pancreatin-EDTA 
solution (lnvitrogen Canada Inc., Burlington, ON, Canada) and plated at an initial density of 3.5 
x 105 cells per 10 cm2 well in 6-well plates, or 1.6 x 106 cells in 78.5 cm2 Petri dishes. Cells were 
cultured in DMEM supplemented witb. 10% fetal bovine serum (FBS), 5.96 glL HEPES, 2.2 glL 
NaHC03, lmM L-glutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin sulphate. 
DMEM containing no fetal bovine serum and no antibiotics was used for transfections. Each 
transfection assay received 1 µg of DNA (500 ng F2 construct (37) containing P450scc-
adrenodoxin reductase-adrenodoxin and 500 ng of pcDNA3.1 + pcDNA3.1-StAR) and 10 µg 
lipofectamine in one ml of media. Twenty-two hours after transfection cells were rinsed witb. 
PBS. Cells were then incubated for 24 hours in DMEM without phenol red containing 10% 
dextran-coated charcoal-treated FBS and antibiotics witb. or without stimulating agents. Media 
were kept for pregnenolone quantification and cells for immunoblotting analyses. 
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Measurement of the hamster StAR activity-In this study, StAR activity is defined as the quantity 
of pregnenolone formed by co-transfected COS-1 cells with F2 and StAR plasmids. 
Pregnenolone formation was analyzed by radioimmunoassay (ICN Pharmaceuticals, Diagnostics 
Division, Orangeburg, NY). 
lmmunoblotting analysis-For lD-SDS-PAGE analyses, cells were scraped and directly harvested 
in hot ( l 00°C) Laemmli buffer. Ali samples were then passed through a 26 gauge needle, then 
boiled for 10 min and finally centrifuged at 12000 x g for 2 min. Protein levels were determined 
on the supematant using the Bio-Rad Protein Assay Dye Reagent (Bio-Rad Laboratories, Ltd. 
Mississauga, ON, Canada). For 20-PAGE analyses, cells were scraped and harvested in the 
homogenization buffer containing 50 mM Tris pH 7.4, 0.25 M sucrase, 5 mM EDTA and 
complete protease inhibitor cocktail tablets (Roche Diagnostics Canada, Laval, QC, Canada). For 
mitochondria preparations, cells w~e suspended in the homogenization buffer and were 
sonicated for 7 seconds. The degree of cell rupture was verified under microscope. When totally 
ruptured, the cell preparation was centrifuged l 0 min at 900 x g, only the supernatant was kept 
and centrifuged at 15 min at 9500 x g. The mitochondria pellet was resuspended in 75. µl 
homogenization buffer and 25 µI Laemmli buffer ( 4X) (38). 
For lD-SDS-PAGE, soluble proteins were electrophoresed on 12% polyacrylamide gels and 
analyzed by immunoblotting as previously described (39;40) using a rabbit polyclonal anti-mouse 
StAR antibody (41). 
Immunoreactive proteins were detected using ECL-PLUS light emitting reagents (Amersham 
Pharmacia Biotech UK Ltd., Amersham Place, Little Chalfont, Buckinghamshire, UK). 
Autoradiograms were observed by exposing the blots to Kodax X-Omat XK films. The results 
105 
were also visualized and quantified on the optical imager STORM 860 using ImageQuant software 
version 5.0. (Molecular Dynamics, Sunnyvale, CA). For 20-PAGE, gel rods (llO mm x 4 mm) 
were made witb SM urea, 4.5% polyacrylamide, 2% triton X-100 and 2% ampholines (0.67% pH 
3-10 and l.33% pH 5-7). Prefocusing (0.66mA per gel rod) was performed during 1 h with a 500 
V maximum limit in NaOH O.lN (catholyte) and 0.06% phosphoric acid (anolyte). Soluble 
proteins from mitochondria preparations were diluted with two volumes of sample dilution buffer 
which contained: 9.5 M urea, 10% triton X-100, 2% ampholines, and 5% 13-mercaptoethanol (v/v). 
Samples were loaded and overlaid witb SM urea, 2% triton X-100 and 2% ampholines. Constant 
400 V were applied for 9000-10000 Volt•hours. Gel rods were equilibrated 2 x 20 min in a 
reducing buffer (62.5mM Tris, pH 6.8, 5% P-mercaptoethanol, 3% SOS, 0.01% bromophenol 
blue). Reduced rods may be stored at-80 • C until used. Thawed rods were tixed with 1 % agarose 
in upper buffer (125mM Tris, pH 6.8, 0.1 % SOS). Sodium dodecyl sulfate-PAGE and 
immunoblotting were performed as described above. Isoelectric points (pl) were determined using 
20-PAGE standards # 161-0320 from Bio-Rad Laboratories (Mississauga, ON, Canada). In 
addition, in some experiments, standards and adrenal preparations were mixed and ran on the same 
gel. After transferring on membranes, standards were stained and StAR was detected as described 
for 10-SOS-PAGE. 
Statistical analyses-Oifferences between experimental groups were analyzed by one way 
ANOVA using the SigmaStat program for Windows (SPSS Science, Chicago IL). 
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RESULTS 
A strong amino acid sequence identity exists between StAR indexed from thirteen different 
vertebrate species. These StARs undergo post-translational changes, which can modify protein 
activity. Indeed, StAR contains putative phosphorylation sites for protein kinases A (PKA), 
protein kinase C (PKC), and casein kinase 2 (CK2). StAR amino acid sequences were thus 
analyzed in silico to determine putative phosphorylation sites conserved among species. Out of 
nineteen putative sites discovered, eleven of them were shown to be conserved among most 
mammal species including the hamster {Table 1). The hamster StAR serines (S) 13, S55, 856, 
S60, S68, 890, 8185, S194, 8276, threonines (T) 5 and T262 putative phosphorylation sites were 
thus mutated; T by valine (V) and S by alanine (A) respectively, in order to systematically study 
their role in 8tAR activity. 
To test StAR activity (defined as the quantity of pregnenolone formed by transfected cells), 
COS-1 cells were co-transfected with the expression plasmid F2 (harboring P450scc-
adrenodoxin reductase-adrenodoxin) and pcDNA3.l-8tAR. Fig.1 shows the enhancing effect of 
increasing concentrations of wild type (WT) StAR DNA in transfection media on StAR activity. 
In this series of experiments, basal activity of cells co-transfected with the empty pcDNA3.1 
vectorand F2 was 47 ng pregnenolone / 3 x 105 cells, and this activity was increased to 348 ng in 
the presence of 75 ng pcDNA3.1-WT-StAR. At this DNA concentration (Bu)2-cAMP further 
stimulated the production of pregnenolone to 1037 ng whereas TPA appeared to have no 
enhancing effect on basal 8tAR activity (results not shown). A background corresponding to 27 
ng pregnenolone in C08-l cells transfected with F2 and pcDNA3.l plasmids was subtracted to 
experimental values. 
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In the next series of experiments, COS-1 cells were co-transfected with the F2 construct and 
either the WT-StAR or mutated-StAR plasmids. Compared to WT, basal StAR activity was not 
affected for mutants TSV, SSSA, SS6A, S60A, S68A, S90A, T262V and S276A (Fig.2A). 
However, StAR activity was significantly decreased by 30%, 81 % and 95% witb the mutants 
Sl3A, Sl85A and Sl94A respectively. When (Bu)2-cAMP was added to the incubation media, 
the activity of all preparations was increased. lncreases observed for the mutants were 
comparable to that ofWT except for mutants Sl85A and Sl94A (Fig.2B). lndeed, the increase in 
activity ofthese two mutants was 40% and 89% lower than that ofstimulated WT. Interestingly, 
the (Bu)2-cAMP stimulated activity of the mutant Sl3A was comparable to that of the WT. 
Compared to their own control, the presence of TP A in incubation media did not change StAR 
activity of any preparation (Fig.2C). 
Fig.3 shows the effects of the double mutations Sl85A/Sl94A and Sl3A/Sl94A, and of the 
triple mutation Sl3A/Sl85A/Sl94A on StAR activity. The double mutant Sl85A/Sl94A and 
triple mutant Sl3A/Sl85A/Sl94A had practically no StAR activity, pregnenolone formed being 
similar to that of the empty pcDNA3. l vector. Ctr-S 13A StAR activity values were signiticantly 
different from Ctr-S l 94A values; Ctr-S l 94A values were significantly different from Ctr-
S 194A/S l 3A values; (Bu)2-cAMP-Sl3A values were sign.ificantly (p< 0.05) different from 
(Bu)2-cAMP-Sl94A values and (Bu)2-cAMP-Sl94A values were significantly different from 
(Bu)2-cAMP-Sl94A/Sl3A values. Compared to other preparations, the stimulated StAR activity 
levels of the mutants decreased in the following order: WT > Sl3A > Sl94A > Sl94A/Sl3A > 
Sl85A/Sl94A = Sl3A/Sl85A/Sl94A = pcDNA3.l. In this series of experiments, the presence 
of TP A in incubation media did not enhance StAR activity of WT or mutants (not shown). 
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We have further studied the implication of S 194 amino acid residue on StAR activity after 
deleting the first 46 amino acid residues fonning the N-terminal mitochondrial import leader 
sequence. For better immunoblotting analysis, 200 ng of StAR pcDNA3.l plasmid were used in 
subsequent co-transfection experiments. Fig.4A shows that both full length and truncated StAR 
were expressed in transfected COS-1 cells. As expected, the truncated protein migrated faster on 
lD-SDS-PAGE than its full-length counterpart. One main StAR band was revealed for the 
truncated protein in comparison of two for the full-length. The intensity of protein bands from 
the full-length Sl94A preparations was similar to that ofits full-length control WT. Higher StAR 
levels were found for the full-length S 194A and WT preparations when cells were stimulated by 
(Bu)2-cAMP. Similarly the intensity of protein bands from the truncated N46-Sl94A 
preparations was similar to its control N46-WT. Higher StAR levels were found for the truncated 
N46-Sl94A and N46-WT preparations when cells were stimulated by (Bu)2-cAMP, although the 
levels of StAR were once again similar in both preparations. The full-length and the truncated 
'N46-WT' proteins had similar basal and (Bu)2-cAMP stimulated activities respectively 
(Fig.4B). The basal activity of the full-length Sl94A mutant was significantly decreased 
compared to the full-length WT confmning results shown in preceding figures. In contrast, the 
N46-Sl94A mutant basal activity did not differ from that of the truncated N46-WT although its 
activity was only slightly increased by (Bu)2-cAMP. 
Fig.SA compares the levels of StAR expression between truncated N46-Sl85A, N46-S194A 
and N46-Sl85A/Sl94A; Fig.SB shows their relative StAR activities. Control experiments were 
also performed using full-length StAR cDNAs. The basal protein expression levels of the full-
length WT and mutants preparations were similar and these were similarly increased with (Bu)2-
cAMP. Also, the basal protein expression levels of the truncated N46-WT and N46-mutants 
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preparations were increased with (Bu)2-cAMP. Data obtained for StAR activity of full-length-
WT and -mutant preparations confirm results shown in preceding figures. However, in contrast 
to the N46-Sl94A mutant, the basal activities of the N46-S185A and N46-Sl85A/Sl94A 
mutants were lower than the activity of their full-length counterparts. Dibutyryl-cAMP slightly 
but significantly increased the activity of the N46-Sl94A mutant (Fig.4B) and had no effect on 
the N46-Sl8SA nor on the N46-S18SA/S194A double mutant. These results indicate that both 
Sl85 and S194 amino acid residues are important for StAR activity although when mutated they 
appear to affect differently StAR activity. 
Upon pbosphorylation, StAR becomes more acidic generating species with different pl. 
Pbosphorylated species can be separated on two-dimensional polyacrylamide gels (20-PAGE) 
by first using isoelectrofocusing and then electrophoresis. 
When proteins from wbole COS-1 cells were analysed by 20-PAGE and Western two main 
StAR immunoreactive bands were revealed for Ctr-WT cells with pl of 5.9 and 5.7 and 
migrating in the 30 kDa area (Fig.6A). These two bands are common to ail other preparations 
sbown on this figure. Other paler bands were also revealed as seen on the right of the figure. 
Almost identical patterns were observed when Ctr-StAR and mutated S13A, Sl8SA and Sl94A 
preparations were analyzed (not shown). 
The addition of (Bu)2-cAMP to the incubation media however, resulted in the formation of 
many StAR species circled in black in Fig.6B. Among the mutant preparations S194A, S18SA, 
Sl3A, it is the migration pattern of the S194A mutant that differed the most from WT. Empty 
circles show the location of the main low pl StAR species present in WT (Fig.6B) but absent in 
the S194A mutant (Fig.6C). An additional band pointed by an arrow was revealed for the Sl94A 
mutant (Fig.6C). Empty circles in panels 0 and E also show the location of bands revealed in 
110 
(Bu)2-cAMP-WT and absent in Sl85A, Sl3A preparations. Furthermore tbree additional StAR 
species were revealed in the S 13A preparation pointed by the three arrows. 
Isolated mitochondria and supernatant preparations from transfected COS-1 cells with WT-
StAR-pcONA3.l and stimulated with (Bu)2-cAMP were analyzed by Westem using an anti-
StAR antibody. StAR was found nearly exclusively in mitochondria preparations (not shown) . .. 
Therefore, in order to improve the resolution on 20-PAGE, we have used StAR enriched 
mitochondria preparations to compare WT and mutant electrophoresis profiles. When 
mitochondria preparations were separated by 20-PAGE and analyzed by immunoblotting, four 
StAR bands were revealed for the control-WT (Fig.7A). The two right protein bands migrated in 
the 33-34 kDa area, and for the two lower bands which have pl values of 5.9 and 5.4 
respectively, migrated in the 29-30 kDa area. These two latter species indicated by arrows are 
common to ail other preparations shown on this figure. Very similar patterns were observed 
when mutated StAR (Sl85A and Sl94A) was analyzed (not shown). However, the addition of 
(Bu)2-cAMP to the incubation media of transfected cells resulted in the formation of many acidic 
StAR species as shown for the WT (Fig.7B). The migration pattern. of the Sl94A mutant 
incubated with (Bu)2-cAMP greatly differed from the WT. Empty circles show the location of 
the main low pl StAR species present in WT but absent in the Sl94A mutant (Fig.7C). In 
contrast, the migration pattern of the Sl85A mutant preparation stimulated by (Bu)2-cAMP did 
not differ a great deal from WT although proteins appeared more clustered in the 33-34 kDa area 
(Fig.70). Circles effectively show that absent protein bands for the Sl94A mutant are present in 
the Sl85A mutant preparation. The double mutation Sl85A/Sl94A lead to a migration pattern. 
(Fig.7E) resembling that of the Sl94A mutant, also suggesting that the loss of acidic species 
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could be attributed to the S194A mutation. These results indicate that the mutation of serine 194 
prevents the formation or entry of low pl StAR species into mitochondria. 
Two-dimensional analyses were also perfonned on mitochondria preparations of StAR ftom 
transfected COS-1 cells incubated with TP A. In this situation, StAR activity was not increased in 
WT and mutant preparations as compared to their own control (Fig.2C). The electrophoretic 
patterns of TPA-WT, TPA-S185A and TPA-S194A mitochondria preparations (FigS.B-D) were 
similar. However, the intensity of the four left StAR bands circled on panels B-D appeared 
stronger in TP A treated than in control samples. Moreover, an additional band was detected in 
the TP A treated samples when compared to control, as shown by the left-circled species in the B-
D panels. These results indicate that TP A did not enhance the presence of StAR into 
mitochondria as much as did (Bu)2-cAMP. They also indicate that TP A did not favor the 
formation or presence of low pl StAR species into mitochondria as did (Bu)l-cAMP (see 
Fig.7B). 
The hamster StAR amino acid residue S194 corresponds to the conserved S195 in human and 
Arakane et al. (26) have efficiently demonstrated that this amino acid residue was 
phosphorylated upon (Bu)2-cAMP stimulation. Yet, nothing is known about the putative 
phosphorylation site Sl85 in the hamster, which is the equivalent to the conserved Sl86 in 
human. To contirm that the hamster S185 could effectively be phosphorylated, we have done 
three additional mutations. We have substituted the serine to the charged glutamic acid (E) or 
aspartic acid (D) residues in order to mimic phosphorylation. We have also substituted the serine 
into a cysteine (C), effectively replacing the serine OH group by a SH group. The SH group bas 
similar properties to the OH group but cannot be phosphorylated. Compared to WT, Sl85E and 
S185D mutants had a decreased basal StAR activity similar to that of the S18SA mutant 
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(Fig.9B). In addition, the activity of these two mutants was not stimulated by (Bu)2-cAMP. In 
contrast to these, the substitution of S 185 by a cysteine residue resulted in a partial recovery of 
basal StAR activity; this activity was stimulated by (Bu)2-cAMP. As analyzed by Western, the 
basal and (Bu)2-cAMP stimulated levels of StAR expression were not decreased by the 
mutations Sl85A, Sl85E, Sl85C (Fig.9A) and Sl85D (not shown). This indicates that the 
change in StAR activity by the mutants was due to the amino acid substitutions and not to 
differences in protein levels. These results also demonstrate that S 185 is not a site of 
phosphorylation for the hamster StAR. 
DISCUSSION 
A strong homology exists between StAR amino acid sequences of the thirteen vertebrate 
species indexed in Table 1. We took advantage of the fact that many phosphorylation consensus 
sites were conserved among these species to elaborate a strategy to study putative StAR 
phosphorylation sites on the hamster StAR. In order to verify StAR activity alterations, we have 
used a previously validated StAR activity test model (37). In this series of experiments this test 
consisted in the measure of cholesterol conversion into pregnenolone by COS-1 cells co-
transfected with expression plasmid F2 and pcDNA3.l-StAR. We have established (Fig.l) that a 
ratio StAR plasmid I F2 plamid in the range of 75-200ng I SOOng was suitable for the assay with 
or without (Bu)2-cAMP stimulation. Furthermore, differences in StAR activity that we observed 
between Ctr-WT, (Bu)l-cAMP-WT and TPA-WT preparations was not due to a difference in the 
level of P450scc-adrenodoxin reductase-adrenodoxin expression. Indeed, the expression levels of 
this protein complex, as analyzed by Western blotting using either an anti-P450scc antibody or 
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an anti-adrenodoxin antibody, were found similar under control and stimulated conditions (not 
shown), therefore showing that the cholesterol side chain cleavage system was not causing the 
changes in StAR activity under (Bu)2-cAMP stimulation. 
The basal activity of cells co-transfected with the empty pcDNA3. l vector and F2 plasmid 
was not increased by the presence of (Bu)l-cAMP indicating that a certain quantity of cholesterol 
was transformed into pregnenolone in the absence of StAR. This also indicates that (Bu)2-cAMP 
alone did not act on the passive entry of cholesterol inside mitochondria. Bose et al. (6) have also 
mentioned StAR independent entry of cholesterol into mitochondria. 
In this study, the three most important changes in StAR activity were induced by the 
mutations of Sl94, Sl85 and Sl3 (Fig.2) demonstrating the importance of these sites. On the 
other hand, differences in the inhibition intensity were noticeable between these three mutants. 
Mutation S l 94A afîected the StAR activity the most, followed in a decreasing order by 
mutations S l 85A and S 13A. Another difference is that (Bu)2-cAMP was able to enhance the 
activity of S l 85A well above the WT basal activity whereas the stimulated activity of the S l 94A 
mutant remained under the WT basal activity (Figs 2-5). This shows the relative importance of 
these two amino acid residues on StAR activity. 
The smaller but significant decrease (30%) in the basal activity of ~tAR induced by the 
mutation Sl3A suggests that this amino acid residue also plays arole in the mode of action of 
this protein. This role is emphasized by the fact that the double mutant Sl3A/Sl94A had 
significant (p < O.OS) lower basal and (Bu)l-cAMP stimulated activity respectively than that of 
the mutant Sl94A. Yet, we cannot interpret the fact that no significant difference in activity was 
found between Sl3A mutant and WT StAR when (Bu)l-cAMP was added to both incubation 
media. It is possible that other mechanisms overrule the importance of this site under acute 
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stimulation by (Bu)2-cAMP. Another possibility is that experimental variations between samples 
is too large to obtain a significant decrease in StAR activity between (Bu)2-cAMP stimulated 
Sl3A and WT preparations. The other putative phosphorylation sites tested involving T5, 855, 
S56, 860, S68, 890, T262 and S276 are not likely involved in 8tAR activity since removal of the 
putative phosphorylation sites of these amino acid residues did not affect StAR activity (Fig.2) 
nor their level of expression (not shown). In COS-1 cell transfection experiments in the presence 
of [y-32P] ATP, mutation of the human StAR serine residues 57 and 195 by alanine decreased 32P 
incorporation into the molecule (26). The S195A mutation resulted in a decrease whereas 
mutation 857 A had no effect on pregnenolone synthesis in transfected COS-1 cells. In agreement 
with these authors, mutation of the hamster StAR S56 corresponding to the human S57, had no 
effects, whereas mutation of the hamster StAR Sl94 corresponding to the human S195, 
decreased pregnenolone synthesis in transfected COS-1 cells. 
Deleting the N-terminal first 46 amino acid residues including the mitochondrial import 
sequence resulted in the formation of only one main StAR band migrating on lD-SDS-PAGE 
(Fig.4}, having a molecular weight lower than the two main bands revealed for the full-length 
molecule preparation (in the 29 kDa vs 31 and 33-34 kDa regions). The calculated molecular 
weight of the full-length and the cleavage site products of the hamster StAR-Myc-His are 34 
315, 29 979 and 29 265 Daltons respectively, which are close to our obtained experimental data. 
The fact that the truncated protein migrated faster than the second band of the full-length 
preparation could be due to the presence of two protease cleavage sites in the leader peptide of 
the hamster StAR (15), and that in C08-l cells, StAR was presumably processed predominately 
at the first N-terminus proteolytic site between amino acids 38 and 39 of the full-length 
preparation. 
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The decrease in basal StAR activity of the Sl94A mutant was not due to a difference in the 
quantity of proteins since the intensity of StAR bands from the full-length Ctr-Sl94A 
preparations was similar to that the full-length Ctr-WT (see histograms, Figs 4A and SA). 
Similarly, the quantities of proteins were comparably increased when both preparations were 
stimulated by (Bu)2-cAMP. These results clearly indicate that the mutation perse, and not the 
protein expression level was the cause of the decrease in activity of the Sl94A mutant. The 
double mutation Sl8SA/Sl94A completely abolished basal and (Bu)2-cAMP stimulated StAR 
activity of the full-length and N46 truncated preparations (Fig.S) indicating that the protein had 
been considerably altered by these two modifications. Once again, under identical incubation 
conditions, the quantities of proteins were comparable between WT and mutated preparations 
confirming that activity changes were not due to differences in protein levels. 
From the results of the N46-truncated proteins, we observed that the Ctr-'N46-WT' activity 
was equal to the full-length Ctr-WT (Figs.4B and SB), both preparations being similarly 
stimulated by (Bu)2-cAMP. This confirms that the presence of the mitochondrial import 
sequence is not mandatory for full StAR activity. Our results are in agreement with those of 
Arakane et al. ( 42) that show that recombinant StAR lacking the import sequence promoted 
steroid production in a cell-free system containing mitochondria. 
Interestingly, the mutation Sl94A in the N46-truncated protein only lowered the basal StAR 
activity slightly compared to the great inluoition observed for its full-length counterpart (Fig.4B). 
Again, no difference in the quantity of proteins was found compared to their relative control. 
However, StAR activity of the N46-Sl94A was not stimulated much in the presence of (Bu)2-
cAMP although the quantity of immunoreactive proteins was doubled compared to its own 
control and was equal to that of the (Bu)2-cAMP stimulated 'N46-WT'. These results confirm 
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again that an increased quantity of StAR per se is not sufticient to explain changes in StAR 
activity and also stresses the importance of an intact S 194 amino acid residue for the 
development of full activity. 
Then, how to explain that basal StAR activity of Ctr-N46-Sl94A is equal to that of the full-
length Ctr-WT, and higher than that of the full-length Ctr-Sl94A? One explanation could be that 
the elimination of the first 46 amino acid residues would expose a StAR surface area favorable to 
the interaction of the molecule with the outer mitochondrion membrane and to the entry of 
cholesterol. Indeed, according to Tsujisita et al. (13) the START architecture appears well 
designed to bind and solubilize a lipid monolayer. 
Therefore, one can speculate that the intact Sl94 residue in the full-length WT would serve at 
least two functions. One function of the phospborylated S 194 amino acid residue would be to 
overcome the rigidity conferred to the molecule by the presence of the mitochondrial import 
sequence under basal conditions. The second fonction of the phosphorylated S194 amino acid 
residue would be to favor the transfer of cholesterol into the mitochondrion. This is evidenced by 
the fact that, although equally expressed, the StAR activity ofN46-Sl94 is lower than that of the 
'N46-WT' (Fig.4A). It is possible that the 8194 phosphorylation would produce conformational 
changes of the StAR molecule that could enhance cholesterol transfer into mitochondria. 
Another possible mode of action of the phosphorylation of S 194 could be through increasing 
StAR stability. Using Yl cells and mutant Kin-8 cells lacking PKA expression, Clark et al. (43) 
proposed that phosphorylation of StAR by PKA might contribute to protein stability. Their 
conclusion was based on the fact that upon (Bu)2-cAMP stimulation, increased StAR protein 
synthesis was observed for both cell types, but in contrast to Yl cells, without a relative 
corresponding increase in steady state levels of StAR protein in Kin-8 cells. In this respect, the 
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increased StAR levels we observed when transfected cells were stimulated by (Bu)2-cAMP (Figs 
4A, SA and SA) could be due to an increased StAR stability since no general increase in total 
cell proteins was found (not shown) under these experimental conditions. 
Using fluorescence energy transfer analysis, West et al. (30) reported that StAR and 
Peripheral-type Benzodiazepine Receptor (PBR) are closely associated in mitochondrial 
membranes and that these molecules may interact in the transportation of cholesterol. However, 
the interaction between StAR and PBR is yet to be definitely established and experiments 
performed up to now to demonstrate any interaction between StAR and mitochondrial membrane 
proteins have not been conclusive. In fact, Kallen et al. (44) demonstrated that StAR could 
promote cholesterol transfer to mitochondria in which the outer membrane proteins have been 
removed by partial proteolysis with trypsin. This suggests that StAR does not have protein 
binding partners on the outer mitochondrial membrane and can instead interact directly with 
membrane phospholipids. 
Another interesting observation is that the full-length S 1 SSA mutant could be stimulated by 
(Bu)2-cAMP but not its N46-truncated counterpart. This suggests that StAR was dramatically 
altered by the mutation S18SA in the absence of the mitochondrial import sequence in a way that 
the mutant activity could not be even partially rescued by phosphorylation ofS194. 
StAR becomes more acidic upon phosphorylation giving rise to species with different pl 
which can be separated by 20-PAGE and revealed by immunoblotting. The 2D-protiles did not 
differ much between unstimulated WT and mutants S13A, Sl85A and Sl94A using either whole 
COS-1 cell proteins or isolated mitochondrial preparations. Under (Bu)2-cAMP stimulation 
bowever, many StAR species were revealed on immunoblots (Figs 6 and 7). These results are in 
agreement with th.ose of Kim Y-C et al. ( 45) who identified eight StAR species migrating in the 
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28 and 30 kDa region in bovine adrenal cell mitochondrial preparations upon hormonal 
stimulation. Similarly, many species were also revealed in mitochondrial preparations of rats 
injected with ACTH (18). 
The 20-profiles ofWT and Sl94A preparations differed in many aspects under (Bu)2-cAMP 
stimulation. Many acidic species were missing in the Sl94A (Figs 6 and 7) suggesting that less 
phosphorylation had occurred in these preparations compared to WT. Fig.6E demonstrates that 
mutation ofS13 could affect the 20-migration pattern ofStAR: two species present in WT being 
absent in the mutant and three new species being generated. lt thus appears that S 13 could be 
involved somehow in the control of StAR action through phosphorylation. 
Surprisingly the 20-profile of the (Bu)2-cAMP stimulated mutant Sl8SA, which greatly 
affected StAR activity, did not differ much from that of the WT. Most of the low pl species were 
revealed in both preparations (Fig.7C vs. Fig.7B). This result indicates that the mutation Sl8SA 
affected StAR activity by another mean than phosphorylation. Indeed, in subsequent 
experiments, we have demonstrated that the decreased activity of the mutant Sl8SA was not due 
to a blockage of phosphorylation at this position. Substituting the amino acid S 185 by either 
glutamic acid or aspartic acid in order to mimic the presence of a negatively charged group on 
Sl8S resulted in no increase, but rather a decrease in StAR activity. Moreover, substitution of 
Sl8S by a cysteine residue, to replace the serine OH group by a SH group having similar 
characteristics, nearly fully restored basal and (Bu)2-cAMP stimulated activities (Fig.9B ). These 
results thus clearly showed that S 185 is not a phosphorylation site. 
If Sl85 is nota site of phosphorylation for the hamster StAR, then how can we ex.plain that 
mutating this serine inhibited StAR activity? One explanation could be that mutations of SlSS 
created StAR conformational changes resulting in a decrease in its binding aftinity for 
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cholesterol. This explanation is based on the fact that the activity of non-stimulated WT differs 
from that of the Sl8SA mutant although they were expressed at similar levels. This is reinforced 
by the observation that although the (Bu)2-cAMP stimulated WT and Sl8SA mutant were 
similarly expressed and similarly processed by the mitochondrial machinery, the mutant activity 
remained much lower than the WT. Moreover the actiyity of the WT was comparable to Sl8SC, 
a mild mutation created by the substitution of an OH by a SH group suggesting that only a small 
conformation change had occurred. The conformation change produced by the mutations S 1 SSD 
and S 18SE however, should have been more drastic to result in the complete abolition of basal as 
well as (Bu)2-cAMP stimulated activity. 
To fully comprehend the effect of the mutations on the hamster StAR, we have constructed a 
molecular model for the hamster StAR. This model was elaborated according to crystallographic 
data of the human protein MLN64 (13). MLN64 possesses a StAR related lipid transfer 
(START) domain found in StAR and in other proteins (46). 
The details of the hamster StAR modeling are given in an article by Axel Mathieu et al. (47). 
Coordinates of the hamster StAR model are available at http://www.rcsb.org, PDB ID number 
lll.J. Brietly, the generated StAR model was very similar to the MLN64 model issued from 
crystallographic data. Like MLN64, the StAR model shows nine antiparallel P-sheet and four a-
helices. Unlike the MLN64 crystallographic data, our model bas a hydrophobie pocket instead of a 
hydrophobie tunnel. This tunnel was proposed to be the site of cholesterol binding in MLN64 (13). 
According to the graphie model, the hamster StAR serine 194 is located to the exterior of the 
molecule and thus accessible to kinases. As mentioned earlier the hamster StAR amino acid 
residue 8194 corresponds to the conserved 8195 in human and Arakane et al. (26) have 
demonstrated well that tbis amino acid residue was phosphorylated upon (Bu)l-cAMP stimulation. 
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In contl'&St, S 185 is hidden inside the protein and consequently is not accessible to kinases 
(Fig.10). However, 8185 is located near a saline bridge formed by amino acid residues glutamic 
acid (E) 168 and arginine (R) 187. It is possible that this salt bridge is involved in the mechanism 
of cholesterol movement since it is the only hydrophilic component of the cholesterol-binding site. 
This suggests that mutating 8185, especially in the case of 81850 and 8185E, could have resulted 
in a perturbation of the saline bridge environment, which would explain the inhibition of StAR 
activity. 
TP A did not induce any changes in StAR activity (Fig.2C) and did not favor the formation or 
presence of 8tAR low pl species in mitochondria as did (Bu)2-cAMP (Fig.SB). This indicates that 
under the experimental conditions used, the protein kinase C pathway was not involved in 
controlling 8tAR activity in COS-1 cells. It is also possible that PKC isoforms necessary for StAR 
phosphorylation may not be expressed in COS-1 cells. Indeed in bovine adrenal glomerulosa cells, 
the PKC signaling pathway was effective in inducing StAR phosphorylation (48). Similarly, we 
have found an enhanced 8tAR expression in vivo in the adrenal zona glomerulosa of rats fed a low 
sodium diet (18) which increases angiotensin II (14). The inhibitor TPA was also shown to 
increase the expression of 8tAR in NCI-H295 cells ( 49). More work will thus be necessary to 
clarify the real role played by PKC if any in controlling StAR activity. 
In conclusion, we have found that in the hamster StAR, the serine amino acid residue 194 
available to kinases is the most important site of phosphorylation supporting StAR activity. The 
serine residue 13 appears to play a minor mie in maintaining basal 8tAR activity. We also found 
that mutations of amino acid serine 185, replacing serine by aspartic acid or glutamic acid, are 
most likely to produce perturbations at a nearby sait bridge formed by amino acid residue 
glutamic acid 168 andarginine 187. 
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FIGURE LEGENDS 
FIG. 1 COS-1 cells co-transfected with the F2 construct (500 ng) and increasing concentrations 
ofWT StAR-pcDNA3.1 and pcDNA3.l (to a total of 1000 ng of DNA), were incubated without 
(Ctr) or with (Bu)l-cAMP (cAMP) (1mM)for24 hours. Pregnenolone was analyzed by RIA. 
Results are mean ::: SD of values obtained from three different preparations performed in 
triplicate. 
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FIG. 2 COS-1 cells co-transfected with the F2 plasmid (500 ng), different StAR-pcDNA3.l 
plasmids (75 ng) and pcDNA3.l (425 ng), were incubated without or with (Bu)2-cAMP (cAMP) 
(1 mM) or TPA (32 nM) for 24 hours. A) Basal StAR activity. B) The Ctr-WT was incubated 
without (Bu)2-cAMP. C) Ctr values are the same as in panel A. Results are mean :t SEM of three 
different experiments performed in triplicate, except for TP A where the values are the mean of 
two experiments performed in triplicate. In this series of experiments, pcDNA3. l values were 
subtracted to other preparation values. A:*p< 0.05 compared to Ctr-WT; B:*p< 0.05 compared 
to (Bu)2-cAMP stimulated WT. 
FIG. 3 COS-1 cells co-transfected with the F2 construct (500 ng), different StAR-pcDNA3.l 
plasmids (75 ng) and pcDNA3.l (425 ng), were incubated without (Ctr) or with (Bu)2-cAMP 
(cAMP) (1 mM) for 24 hours. Values are the mean ::1: SEM obtained from three different 
experiments performed in triplicate using three different plasmid preparations. In this series of 
experiments, pcDNA3.l values were subtracted to other preparation values. lnterestingly, Ctr-
S 13A StAR activity values were significantly (p < 0.05) different from Ctr-S 194A values, Ctr-
S 194A values were significantly different from Ctr-S194A/Sl3A values, (Bu)2-cAMP-Sl3A 
values were significantly different from (Bu)2-cAMP-Sl94A values and (Bu)2-cAMP-Sl94A 
values were significantly different from (Bu)2-cAMP-Sl94A/Sl3A values. 
FIG.4 COS-1 cells co-transfected with the F2 construct (500 ng), different StAR-pcDNA3.l 
plasmids (200 ng) and pcDNA3.l (300 ng), were incubated without or with (Bu)2-cAMP 
(cAMP) (1mM)for24 hours. A) Immunoblotting analysis is from three different preparations 
performed in duplicate. Twenty µ.g of proteins from total COS-1 cell were used in each lane. B) 
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Relative StAR activity, mean :t SEM of seven different experiments performed in triplicate. •p < 
0.05 compared to Ctr-WT. 
FIG.S COS-1 cells co-transfected with the F2 construct (500 ng), different StAR-pcDNA3.l 
plasmids (200 ng) and pcDNA3.l (300 ng), were incubated without or with (Bu)l-cAMP 
(cAMP) (1 mM) for 24 hours. A) Immunoblotting analysis of three different plasmid 
preparations. Twenty µg of total COS-1 cell proteins were used in each lane. C = Ctr; A= (Bu)2-
cAMP. B) Relative StAR activity compared to Ctr-WT. Values are the mean :t SD obtained from 
three different plasmid preparations performed in triplicate. 
FIG.6 COS-1 cells co-transfected with F2 construct (500 ng), clifferent StAR-pcDNA3.l 
plasmids (75) and pcDNA3 .1 ( 425 ng), were incubated without or with (Bu)l-cAMP ( cAMP~ (1 
mM) for 24 hours. One hundred µg total COS-1 cell proteins of each preparation were separated 
on 2D-polyacrylamide gels, first by electrofocusing and then electrophoresis. Proteins were then 
transferred on membranes and revealed by an anti-StAR antibody. 
FIG. 7 COS-1 cells co-transfected with the F2 construct (500 ng), clifferent StAR-pcDNA3.l 
plasmids (200 ng) and pcDNA3.l (300 ng), were incubated without or with (Bu)2-cAMP 
(cAMP) (1 mM) for 24 hours. Fifty µg mitochondrial proteins of each preparation were 
separated on 20-polyacrylamide gels first by electrofocusing and then electrophoresis. Proteins 
were then transferred on membranes and revealed by an anti-StAR antibody. 
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FIG. 8 COS-1 cells co-transfected with the F2 construct (500 ng), different StAR-pcDNA3.l 
plasmids (200 ng) and pcDNA3 .1 (300 ng), were incubated without or with TP A (32nM) for 24 
hours. Fifty µg mitochondrial proteins of each preparation were separated on 20-polyacrylamide 
gels first by electrofocusing and then electrophoresis. Proteins were then transferred on 
membranes and revealed by an anti-StAR antibody. Ctr-Wt values are the same as in Fig.7A). 
FIG. 9 COS-1 cells co-transfected with the F2 construct (500 ng), different StAR-pcDNA3.l 
plasmids (200 ng) and pcDNA3.l (300 ng), were incubated without or with (Bu)2-cAMP 
(cAMP) (1mM)for24 bours. A) lmmunoblotting was done in duplicate on three different total 
COS-1 cell preparations (20 µg proteins) using an anti-StAR antibody. 8) Relative StAR 
activity. Values are the mean ±SEM ofthree different experiments performed in triplicate. •p < 
0.05 compared to Ctr-WT. 
FJG.10 Localization of serine 185 and serine 194 on the hamster StAR molecular model. Alpba-
helices in red, ~-sheets in blue, loops in white, and Sl85 and 8194 in pink and yellow 
respectively. Left: the model is shown as a ribbon diagram with 8185 and Sl94 as wireframes. 
Rigbt: same representation as on the left, but as an accessible surface diagram. Sl94 is clearly 
accessible for kinases, yet S 185 is not. 
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TABLE I 
Putative phosphorylation sites in StARfrom various animal species 
StAR sequences were obtained from Genbank and aligned by Clustal method using Lasergene 
software from DNASTAR Inc. Madison WI. Putative phosphorylation sites were determined 
using PhosphoBase v2.0, a database of phosphorylation sites provided by Center for Biological 
Sequence Analysis at the Technical University of Denmark 
(http://www.cbs.dtu.dk/databases/PhosphoBase). PK.A, protein kinase A; PKC, protein kinase C; 
CK2, casein kinase II; -, absence and+, presence of a phosphorylation consensus sequence. 
Position T5 813 855 856 860 868 890 8185/ 8194 T262/ 8276/ 
I / / / / 8186 / T263 8277 
856 857 861 869 891 8195 
Kinase PK PK PK PK CK CK CK PKC PKA CK2 PKA 
c c A A 2 2 2 
Hamster + + + + + + + + + + + 
Mouse + + + + + + - + + + -
Rat + + + + + + - + + + + 
Hum an + + + + + + + + + + + 
Porcine + + + + + + + - + + + 
Bovine + + - + + + - + + . + + 
Ovine + + - + + + - + + + + 
Horse + + + + + + - + + + + 
Chicken + - + + + + - + + + -
Froe + + - + + - - + + + + 
Rainbow + + + - + - - + + + -
Trout 
Brook Trout + + + + - - - + + + -
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MOLECULAR MODELING OF THE HAMSTER ADRENAL P450Cl 7 . 
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ABSTRACT 
The cytochrome P450Cl 7 (Cl 7) is the steroidogenic enzyme responsible for the 
conversion of pregnenolone and progesterone to dehydroepiandrosterone (DHEA) 
and A4-androstenedione (AD) respectively. This conversion is achieved by two 
enzymatic activities, l 7a-hydroxylase and 17,20-lyase, located at the same active 
site. In man, the adrenal Cl 7 basically only produces DHEA. We have shown that 
144 
the hamster adrenal Cl7 produces DHEA as well as AD. Moreover, the hamster 
like man produces cortisol as its major glucocorticoid. We can thus compare the 
hamster' s and man's adrenal C 17, and use their differences in order to elaborate a 
strategy for structure-:function studies. We have thus engineered hamster adrenal 
Cl 7 mutants which possess modified enzymatic activities. We also proceeded to . 
elaborate a three-dimensional model of the hamster C 17 to visualise the structural 
impact of these mutati_ons. This model demonstrates that the mutations created are 
not localised at the active site, but rather in surrounding regions. These could 
affect the conformation of the active site, in turn, modulating the l 7a-hydroxylase 
and 17,20-lyase activities. For example, the mutation T202N is located next to 
Val 482 and Val 483 which compose the roof of the active site. This mutation 
decreased both l 7a-hydroxylase and 17,20-lyase activities, indicating the 
importance of the roof of the active site for general functionality of the Cl 7. 
INTRODUCTION 
The specificity of the cytochrome P450C 17 (C 17) towards its substrates differs 
among species. In human and bovine adrenals, Cl 7 hydroxylates both 
pregnenolone and progesterone but selectively produces dehydroepiandrosterone 
(DHEA) in a more abundant concentration than for ll.4-androstenedione (AD) (1-
3). In the case of the guinea pig adrenals, both substrates are hydroxylated but AD 
is the preferred final product (4, 5). In rats and mice adrenals, Cl7 is not 
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expressed but the Cl 7 expressed in the gonads preferentially produces AD (6-9). 
In contrast to other laboratory animais, and like man, the hamster expresses 
adrenal Cl 7 and produces cortisol as its major glucocorticoid (10, 11). We have 
isolated the hamster adrenal Cl7 and demonstrated that it produces both DHEA 
and AD in transiently transfected COS 1 cells, adrenal c~ll suspensions, and 
microsomal preparations (12, 13). Moreover the hamster adrenal Cl 7 is inducible 
by adrenocorticotropin hormone (11). 
Due to the importance of the Cl 7 for the production of cortisol, DHEA, and 
sex steroids, we have decided to study the structure/activity of the hamster 
enzyme. We also elaborated a 3-dimensional model of the hamster Cl7 based on 
the previously published human Cl 7 model (14). 
MATERIAL AND :METHODS 
Ali energy minimi:zation and molecular dynamic studies were performed on 
"Socrates" in San Francisco using AMBER 5.0 program suit, through Secure 
Shell Protocol (http://www.ssh.org/). AU Brookhaven files were renamed using 
"fixatname" of Midas Plus 2.1 in order to be visualized, and the structures were 
visualized with either Midas Plus 2.1 or RasMol 2.7.1; ail images were created 
with RasMol (http://www.klaatu.oit.umass.edu/microbio/rasmol/). The hamster 
Cl 7 amino acid sequence was compared to the human Cl 7 amino acid sequence 
by manually aligning them. Due to the explicit alignment, the human Cl7 
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sequence was immediately replaced by the amino acid side-chains of the hamster 
C 17 using Midas Plus 2.1. This initial model was then subjected to energy 
minimization (1000 cycles) and asymmetrically solvated within a radius of 65 A. 
The asymmetric solvated protein excluded the hydrophobie membrane bound 
region. After the initial 10 picoseconds (ps) molecular dynamics of the solvent 
molecules only, the entire model was subjected to another 100 ps of molecular 
dynamics. The final model represents an average structure of the last 40 ps of 
molecular dynamics, energy minimized for another 1000 cycles using the steepest 
descent method. For more information, examine references 14 and 15. 
RESULTS AND DISCUSSION 
The hamster Cl 7 model obtained (Fig 1) greatly resembles the human Cl 7 
model (14). First of ail, ~ere is conservation of characteristic features of P450 
crystallized proteins (16): A) the formation of a (3-sheet rich region, B) the 
intersecting I-Helix with the adjacent heme prosthetic group, and C) the a-helix 
rich region. In tenns of comparison to the human model, three subtle alterations 
are observed in the hamster Cl7 model, when compared to the human: 1) 
consolidation of the membrane attachment domain, 2) protrusion of the J' -helix, 
and 3) slight modification of the hamster Cl 7 model active site. 
First, the membrane attachment domain defined by the A-, F-, and G-helices, 
along with the (3-sheets (sheets) 1.1-1.3 and 2.1-2.2, is consolidated 
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predominantly by the internalisation of two loops, the first between the F- and G-
helices, and the second between sheets 2.1 and 2.2. Although, the F-G loop is 
likely to be disordered as in P450terp. In addition, the F- and G-helices in the 
hamster Cl 7 model run more parallel than in the human Cl 7 model. 
Secondly, the "J'-helix seems to have been extended frpm its end, causing 
tlattening of the helical structure and rotation of its axis, resulting in a net 
protrusion of the helix outwards from the protein. This affects the region defined 
by the J-J' -loop, J' -helix, and the C-D loop located on the cytoplasmic exposed 
area, opposite the membrane attachment domain. The significance of this 




Tbree Dimensional Madel of the Hamster P450Cl 7. Representation of the hamster 
P450C17 rnodel as seen frorn above the protein. A, P-Sheet rich region; B, I-helix with 
prosthetic berne group; C, a.-Helix rich region; Arrow: substrate entrance. Herne 
prosthetic shown in black wirefra.me, P-sheets as black cartoon arrows, a.-helices in 
black strands, and I-helix in black cartoon strand. 
Finally, in the hamster Cl 7 mode! active site compared to the human Cl 7 
mode!, the I-helix has a large bulge at position Lys302 and kinking at the N-
terminus causing the Thr3 06 ( 17, 18) to be located slightly higher from the heme 
prosthetic group, and allowing the H-I loop to shift closer to the substrate entrance 
defined by sequence between P-sheet 1.5 and B'-C loop. Thus, slight alterations 
in the active site as seen here, appear to define the activity specificity of the Cl 7 
in various species (1-9). 
Much like the human Cl 7 mode! (14), the hamster mode! explains the 
functionality of various mutants. For example, the mutant T202N reduced the 
overall activity of the hamster Cl 7 for both t:.5 and !::. 4-substrates (15). This 
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threonine is located adjacent to the 482 and 483 valines, composing the roof of 
the active site. The change of the threonine to an asparagine in the hamster, results 
in "kinking" of the G-helix, resulting to the overall shifting of the active site 
approximately 0.7 A deeper, closer to the I-helix (15). In conclusion, shifting such 
as obtained by the T202N mutation, certainly results in displacement of the 
' 
substrates such that reactivity is not optimal suggesting that more information 
about activity specificity of the C 17 of various species is to be obtained by 
mutations surrounding the active site rather than directly in the active site. 
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Abstract 
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In order to understand the activity specificity of the hamster cytochrome P450 l 7a-
hydroxylase/17 ,20-lyase (P450c 17), we have studied its structure/activity using three 
hamster P450c 17 recombinant mutants (T202N/D240N/D407H). In transiently 
transfected COS-1 cells, the mutation T202N reduced 17a-hydroxylation of 
pregnenolone and progesterone to 24% and 44% of wild type, respectively, followed by . 
reduced 17,20-cleavage to 71% and 67%, respectively. On the other band, the mutation 
D240N decreased specifically 17 ,20-lyase activity to 61 % of wild type when incubated 
with pregnenolone while the mutation D407H only decreased 17a-hydroxylation to 46% 
when incubated with progesterone. 
To comprehend the altered activity profiles of these hamster P450c17 mutants, we have 
elaborated a three-dimensional model of the hamster P450c 17 and compared it to our 
preceding model of the human P450cl7. Analysis of the mutants with this model showed 
that, without direct contact to the substrates, these mutations transmit structural changes 
to the active site. By analogy, these results support the concept that any cellular changes 
modifying the externat structure of P450cl 7, such as phosphorylation, could have 
influence on its active site and enzymatic activities. 
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1. Introduction 
The cytochrome P450 17a-hydroxylase/17,20-lyase (P450cl7, the gene product of 
CYP 17) is a major branch point in steroidogenesis in the adrenal glands and the gonads. 
In humans, P450cl 7 is necessary for the production of the major glucocorticoid, cortisol, 
and for the production of androgens via dehydroepiandrosterone (DHEA). A non-
functional or reduced P450c 17 activity results in a diminution of sex steroid production in 
males and can lead to ambiguous genital formation, and in females, lack of progression 
into puberty [1,2]. 
P450cl7 is an endoplasmic reticulum membrane bound multifunctional enzyme [3,4] 
that exhibits 17a-hydroxylase and 17,20-lyase activities. The first activity, 17a-
hydroxylase, converts pregnenolone and progesterone into their respective 17a-
hydroxylated products 170Hpreg and 170Hprog, and the second activity, 17,20-lyase, 
can cleave the steroid side chain to yield their respective androgens, DHEA and 
androstenedione (AD). The specificity of the P450cl 7 towards its substrates differs in 
various species and tissues. In human and bovine adrenals, P450cl 7 17a-hydroxylates 
both pregnenolone and progesterone but selectively produces DHEA in greater quantities 
than for AD [5-7]. P450cl7 is notexpressed in the adrenal glands of rats [8-10] and mice 
(11] but the gonadal P450cl 7 in these species preferentially produces AD. In the case of 
the guinea pig adrenals, both substrates are also 17a-hydroxylated whereas AD is the 
preferred final product [12,13]. In contrast to other small laboratory animais, the hamster 
also expresses P450cl 7 in the adrenal and produces cortisol as its major glucocorticoid 
[14,15]. 
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We have isolated the hamster adrenal P450cl 7 cDNA and have demonstrated that this 
enzyme produces both DHEA and AD in transiently transfected COS-1 cells, adrenal 
cell suspensions, and microsomal preparations (16,17]; AD is the favoured product. 
Moreover, we have immunolocalized the hamster P450cl 7 in the zona fasciculata and 
reticu/aris of the hamster ad.renais [18], and we have shown that the hamster P450c17 
mRNA is inducible by adrenocorticotropin hormone (15]. Because of these similarities 
between the hamster and human adrenal P450c 17 enzymes, the hamster is an attractive 
animal model to study how P450c 17 regulates steroidogenesis in human beings. 
Due to the small number of discrete differences in the enzymology of the hamster and 
human P450 enzymes, we have attempted to compare the structures and activities of the 
hamster and human enzymes. First, from sequence comparison of various species, amino 
acids (AAs) that might be responsible for the unique activities of the different P4S0cl 7 
enzymes were identified, substituted, and studied in transiently transfected COS-1 cells. 
The substitution of the amino acids were based entirely on their conserved patterns in the 
sequence alignment. For example, a threonine conserved in AD producing animais (rat, 
mice, guinea pig, and hamster), was substituted for a conserved asparagine in DHEA 
producing animais (ex: T202N). Of ail the possibilities, three have retained our attention: 
T202N, D240N, and D407H. Second, we have elaborated a molecular model of the 
hamster P450cl 7 in an effort to comprehend altered activity profiles of the selected 
mutants and ultimately describe their activity distinctions. By combining rational 
mutagenesis with molecular graphies, we have developed testable models of regions of 
the P450cl 7 protein that might be responsible for the difference in substrate utilization 
amongst species. 
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2. Materials and metbods 
2.1. Materials 
Ail restriction and modifying enzymes were purchased from Pharmacia Biotech (Baie 
d'Urfé, QC, Canada). Oligonucleotides were either purchased from BRL Life 
Technologies (Gaithersburg, MD) or Biosource International (Camarillo, CA). The 
expression vector pSVSPORT• l was obtained from BRL Life Technologies, amplified in 
XLl Blue E coli competent cells (Statagene, La Jolla, CA}, and puritied on Qiagen anion-
exchange columns (Qiagen, Chatsworth, CA). HPLC-purified [7-3H]pregnenolone (21.0 
Ci/mmol) was purchased from Mandel Scientific (Guelph, ON, Canada}, wbile [l,2,6,7-
3H]progesterone (95.0 Ci/mmol) was purchased from Amersham Canada (Oakville, ON, 
Canada). Pregnenolone and progesterone were purchased from Sigma-Aldrich (Oakville, 
ON, Canada). Polymerase chain reaction (PCR) reagents were obtained from Roche 
Molecular Biochemicals (Pwo DNA polymerase - Laval, QC, Canada). 
2.2. Hamster P450cl 7 mutagenesis by PCR 
The hamster P450cl 7 cDNA was isolated and cloned into the vector pSV-SPORT• l 
as previously described [16]. P450cl 7 seqvences of man, cow, pig, sheep, guinea pig, 
mouse, and rat were obtained from Genbank and aligned by Clustal method using DNA 
STAR software. Various AAs were determined as potential sites of activity control. Site-
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directed mutagenesis was obtained by PCR. Brietly, two series of PCR amplifications 
were obtained using the following conditions: Hot start of S min at 94°C (without DNA 
polymerase) followed by a touch down of2°C from 70-50°C, completed with 30 cycles of 
94°C/50°C/72°C and a final 72°C elongation of 15 min. The first series consists of 
amplifying pSV-hamP450cl 7 in two different reactions: 1) a wild type (WT) upstream 
(sense) oligonucleotide to the downstream mutant (antisense) oligonucleotide at the site 
of interest for mutagenesis and 2) a mutant sense oligonucleotide from the site of interest 
for mutagenesis to a WT antisense oligonucleotide. The second series consists of pooling 
both PCRs previously obtained, purified by agarose gel electrophoresis, and amplifying 
using WT 5' and 3' oligonucleotides. The WT upstream oligonucleotide used was termed 
"486" with the sequence 5'-GGAGTCCATAGATC7TICCG-3' containing a Bgfil 
restriction site indicated in italics. The wild type downstream oligonucleotide used was 
T7Hot with the sequence 5'-AATIGTAATACGACTCACTATAGGG-3'. Ail mutants 
were cloned into recombinant pSV-hamP450c 17 using unique Bglll and XhoI (just 
upstream from the T7Hot oligonucleotide) restriction sites, sequenced entirely between 
these restriction sites using T7 sequencing kit from Pharmacia Biotech, amplified, and 
purified on Qiagen anion-exchange columns. 
2.3. Hamster P450cl 7 expression 
Either WT or mutated pSV-hamP450cl 7 was transiently transfected into monkey 
kidney COS-1 cells (American Type Culture Collection, Rockville, MD) using the 
calcium phosphate method [19]. Twenty-four hours before transfection, the cells were 
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harvested with trypsin-EDTA solution (GIBCO BRL, Burlington, ON, Canada) and 
plated at an initial density of 4.0x105 cells per 10.0 cm2 well in 6-well plates. Cells were 
cultured in DMEM supplemented with 10% dextran-coated charcoal-treated fetal bovine 
serum (FBS), 2.2 g/L NaHC03, lmM L-glutamine, 100 IU/ml penicillin, and 50 µg/ml 
streptomycin sulphate. Each transfection assay received 8 µg of DNA. 
2.4. Measurement of the hamster P450cl7 activity 
F orty-eight hours after the COS-1 cells were transiently transfected, each well of cells 
was incubated for 1 hour with 2.S µM of pregnenolone or progesterone containing 
l.4SµCi of [3H]-steroid. The reactions were stopped with SO µL of O.S N acetic acid. The 
steroids were extracted twice with diethyl ether, applied on silica gel-coated thin-layer 
chromatography (TLC) plates with unlabelled standards for identification, and developed 
with chloroform/ethyl acetate (3:1 v/v) three times for pregnenolone reactions and once 
for progesterone reactions. The TLC plates were then dried overnight and exposed to 3H-
sensitive STORM 860 (Molecular Dynamics, Sunnyvale, CA) screens for 24 hours. The 
results were visualized and quantified on the optical imager STORM 860 using 
lmageQuant software version 5.0. 
2.5. Statistical analyses 
A11 data were analysed using SigmaStat (Jandel Corporation, San Rafael, CA) 
software. One-way ANOV A statistical analyses were perfonned between groups in order 
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to obtain significant results as compared to hamster P450cl 7 WT. Ail experiments were 
performed using three DNA preparations, each in triplicate (n = 3). 
2.6. Mode/ingofthe hamster P450cl7 
Ail AA side-chain alterations were performed using the Midas Plus 2.1 Graphies 
program (20] on a Silicon Graphies Octane workstation. Energy minimization (EM) and 
molecular dynamics (MD) were accomplished using the Amber 5.0 suite of programs 
[21] remotely on the Digital Equipment Corp. AlphaServer host socrates at the UC San 
Francisco Computer Graphies Laboratory. 
In order to be able to compare the human and hamster models, EM and MD 
calculations for the hamster model were performed following the same protocol as for the 
human P450c17 modeling. Basically, the hamster model was subjected to 1000 cycles of 
EM in the SANDER module of Amber 5.0. The favourable energetics at this stage (-
5.0766 x 103 kcaJ/mol) allowed us to proceed immediately with the solvation of the 
hamster molecule. Solvation was performed asymmetrically with a sphere of radius 33.65 
A by means of the EDIT module of AMBER 5.0. This asymmetric solvation excludes the 
hydrophobie, presumed membrane-bound N-terminal region of the P450cl7. The water 
molecules were then pre-equilibrated for 10 ps and a temperature gradient of lOOK to 
300K using the BELL Y option in the SANDER module. Once achieved, MD calculations 
were performed on the whole model, including the water molecules, for an additional 1 OO 
ps with a rapid temperature gradient of 200K to 300K. An average structure was captured 
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for the last 40 ps using the CARNAL module of Amber 5.0 and subjected to another 1000 
cycles ofEM using the steepest-descent method of the SANDER module. 
Modeling of the mutants was obtained as mentioned above with the desired altered 
AA side cbains following the same protocol as for the WT modeling. Protein database 
files were generated using Amber 4.1 "ambpdb" program, and visualized with either 
Midas Plus 2.1 or RasMol 2. 7 .1. Ail images were created with the RasMol 2. 7.1. 
visualization program (http://klaatu.oit.umass.edu/microbio/rasmol/). 
3. Results 
3.1. Hamster P450cl7 mutagenesis 
Three recombinant hamster P450cl 7 mutants were constructed and tested, based on 
the bomology analysis of the AA sequences of eight species: hamster, mouse, rat, guinea 
pig, human, sheep, bovine, and porcine. As mentioned previously, P450cl 7 isozymes 
from different species have different reactivity; small laboratory an;mals generally 
produce AD while larger an;mals such as cows produce DHEA like humans in vivo. Thus 
substituting specific residues that consistently track with ditTerent P450cl 7 activities into 
hamster P450cl 7, we hypothesized that we would identify important AAs for the reaction 
specificity displayed by the various species. 
Using this approach, the hamster P450cl7 was mutated at three different positions to 
resemble the human sequence (Table 1). At position 202 of the hamster P450cl7, the 
conserved thr (T) in the hamster, mouse, rat, and guinea pig (all species with bigh A4 
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lyase activity) was mutated to asn (N), conserved in human, sheep, cow, and pig 
P450cl 7s (ail species with high As lyase activity), yielding mutant T202N. D240N is an 
AA alteration from an asp (D) in the hamster P4SOcl 7, to an N conserved in rat, human, 
sheep, cow, and pig at position 240 of the hamster P4SOcl 7 sequence. Finally, a D at 
position 407 of the hamster P4SOc 17, also conserved in the mouse, rat, and guinea pig, 
was changed into a his (H) found in human P450cl 7 only. 
To compare the activities of mutant and WT hamster P450cl 7 enzymes, transiently 
transfected COS-1 cells were incubated with 2.S µM of substrate for 1 h, since the 
substrate utilization was linear with time under such conditions (data not shown). The 
hamster T202N showed decreased l 7a.-hydroxylase and 17 ,20-lyase activities for both 
the As - and A 4-pathways. When incubated with pregnenolone, a 32% decrease in 
170Hpreg accumulation was observed, with a 70% decrease in DHEA production (Fig. 1 
and Table 2). Similarly, incubation with progesterone resulted in a 46% reduction in 
170Hprog production and 66% reduction in AD. 
The hamster D240N and D407H mutations are unique in their effects to the hamster 
P450cl7 since they decreased specifically a single activity or pathway. D240N only 
decreased DHEA and AD formation to 60% and 18% of the wild-type enzyme, 
respectively (Fig. 1 and Table 2). In contrast, the D407H mutant only decreased 17a.-
hydroxylase activity for the A4-pathway by 46%, leading to a comparable decrease in AD 
formation (51% - Fig. 1 and Table 2) which can be almost entirely attributed to the 
reduced production of the intermediate l 70Hprog. 
It becomes difticult to hypothesize why these single AA substitutions alter the activity 
profiles of the hamster P450cl 7 as observed. Therefore, to have a more complete 
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understanding of the effects of the site-directed mutagenesis, we thus elaborated 30-
models of wild type and mutant hamster P450c 17. 
3.2. Hamster P450cl 7 three-dimensional modeling 
3.2.1. HamsterP450cl 7 wi/d type modeling 
The hamster P450cl7 AA sequence was manually aligned to the human P450cl7 
sequence (22]. Fig. 2 shows perfect alignment between both species of the highly 
conserved residues: C-helix Trp (W), catalytically important Tin the I-helix (T306), the 
ExxR sequence in the K-helix, and the axial heme-liganding cys (C442). Because the 
hamster and human AA sequences align perfectly without discrepancies in lengths, the 
first process (graphies) was unambiguous. The side-chains of the hamster P450cl 7 
sequence were substituted in the human model (22], and the EM and MD were perfonned 
following the same protocol as for the human P450cl 7 modeling in order to be able to 
compare the models. The final hamster P450cl 7 model is represented in Fig. 3. 
At first glance, there are three noticeable global dissimilarities between the hamster 
and human models (Fig. 4). The most obvious difference ofthese global dissimilarities is 
in the consolidation of the hydrophobie domain described by the a-helices (helices) A, F, 
and G along with the P-sheets (sheets) 1.1-1.3 and 2.1-2.2. This consolidation is due to 
the internalization of the F-G loop in addition to the loop between sheets 2.1 and 2.2 (Fig. 
4A and B). However, the F-G loop of P450cl7 is likely to be disordered as in P450terp 
(23], so this motion is to be expected. The F- and G-helices have also slightly changed in 
position with respect to each other: in the human model, they tend to cross each other in 
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the plane of view in Fig. 4A, but nm parallel when observed from above the molecule 
(not shown); in the hamster model, these helices nm parallel in both views. 
The second difference between the hamster and human models is in the positioning of 
the J' -helix (Fig. 4A and B). The hamster J' -helix (Fig. 4B) seems to have been pulled by 
its ends as compared to the human J' -helix, causing a slight tlattening of the helix as well 
as a slight rotation of the helix axis. This causes the J' -helix in the hamster to protrude 
from the protein more than in the human model. The affected region is the domain 
structured by the J-J' loop, J' -helix, and the C-D loop. 
Finally, the active sites of the hamster and human P450cl 7 are also different due to 
more subde changes in amino acid positioning. In each case, the active site is the volume 
delimited by the heme, which forms the tloor of the pocket; the Val (V) 482 and 483 
which fonn the roof; the I-helix forming the far wall, running next to the heme; the K-
helix, 13-sheet 1.4, and loop between them, which form the right wall (as viewed in Fig. 
4C and D); the 13-sheet 1.5, B'-helix, and the loop between these two, forming the front 
wall; and the B '-C loop, specifically the De (1) 112, forming the left wall. The substrate 
entrance is shaped by the 13-sheet l.S, loop between sheet l.S and B'-helix, B'-helix, and 
B'-C loop. 
The first difference between the hamster and human active sites is the larger bulge at 
position Lys (K) 302 in the hamster I-helix which, when compared to the human model, 
displaces the catalytic important T306 higher from the heme. The methyl hydrogen on 
this T in the human model is located at 4.049 A from the heme iron and 2.806 A from the 
V483 methyl group, white it is displaced to 4.537 and 2.862 A, respectively, in the 
hamster model. Thus, this ''bulge" could have an implication in the overall reactivity of 
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the protein. Another difference in the active sites is that the hamster I-helix bas a kink 
towards the heme at its N-terminal which changes the orientation of the H-I loop with 
respect to the B' -C loop of the substrate entrance, as well as creating some distortion in 
the B '-helix C-terminal. This "kink" allows the H-I loop to interact more closely with the 
B '-C loop, changing its conformation. The significance of this new interaction is 
unknown but suggests the implication of the substrate entrance in the protein's reaction 
specificity, since this is the major difference in the hamster and human active sites. 
3.2.2. Hamster P450cl7 mutant modeling 
Modeling of the mutants without the substrates suggests explanations for the activities 
of mutants T202N, D240N, and D407H. T202N is located in the F-helix directly above 
the substrate, interacting with residues V 482 and V 483 that form the roof of the active 
site (Fig. S). In this case, all activities of the hamster P450cl 7 are decreased (Table 2). 
These data are consistent with the model of V 482 and V 483 forming the roof of the 
active site (22], and surrounding residues stabilizing the position of these valines. 
Although H-bonding still occurs between N202 and V482 as seen in the WT, the 
interactions of N202 with V482 shifts the active site pocket by approximately 0.7 A 
closer to I-helix with respect to the substrate entrance. Also, the amide nitrogen of Il 12 in 
the T202N model is located about 0.6 A closer to the heme group than in the WT. This 
Il 12 displacement is caused by the bending of the F-helix (where residue 202 is located), 
which distorts the G-helix. So the twisting displacement of the active site pocket with 
respect to the heme group, created by differential H-bonding of N202 to V482 and the 
AAs in the substrate entrance, appears to interfere with the positioning of the active site 
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and with substrate entrance sufficiently enough to reduce both l 7a.-hydroxylase and 
17 ,20-lyase activities of the hamster P450cl 7. 
D240N however, is located in the mid-portion of the G-helix, near the junction of the 
1- and B'-helices close to the H-1 loop. Alteration in this position also modified the active 
site pocket, further lowering Il 12 closer to the heme and elevating T306 due to kinking 
of the 1-helix similarly. lmportantly, Arg (R) 96 and R440 have also changed in position. 
R96 and R440 are approximately 1.0 and 1.5 A closer to the heme than in the WT model, 
which twists and shrinks the active site pocket. Since R96 is located in the substrate 
entrance (between sheet 1.5 and B'-helix) and since R440 is directly under R96 just 
beyond the opening, displacement of these arginines would be expected to interfere with 
the substrate entrance conformation and overall reactivity of the P450c 17. In this case, 
the resultant reduction in 17,20-lyase activity (Table 2) seems to be due to decreased 
l 7a-bydroxysteroid access to the active site because of the reduced substrate entrance, 
and reduced active site pocket volume. 
On the other band, it is less apparent why mutation D407H, located remotely from the 
active site, specifically reduces the reactivity of the hamster P450cl7 towards the 
progesterone pathway. Once again, the model obtained for this mutation bas a greater 
kink of the 1-helix, but this change atone is unlikely to account for the selective & 4 
activity loss. Given that Asp407 is upstream the heme binding C442 in the meander, the 
Asp-+Asn change in this position alters the conformation of the heme binding AA 
sequence leading to a sbift of the heme and a change in active site volume, wbich might 
specifically reduce reactivity of the hamster P450cl 7 when progesterone is the substrate. 
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Taken together, these single AA substitutions appear to alter P4SOcl 7 reactivity by 
transmitting structural changes from their positions to the active site as demonstrated 
through molecular modeling. Other examples have also demonstrated similar results 
through molecular modeling supporting our findings. Of which, the most pertaining 
examples are the human P4SOcl7 [22] and mineralocorticoid receptor [24] models where 
molecular modeling <:oupled with experimental data can sufficiendy explain activity 
alterations. 
4. Discussion 
4.1. Hamster P450cl7 mutagenesis 
Since T202, 0240, and 0407 were mutated in the hamster to resemble the 
corresponding human AAs, we hypothesized that the mutations would engineer hamster 
P4S0c 17 to act more like the human enzyme, shifting the relative rates of 17 ,20-lyase 
activity towards increased DHEA production. However, these single AA substitutions 
alone cannot explain activity differences between the hamster and human P4SOc l 7s. 
The T202N AA alteration resulted in a greater reduction in l 7a-hydroxylase activity 
for the A4-pathway than for the â5-pathway, although the overall final product formation 
is similar for both pathways. Since in both pathways the final product formation is 
decreased to a greater extent than the l 7a-hydroxylated intennediate, these data suggest 
that this mutation affects ail activities for both pathways. In contrast, Beaudoin et al [25] 
have studied the nearby mutant R200N in the guinea pig P4SOcl 7 that exhibits increased 
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hydroxylation of pregnenolone but decreased 17,20-lyase activity of 170Hprog. Their 
double mutant R200N/I'202N did not result in further reactivity alteration. 
The D240N mutant specifically decreased 17 ,20-lyase activity for both â 5 -and à 4-
pathways. No structure/function data are available from previous stuclies of mutations in 
this region; the only documented mutant in this region is a stop codon leacling to a 
truncated human P4SOcl 7 protein conferring combined l 7a-hydroxylase/l 7,20-lyase 
deficiency [26,27]. Since the D240N mutation alters the positioning of R96 and R440 in 
30 space, it is likely that this mutation affects the P450cl 7 enzymatic activities through 
these AAs. The mutation of the conserved R96 to Win human P450cl7 bas been shown 
to virtually abolish all reactivity [28], consistent with the role of R96 in substrate 
entrance, and the conserved R440 bas been demonstrated to be crucial for heme bincling 
and positioning [29,30]. 
Analogously for the mutant D407H, a splice site mutation causing exon 7 to be 
excised and leacling to a frame shift and a premature stop codon at position 410 was 
described [31] abolishing P450cl 7 reactivity. In addition, Lam et al. recently reported 
that the mutation of Pro(P) 409R causes l 7a-hydroxylase deficiency [32], emphasizing 
the importance of the meander region for ail activities. Consistent with these reports we 
have observed specific but not complete loss of l 7a-hydroxylase activity in the hamster 
P450cl 7 with the nearby D407H mutation, suggesting that this region of the protein 
distant from the active site is an important determinant of substrate utilization. 
169 
S. Conclusions 
At this time, we have been unable to identify single AA substitutions that account for 
the difference in activities of the P450c 17 enzymes from various species such as the 
hamster and the human. Although specific AA substitutions within the active site would 
be expected to alter the catalytic activities of the P450cl7, our results also indicate that 
changes in surrounding or "second tear'' residues [33] can also modulate active site 
geometry. We therefore conceptualize P450cl 7 structures as having three key features: 1) 
residues that constitute the core elements and preserve the structural integrity of the 
enzyme; 2) residues that participate direcdy in heme binding, redox partner interactions, 
and catalysis; and 3) residues that directly or indirectly influence active site geometry and 
bence substrate selection. Furthermore, any given residue may participate in one or more 
of these functions, and these functions can also be modified by mutagenesis or post-
translational modification(s). Therefore any cellular alterations leading to the 
modification of the P450cl 7 external structure, such as phosphorylation, could directly 
modulate its activities through the conformational transformation of its active site. 
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Table 1. Sequence alignment of P450cl 7 
f . . o vanous spec1es. 
Mutation: T202N D240N D407H 
Hamster SF T EG .IR D EV EW D QP 
Mo use TF T EG IRE KT EW D QP 
Rat TF T EG VR N EV EW D QP 
G. Pig RF T TG IR G AM EW D RP 
Human NY N EG IR N DL EW H QP 
Aries NV N DG TR N EL EW Q QP > 
Bovine NV N DG TR N EL EW Q HP 
Porcine NF N DG MR N EL EW L RP 
Table 2. Summary of activity 
alterations by site-directed mutagenesis,_ 
compared to wild type hamster .. 
P450cl 7. 
Pregnenolone Progesterone 
170Ha 17!20b 170H 17120 
T202N -32% -70% -46% -66% 
D240N =c -60% = -18% 
D407H = = -46% -51% 
al 70H is 17a.-hydroxylase activity 
bl 7,20 is 17,20-lyase activity 
c= no significant change in activity 
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Fig. 1. Mutant Activity Alterations of the Hamster P450cl 7. 
A, 17a-hydroxylase activity; B, 17,20-lyase activity. Wild type hamsterP450cl7 in black 
solid bars; light grey solid bars, mutants as designated by x-axis; SEM denoted by lines; • 
representing statistically significant results (•p<0.05 and cp<0.01, 3 experiments 
performed in triplicate). 
Fig. 2. Alignment of the Hamster (Ham) and Human (Hum) P450c 17 Amino Acid 
Sequences. 
The models begin at amino acid position 48 and terminate at position 501. Residues 
belonging to structured elements are in bold/ace type with the highly conserved residues 
(C-helix tryptophan, catalytic threonine in the I-helix, the ExxR sequence in the K-helix, 
and the axial heme-liganding C442) underlined. Alpha-helices are alphabetically 
identified and the P-sheets are numbered. HB, Heme-binding. 
Fig. 3. Final Hamster P450cl 7 Model. 
The molecule is shown as a ribbon diagram with the a-helices in light blue, the ~-sheets 
in yellow, the loops in white, the heme and axial C442 in red, and the heme iron in gold. 
Fig. 4. Comparison of the Human and Hamster P450cl 7 Models. 
A, Trace diagram of the human P450cl 7 model. The heme is shown in red with the gold 
iron atom, a-helices blue, P-sheets yellow or green, notable loops in orange, and the rest 
of the molecule in white. B, Same representation as in panel A but for the hamster 
P450cl 7 model. C, Ribbon diagram of the human P450cl 7 model's active site. The heme 
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is shown in red with the gold iron atom and axial C442, substrate entrance composed of 
(3-sheet 1.5, B'-helix and adjacent loops in cyan, and remaining loops in white. D, S81De 
representation as in panel C, but for the hamster P450cl 7 model's active site. a= a-
helix, P = (3-sheets, Q = loops. 
Fig. S. Localisation of the mutants. 
Ribbon diagram of the wild type hamster P450cl 7 model viewed from the substrate 
entrance, demonstrating localization of the mutants created: T202N, D240N, and D407H. 
Substrate entrance and mutant positions in dark grey; everything else in light grey but the 
beme iron in black. a = a-belix, f3 :;: (3-sheets, Q = loops. 
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The cytochrome P450c 17 isofonns from various animal species have different substrate 
selectivity, especially for 17,20-lyase activity. In particular, the human P450cl 7 
selectively produces dehydroepiandrosterone with little androstenedione. Hamster 
P450cl 7, on the other band, produces both of these steroids at comparable rates. We thus 
investigated if computational analysis could explain the difference in activity profiles. 
Therefore, we inserted the four P450c 17 substrates-pregnenolone, progesterone, and 
their l 7a-hydroxylated forms-inside our hamster P450cl 7 model, which we derived 
from our human P450cl 7 model based on the crystal structure of P450BMP. We 
performed molecular dynamics simulations on the complexes and analyzed the resultant 
trajectories to identify amino acids that interact with substrates. Starting with substrates 
in two different orientations, we obtained two sets ofbinding trajectories in each case. 
The first set of trajectories reveal structural rearrangements that occur during binding, 
whereas the second set of trajectories retlects substrate orientations during catalysis. Our 
modeling suggests that three distinct steps are required for substrate selectivity and 
binding to the hamster P450cl 7: 1) recognition of the substrate at the putative substrate 
entrance, characterized by a pocket at the surface of the hamster P450c 17 containing 
charged residues R96 and D 116; 2) entry of the substrate into the active site, in an 
intermediate position directed by possible hydrogen bonding of the substrates with the 
heme D-ring propionate group, R96, R440, and T306; followed by 3) 90° counter-
clockwise rotation of the substrates, positioning them in optimal position for reactivity, a 
process that may be directed by hydrogen bonding to the 110-112 region of the hamster 
P450cl 7. With some substrates, we obtained trajectories which suggest that major 
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distortions in the I-helix and opening of the H-I loop occur during substrate binding. ln 
conclusion, these modeling exercises provide insight to possible structural 
reorganizations that occur during substrate binding and suggest that amino acids that 
participate in three distinct steps of this process may all contribute to substrate binding 
and activity. 
Abbreviations: Cytochrome P450 l 7a-hydroxylase/l 7,20-lyase (P450cl 7), 
dehydroepiandrosterone (DHEA), androstenedione (AD), l 7a-hydroxypregnenolone 
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(l 70HPreg), l 7a.-hydroxyprogesterone (l 70HProg), energy minimization {EM), 
molecular dynamics {MD), carbon 17 (C11), carbon 20 (C20), hy~oxy oxygen on C11 
(Oc11), heme iron (Fe), heme oxene oxygen (Ope) the 3f3-hydroxyl group (C3-0), C20 
ketone (C2o=O), C3 ketone oxygen (C3=0), backbone nitrogen (Nb), backbone oxygen 
(Ob), the C11 hydrogen to heme ferryl oxygen distance (Hc11-()pe), and the C11 oxygen to 
heme iron oxygen distance (Oc11-0,e)· 
Running Title: Molecular dynamics P450cl 7-substrate complexes 
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1. Introduction 
The cytochrome P450 l 7a-hydroxylase/l 7,20-lyase (P450cl 7) plays a central rote in 
the control in steroid hormone metabolism, regulating the flux of precursors to 
glucocorticoids and androgens. P450cl 7 is an endoplasmic reticulum membrane-bound 
bi-functional enzyme harboring two distinct activities in a unique active site. The tirst 
activity of the P450c 17 is l 7a-hydroxylation, wbich hydroxylates both pregenenolone 
and progesterone at the steroid carbon 17 (C11). The l 7a-hydroxyprogesterone 
(l 70HProg) can then be converted into cortisol, the major glucocorticoid in bumans, 
through the activities of other steroidogenic enzymes. Both the l 7a-
hydroxypregenenolone (l 70HPreg) and l 70HProg can be converted to their 17 ,20-
cleaved products, dehydroepiandrosterone (DHEA) and androstenedione (AD) 
respectively, by the 17,20-lyase activity of P450cl 7. In humans however, the 17,20-lyase 
activity for the production of AD is approximately 50 times less efficient than for the 
production of DHEA [1;2]. 
P450cl 7 is expressed from a single gene ( CYP 17) in human adrenal glands and 
gonads [3], but the adrenal 17,20-lyase activity, and hence DHEA formation, is subjected 
to developmental regulation (adrenarche) [ 4]. Adrenal expression of the CYP 17 gene is 
stimulated by adrenocorticotropic hormone (ACTH), which in tum is negatively 
regulated by cortisol, creating a tigbt control of P450cl 7 expression [5;6). Contrary to 
hnmans, rats [7-10) and mice [11;12] do notexpress adrenal P450cl7; corticosterone is 
the major glucocorticoid in these species. Moreover, since rat and mouse P450cl 7 
preferentially produce AD instead of DHEA, these animal models are not ideally suited 
for the study of human steroidogenesis. However, we have demonstrated that the hamster 
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does express adrenal P450cl 7 [13; 14] and that hamster P450cl 7 is located in the adrenal 
smooth endoplasmic reticulum [15). Unlike the human and bovine isoforms, hamster 
P450c 17 exhibits comparable 17 ,20-lyase activity for both Il. 4 and Il. 5 pathways, 
producing both AD and DHEA from their respective precursors in abondant quantities 
[14]. Moreover, as in humans, cortisol is the major glucocorticoid in the hamster [16; 17]. 
Recently, we have modeled hamster P450cl 7 using the human P450cl 7 coordinate file as 
template and have shown that rational site-directed mutagenesis can specifically alter the 
activities of hamster P450cl 7 [18]. Moreover, our analysis of the structural differences 
between the human and hamster models identified regions, most notably the I-helix, that 
might account for differences in substrate specificity of the two enzymes. The hamster 
P450cl 7 model showed a bulge near the catalytically important T306 and a kinking of 
the H-1 loop, allowing the latter to interact with the B'-C loop of the putative substrate 
entrance. This analysis suggests at least two determinants of substrate selectivity: T306 
and residues near the substrate entrance. We thus investigated if molecular dynamics of 
substrates bound to the hamster P450c 17 model could explain the contrasting activity 
profile of the hamster and human P450cl 7 isoforms. Here, we modeled the four P450cl 7 
substrates-pregnenolone, progesterone, and their l 7a-hydroxylated forms-inside our 
hamster P450cl 7 model and performed molecular dynamics on the docked complexes. 
Our results suggest that the mechanism of substrate selectivity and intake into the 
hamster P450c 17 requires several steps: 1) recognition of the substrate at the putative 
substrate entrance by the residues R96 and Dl 16; 2) entry of the substrate in a temporary 
conformation, directed by possible hydrogen bonding (H-bonding) of the substrates with 
the heme D-ring propionate group, R96, R440, and D06; followed by 3) a 90° counter-
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clockwise rotation, settling the substrates in an optimal position for reactivity, directed by 
H-bonding to the residues in the 110-112 region. 
2. Material and methods 
2.1 Instrumentation 
Ail the substrates were manually docked inside the hamster P450cl 7 model using the 
Midas Plus 2.1 Graphies program [19] on a Silicon Graphies Octane workstation. Ail 
energy minimi:zation (EM) and molecular dynamic (MD) calculations were accomplisbed 
using the Amber 5.0 suite of programs (20] remotely on the Digital Equipment Corp. 
AlphaServer host sacrales at the University of California at San Francisco (UCSF) 
Computer Graphies Laboratory. 
2.2 Substrate doclcing and molecular modeling 
The hamster model (PDBID: 1109, (18]) was constructed by amino acid substitution on 
our human P450cl 7 model (PDBID: 2Cl 7, [21]), which, in turn, used the crystal 
structure of P450BMP as template (PDBID: 2HPD, (22]). These models delete the 
membrane-spanning amino-termini and start at residues 48, corresponding to the first 
structured element of P450BMP. The hamster model was overlaid on a pregnenolone-
docked human model by superimposing the heme nitrogens to allow proper substrate 
positioning. The hamster P450cl 7 heme was modeled as the ferryl oxene species using 
files and parameters develop for the human P450cl 7 model [21]. Other substrates were 
then substituted for pregnenolone, taking care not to overlap any atoms in the hamster 
model. The substrates were placed in similar positions with the carbon-17 (C17) above the 
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heme iron. The substrates were then fixed in space as the protein was allowed to adjust to 
accommodate the docked steroids during 200 cycles of EM using the BELL Y option of 
the Sander module. The models were then solvated as previously described [18], with a 
solvent sphere radius of 25 A in order to completely solvate the area surrounding the 
active site. Then, the docked complexes were subjected to MD, first pre-equihbrating the 
water molecules for 10 ps, and then nmning the entire solvated structure for another 1 OO 
ps. Average structures were obtained as previously described [18]. 
2.3 Rendering 
Ail images were rendered using WebLab Viewer (www.accelrys.com) for the tube and 
stick snapshots, and Insightll (www.accelrys.com) for ail the accessible surfaces. 
3. Results 
3.1 Comparison to human P450c17 mode/ and generation of two sets of trajectories 
In order to understand the reaction specificity of the different P450cl 7s, we compared 
the active sites with the appropriate substrates bound. Upon visualization of the resultant 
model for the progesterone-docked hamster P450cl 7 model, we realized that 
progesterone had caused a depression of the heme and an elevation of the H-1 loop 
compared to the substrate-free model, leading to the distortion of the 1-helix (Fig. 1 ). 
Since this distortion had not been previously observed during MD of substrate complexes 
with the human P450cl 7 model [21], we carefully compared the docking of substrate to 
the two models. Upon re-examination, the starting positioning of progesterone was 
clifferent in the hamster and human P450cl 7 substrate-docked models. In the human 
model, the progesterone A-ring was located above the heme D-ring, to the right of the 
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propionate groupas viewed from the putative substrate entrance (as in Fig lC). In the 
tirst series of the hamster P450cl 7 substrate-docked models, in contrast, the steroid A-
ring was located to the left of the propionate group of the same heme D-ring (Fig. lB). 
This difference positioned the steroid A-ring closer to the substrate entrance and caused 
the heme D-ring propionate group to settle in the plane of the heme, rather than upwards 
as in the human model. In order to verify that the observed distortion of the I-helix was a 
consequence of the substrate positioning on the active site conformation, we obtained a 
second series of substrate-docked hamster-P450cl 7 models (Fig. lC). 
In the second series, the substrates were docked with the steroid A-ring to the right of 
the heme D-ring propionate group and lifted from the heme, being careful to not overlap 
atoms in the "roof' of the active site, thus leaving more space for the heme propionate 
group. The second set of models wt1s then subjected to EM, solvation, and MD as for the 
first models. 
3.2 Progesterone-docked hamster P450cl7 
A great deal of model distortion occurred in the first attempt to dock progesterone in 
the hamster P450cl 7 model. In this distorted conformation (Fig. lB and Fig. 2A), the C20 
carbonyl (C20=0) can H-bond with the y-hydroxyl of T306 (2. 73A) and lies near the 
backbone oxygen (Dt,) of G303 (3.37A); the C3 carbonyl oxygen (C3=0) interacts with 
R96 and R440 guanidinium groups (3.61A and 4.09A, respectively). Interaction with 
T306 is unlikely to be maintained because during catalysis, because T306 is believed to 
be involved in oxygen homolysis [23]. In the second series of models (Fig lC and Fig. 
2B), the progesterone settled after a quarter tum counter-clockwise above the heme. The 
closest polar group for C3=0 in this position is the backbone nitrogen (Nb) of L370 
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(3.60A). The counter-clockwise rotation ofprogesterone causes the C11 hydrogen to be 
closer to the heme iron: the C11 hydrogen to heme ferryl oxene distance CHc11-0Fe) 
decreased by 1.07 A from 3.SSA to 2.48A. 
3.3 Pregnenolone-docked hamster P450cl 7 
When pregnenolone was docked into the hamster P450cl 7 model, the initial model 
only had slight distortion of the I-helix (data not shown). The heme remained fixed 
relative to the I-helix, and the N-terminus of the I-helix kinked only slighdy as compared 
to the initial progesterone-docked hamster P450cl 7 model. In this case, pregneno!one 
remains in position by possible interaction of C2o=O to the T306 hydroxyl group and/or 
Nb ofV366 (4.0lA and S.16A respectively-Fig. 2C). The 3~-hydroxyl group (C3-0H) 
could interact with R440 and/or R96 guanidinium groups (3.29A and 3.1 lA respectively 
- Fig. 2C), but the heme D-ring propionate group is closer than these polar groups 
(2.88A), suggesting that the heme itself may help to position pregnenolone tbrough H-
bonding. In the second series of models (Fig. 20), pregnenolone also rotated a quarter 
turn counter-clockwise as viewed from above the heme. In this position, the C2o=O is 
surrounded by the R440 guanidinium nitrogens (2. 79A). However, the C3-0H does not 
appear to be anchored by any specific interactions; the closest polar atoms are the Nb of 
A367 and P32 l ( 4.22Aand 4.46A, respectively- Fig. 20). Curiously, the only H-bonding 
obtained in these pregnenolone-docked models is the bonding of pregnenolone to the 
heme propionate groups seen also in the first model series. Through the change from the 
first to the second model series, the Hc11-Ûpe ranged from 2.40A to 4.20A. 
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3.4 Doc/cing of 170HPreg and 170HProg in the hamster P450c17 
When l 70HPreg and l 70HProg are inserted in the hamster P450cl 7 model, they both 
greatly resemble the models obtained for the progesterone-docked hamster P450cl 7. In 
the first l 70HPreg model (Fig. 2E), the 170HPreg is restrained in position by H-bonding 
of C20=0 to the E-amino group of Kl 10 (2.92A) and by H-bonding of C3-0H to Nb of 
R96 (3.39A). The C3-0H however, can also H-bond to the heme D-ring propionate group 
(2.84A) or to the guanidinium group of R440 ( 4.32A). After the counter-clockwise 
rotation (Fig. 2F), only C20=0 H-bonding is maintained; C2o=O can H-bond to the Nb of 
G 111 or Il 12 (3.12A and 3. lSA respectively), wbile the C3-0H could interact with the 
Ûb ofM369 (2.78A). The rotation of the 170HPreg inside the active site of the hamster 
P450cl 7 brings the C11 center closer to the heme iron; the C11-0 to the ferryl oxene 
(Oc11-()pe) distance is brought closer from 2.48A to 2.43A. 
Docked 170HProg (Fig. 20) is maintained in position by possible H-bonding of the 
C3=0 to R96 (2. 79A) and the C2o=O to TI06 (2. 73A). Moreover, other polar groups are 
accessible to C3=0, such as the guanidinium group ofR440 (3.2A) and the hydroxyl 
group of S94 ( 4.03 A). After the counter-clockwise rotation (Fig. 2H), no H-bonding is 
observed, although the C3=0 is near Nb of L370 ( 4.63A). The C20=0 is located near the 
Kl 11 amino group (2. 75A) and the Nb of 0303 and A302 (3.60A and 3.88A, 
respectively). The Oc11-Ûpe distance is reduced from 2.75A to 2.41A after the counter-
clockwise rotation. 
3.5 Mo/ecu/ar surface of the putative substrate entrance and of the hamster P450cl7 
active site 
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The molecular surface of the substrate-free hamster P450cl 7 putative substrate 
entrance was investigated for possible features that might facilitate substrate uptake into 
the active site. The first observation is that the putative substrate entrance forms a cleft in 
the hamster P450cl 7 surface, characterized by a mostly hydrophobie surface with the 
exception of two charged residues: R96 and Dl 16 (Fig. 3A and 3B). As viewed in Fig. 
3A, R96 and D 116 align with T306 located in the middle of the I helix immediately 
across the substrate binding site, and these two residues are perfectly placed to orient 
entering substrates close to and parallel to the heme. This analysis therefore suggests that 
these amino acids are not only important for restraining the substrates in the hamster 
P450cl 7 active site, but might also participate in the mechanism of substrate uptake and 
selectivity, placing steroids inside the active site pocket. This participation in substrate 
selection could be driven by the polar C2o=O common to most P450cl 7 substrates. The 
hamster P450c 17 active site pocket itself is mostly hydrophobie with the exception of the 
R96 and R440 closing the substrate entrance and T306 hydroxyl group located directly 
opposite these residues (Fig. 3C). Interestingly, as the substrate enters the active site (Fig. 
3C), distortion of the I-helix and movement of the 110-112 region creates space adjacent 
to the entering substrate allowing the substrate to reposition by a counterclockwise 
rotation. This process is shown in the close-up view in Fig. 3E, depicted by the "empty" 
volume immediately adjacent the C2o=O (next to Il 12 in grey), which may permit or 
direct the substrate to rotate counter-clockwise a quarter turn (Fig. 30 and 3F). 
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4. Discussion 
For each docked substrate inside the hamster model, we obtained two sets of 
molecular dynamics trajectories depicting two possible binding modes of the substrates 
inside the hamster P450cl 7 binding site. lt was previously predicted that P450cl 7 would 
have a bi-lobed active site, based on initial models based on structures of P450cam 
[24;25] and P450BMP [26]. On the other band, the tight association of the substrates in 
the active site of a more recent and more carefully validated human P450cl 7 model 
suggested that only one binding conformation was possible [21] and that perpendicular 
binding of substrates to the heme in the P450cl 7 is not possible. Here, tight association 
of the substrates inside the hamster P450cl 7 model is also obtained; perpendicular 
binding of the substrates is impossible as there is insufficient space in the substrate-
binding pocket [18]. The first set of models and the trajectories obtained during MD, in 
which the active site opens somewhat, appear to retlect conformational changes that 
occur during substrate binding rather than catalysis. The second set of substrate-bound 
models show substrate orientation during catalysis. This conclusion is supported by the 
fact that, with the exception ofpregnenolone, ail substrates' Hc11 (or Oc11) moved closer 
to the heme reactive ferryl oxene (Table l) after the counter clockwise rotation in the 
second set of models. The unexpectedly discordant interactions observed in the two sets 
of models, despite only subde differences in starting substrate orientation, also illustrates 
the importance of careful substrate positioning when conducting MD calculations on 
docked complexes. 
Interestingly, the C3-0H of pregnenolone and l 70HPreg seem to be H-bonding to the 
heme D-ring propionate group (Table 2), which suggests that the heme may participate in 
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positioning of the 6.5-substrates in the active site. These interactions were not observed 
with the progesterone substrates, as these steroids do not have the required hydroxyl 
group at C3 to donate a H-bond to the heme propionate group. This H-bonding may 
provide sufficient substrate stabilization for mutation D240N to retain nearly normal 
17a-hydroxylase activity with pregnenolone, despite impaired 17: 20-lyase activity for 
170HPreg, presumably due to active site crowding [18]. 
Careful investigation of the substrate entrance and binding site inside hamster 
P450c 17 reveals key residues that may mediate different stages of substrate binding. The 
exterior surface of the entrance is composed of two charged residues, R96 and D 116, 
aligned directly with the active site. Previously, the mutation R96W bas been 
demonstrated to abolish all activity in human P450cl 7, supporting its role in substrate 
recognition and binding (27], and we note that the hamster and human enzymes are 
nearly identical in the region of residues 90-120: 
Hamster 
Human 
G KEFSGRPHMV TLGLLSDQGK GIAFADSGGS 
G KDFSGRPQMA TLDIASNNRK GIAFADSGAH 
We have also demonstrated that the mutation D240N in hamster P450cl 7 alters R96 
positioning, which may account for the specific reduction in 17,20-lyase activity 
observed in this mutation [18]. Thus, complete removal of the charged group on R96 
abolishes P450cl 7 activity, and improper positioning of this residue alters substrate 
selectivity. Therefore, the functional domain composed of the substrate entrance (i.e.: (3-
sheet 1.5, the loop from (3-sheet 1.5 to a-helix B', a-helix B', and the B'-C loop to amino 
acid Dl 16) all contribute to substrate entry. 
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Independent molecular dynamics studies of P450s -<:am, -BMP, and-eryF have 
likewise suggested a role of buried arginine residues in guiding substrate expulsion and 
entry [28]. In the case of P450BMP, R47 forms a sait bridge with the carboxyl group of 
the substrate palmitoleic acid at the opening of the active site cleft. The R47 side chain 
rotates outward during substrate expulsion, guiding and neutralizing the negatively 
charged carboxylate out of the active site cavity. Our molecular dynamics simulations 
suggest an analogous role of R96 in forming hydrogen bonds with substrate oxygen 
atoms during the docking process. Residue R96 of P450cl 7 is located adjacent to K72 
(which corresponds to R47 in P450B:MP), three strands away on the same P-sheet and 
somewhat closer to the interior of the protein. Since steroid molecules are more compact 
than palmitoleic acid in its extended conformation, it is not surprising that the adjacent 
but more buried R96 side chain, rather than K72, participates more extensively in 
substrate transit for P450c 17. 
Two additional sets of residues are identified from the two sets of models that appear 
to be responsible for directing the substrates into the active site and for properly 
orientating the substrates for catalysis. The amino acids clustered around T306 and R96 
appear to direct or guide substrate entry. In this process, Kl 10, 0303, T306, and V366 
interact with C20=0, and the heme D-ring propionate group, S94, R96, and R440 are 
positioned to H-bond with C3-0H (Table 2). Residues that appear to direcdy interact with 
substrate during catalysis include amino acids are amino acids A302-G303, Kl 10-1112, 
and R440 (at C2o=O), and P321 and A367-L370 (at C3-0H). This analysis of substrate 
dynamics during binding may explain why some mutations distant from the active site 
also destroy activity-by interfering with earlier steps in the binding process. 
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These results are consistent with previously reported human P450cl 7 mutants. For 
instance, the mutations R96W [27], S106P [29], and 1112 duplication (Il 12dup) [30] 
have ail been reported to abolish ail P450cl 7 activity. R96W was previously implicated 
in active site formation; here we present evidence that the specific function ofR96W in 
substrate recognition involves initiating substrate entrance. Moreover, mutations Il 12dup 
and S106P have been directly implicated in substrate binding in the human P450cl 7. Our 
results also support the importance of the amino acids 110-112 in substrate positioning 
during catalysis. 
Obviously, certain amino acids are not constrained to one function but may participate 
in several stages of binding and turnover. Specifically, 0303, Kl 10, and R440 are located 
at positions that allow for several functions. 0303 and Kl 10 are located adjacent to 
residues that interact with C20=0 during the latter stages of substrate entry and catalysis, 
while R440 is located near residues that interact with either C2o=O or with C3-0H. Thus, 
due to their positioning in the active site, these amino acids can participate at different 
stages of substrate binding and catalysis in the hamster P450cl 7. Moreover, T306 and 
R440 have been previously reported to be important for proton donation [31] and heme 
binding [32], respectively. Here, our results suggest that T306 and R440 may also 
participate in substrate alignment during active site entry at C2o=O and C3-0H 
respectively. Although we were not able to clearly identify the structural basis for the 
similar and high 17,20-lyase activities for both l 70HProg and l 70HPreg in hamster 
P450cl 7, we suspect that differences in the interactions of â 4 steroids with T306 may 
contribute to substrate discrimination. 
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In conclusion, we conceptualize that the substrate selectivity and intake into hamster 
P4SOcl 7 requires three distinct steps using three sets ofresidues (Fig. 3): l) recognition 
of the substrate at the membrane interface with the solvent accessible surface in the 
putative substrate entrance by residues R96 and D 116; 2) entrance of the substrate into 
the active site, directed by possible interactions or H-bonding to the heme D-ring 
propionate group, R96 and R440 at the C3 oxygen and by T306 at the C20=0; followed by 
3) counter-clockwise rotation of the substrate in the active site for optimal positioning 
allowing reactivity. 
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Figure Legends: 
Fig. 1. Distortion of the hamster P450cl 7 active site upon progesterone binding. 
Panel A, Unliganded hamster P450cl 7 modelas previously obtained [18]. Panel B, First 
model obtained upon progesterone binding, demonstrating distortion of the 1-helix. Panel 
C, Second model obtained upon progesterone binding, demonstrating a counter-
clockwise rotation of the progesterone in the active site, settling in a similar position as 
previously descnbed for the human P450cl 7 model [21]. The 1-helix backbone is shown 
in tubular form with the heme and progesterone as stick diagrams. Color code: 1-helix, 
heme, and progesterone in dark, medium, and light grey, respectively. 
Fig. 2. Enzyme-substrate interactions in the hamster P450cl 7 active site. Two sets of 
substrate-bound models were obtained: the first series of models are depicted in panels A, 
C, E, and G, while the second series are depicted in panels B, D, F, and H. Bound 
substrates: progesterone (Prog) in panels A and B; pregnenolone (Preg) in panels C and 
D; l 7a.-hydrox.ypregnenolone (l 70HPreg) in panels E and F; 17a-hydroxyprogesterone 
(l 70HProg) in panels G and H. The heme is rendered as an accessible surface. Color 
code: Carbon in grey, oxygen in red, nitrogen in blue, distance monitors in green, and 
labels in yellow. Hydrogen atoms are not shown. 
Fig. 3. Accessible surfaces of the hamster P450cl 7 putative substrate entrance and 
active site. Panel A, Ribbon representation of the hamster P450cl 7 without substrate, 
depicting the location of important structures: I-helix in red, heme in yellow sticks, 
putative substrate entrance (composed of J3-sheet 1.5, the loop from J3-sheet 1.5 to a.-helix 
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B ', a-helix B', and the B '-C loop to amino acid D 116) in blue, and the amino acids R96 
and Dl 16 in green sticks, circled in blue and red respectively. Panel B, Accessible 
surface representation of Panel A. Panel C, Accessible surface representation of the 
hamster P450cl 7 active site with bound progesterone, as obtained in the tirst series of 
substrate-bound models. Panel D, Same representation as in panel C but after the counter . 
clockwise rotation (second series of substrate bound models). Panels E and F, Identical 
representations as in C and D but at a closer perspective. Note that in order to expose the 
active site surface, the covering amino acids had to be removed from the top. Color code 
for surface representations: hydrophobie atoms in grey, and polar atoms in yellow, 
potentially charged atoms in red or blue ( oxygen or nitrogen respectively), except for 
Il 12 and T306, which the hydrophobie atoms are colored deep grey and green, 
respectively. Also, the heme nitrogens are colored sky blue, the heme iron atom is pink, 
the heme propionate group oxygens are orange, and the iron oxene oxygen is purple. R96 
and Dl 16 are also circled in panels C and D, blue and red respectively. 
Fig. 4. Proposed mechanism of substrate entrance inside the hamster P450cl 7 based 
on molecular dynamics trajectories. The tube and stick representation shows substrates 
entering the active site of hamster P450cl 7. The left and right panels are identical except 
for the point of view. The left panel in is the same point of view as Fig. 3A, and the right 
panel is rotated 90° clockwise in the plane of the page. Top: approaching substrate to the 
P450cl 7 putative substrate entrance, with recognition by R96 and D 116 (D 116 is omitted 
for simplicity). Middle: Entering substrate, directed by interactions of the C2o=O with 
T306 and the C3-0H with R96. Bottom: Counter-clockwise rotation of substrate in the 
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Table 1. Distances of the fer ryl oxene to the sites of 
reaction on steroid substrates. 
Substratea Set Hc1rÛFe(A) oC17-0Fe (A) 
Preg 1 2.40 NA 
Preg 2 4.20 NA 
170HPreg 1 NA 2.48 
170HPreg 2 NA 2.45 
Prog 1 3.55 NA 
Prog 2 2.48 NA 
170HProg 1 NA 2.75 
170HProg 2 NA 2.41 
'Abbreviations are those used in the text 
Hc17-Fe =Distance between the hydrogen at substrate 
carbon 1 7 and the heme iron 
Oc11-0FE = Distance between the substrate hydroxyl 
oxygen at carbon 17 and the heme ferryl oxene 
NA = Not applicable 
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Table 2. Summary of the important atomic interactions 
restraining substrate positioning in the hamster 
P450cl 7 models. 
Substrate" Set Restraining Interactions 
C3-0 (À) C2o=O (À) 
Preg 1 HProp (2.88t T306 (4.01) 
R440 (3 .29) V366 (5.16) 
R96 (3 .11) 
Preg 2 A367 (4.22) R440 (2.79) 
P321 (4.46) Glll (3 .84) 
170HPreg 1 HProp (2.84)tt 
R96 (3.39)H Kl 10 (2.92)H 
R440 (4.32) 
170HPreg 2 M369 (2.78) Gl 11 (3 .12)H 
1112 (3.15)H 
Prog 1 R96 (3.61) T306 (2.73t 
R440 (4.09) G303 (3.37)H 
Prog 2 L370 (3.60) Gl ll (3 .08)H 
M369 (4.19) Il 12 (3.46) 
170HProg 1 R96 (2.79t 
R440 (3.20) T306 (2.73)H 
894 (4.03) 
170HProg 2 M369 (3.49) KllO (2.75) 
L370 (4.63) G303 (3.60) 
A302 (3.88) 
• Abbreviations are those used in the text 
CrO = Substrate oxygen at carbon 3 (Hydroxyl group for 
pregnenolone and ketonic group for progesterone) 
C20=0 = Substrate ketonic group at carbon 20 
HPossible hydrogen bonding 





4.1.1. Homo/ogy Modeling: The hamster and human StAR models were obtained by 
homology modeling based on the r:ecent structural crystallographic data of the human 
:MLN64 (Tsujishita and Hurley, 2000). As predicted by the stronç homology of the amino 
acid sequences, the overall structure of the MLN64 and StAR models resemble to a great 
extent. The most notable difference between the models and the MLN64 crystal is the 
loss of the hydrophic tunnel in the StAR models, replaced by a closed hydrophobie 
cavity. This cavity therefore suggests that physical opening of StAR secondary structures 
is necessary to allow cholesterol inside, to transport cholesterol into mitochondria. 
This hydrophobie cavity is characterized by an entire hydrophobie surface except for 
the presence of the sait bridge composed of amino acids E 168 and Rl87 in the hamster 
model (El69 and Rl88 in the human - for simplicity, only the hamster model will be 
discussed unless stated otherwise - Chapter 2.1. Fig. 3B). As it turns out, this 
characteristic is crucial for StAR-dependent cholesterol transfer. Since water was trapped 
inside the MLN64 crystal, it is conceivable that water molecules are also present inside 
the StAR cavity. The contrast in properties between the polar water molecules and the 
hydrophobie cavity can be conceptualized as the driving force allowing the StAR to open, 
exposing the cavity and permitting cholesterol to bind. Indeed, according to our 
calculations, the presence of the water molecules inside the StAR cavity destabilizes 
StAR making a significant population of open unfolded StAR available for the transfer of 
cholesterol inside mitochondria. Moreover, the cavity took the shape of a cholesterol 
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molecule (Chapter 2.1. Fig. 3A), supporting the existence of the cavity in StAR and 
making it unambiguous to model a cholesterol molecule inside. 
The cavity can be conceptualized as having two major fonctions: 1) acting as an 
anchor for proper cholesterol binding, and 2) serving as a locking-key to maintain proper 
minimal structure for cholesterol binding. The first fonction of the sait bridge is rather 
explicit; cholesterol is hydrophobie except for the 3P-hydroxyl group, matching the 
characteristics of the StAR cavity. lt is not surprising that nature bas developped the 
perfect environment in StAR for the transfer cholesterol. As a matter of fact, the sait 
bridge is perfectly positioned in the cavity such that when cholesterol is bound inside 
StAR, the sait bridge is located just the right distance from the cholesterol 3P-hydroxyl 
group to allow hydrogen bonding through one water molecule (Chapter 2.1. Fig. 4). 
Since it is highly unfavourable to bury polar species inside a hydrophobie 
environment, the formation of the sait bridge is favoured to stabilize the charges on E 168 
and Rl 87. Although some water molecules are certainly present inside the cavity, the 
nature of the cavity enviroment is principally hydrophobie (Chapter 2.1. Fig. 4). 
Therefore, the sait bridge can be visualized as a key feature responsible for maintaining a 
basic cavity structure for cholesterol binding. In fact, once StAR opens to allow 
cholesterol access to the cavi_ty, the sait bridge is the only feature in the cavity that cannot 
change as the water molecules are displaced by cholesterol. It is imaginable that the 
hydrophobie residues in the cavity move as they interact with the entering hydrophobie 
cholesterol. dn the other band, the sait bridge can only interact with the 3p-hydroxyl 
group of cholesterol reducing the possibility of the sait bridge to dissociate as cholesterol 
enters the cavity. El68 and Rl87 are located on P-strands Sand 6 respectively, basically 
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opposite the movable C-terminal a-helix and forming the pit of the bowl shape cavity. 
Thus it is foreseeable that the salt bridge maintains the cavity's bowl shape for proper 
cholesterol binding. 
The importance of the sait bridge in StAR activity is demonstrated both in vivo and in 
vitro by mutagenesis. Indeed, previous studies show that the human StAR mutant El69G 
(corresponding to the hamster El68) is improperly folded and causes LCAH (Bose et al., 
1998). Here, we replaced the hamster sait bridge by hydrophobie residues of similar 
volume. When either El68L or Rl87M is co-expressed in COS-1 cells with the F2 
construct (vector constaining ail necessary enzymes for P450scc activity), ail 
unstimulated StAR-dependent cholesterol transfer is lost without a change in the protein 
expression levels as compared to controls (Chapter 2.1. Fig. 5). Under stimulating 
conditions (Bu2-cAMP = cAMP), the StAR-dependent cholesterol transfer never attains 
wild type activity (Chapter 2.1. Fig. 5). Taken together, it is unlikely that the mutants fold 
properly but it bas not been verified. In the case that they do fold properly, their reduced 
activity can result from either of two possibilities: 1) StAR does not open to allow 
cholesterol to bind, or 2) cholesterol cannot exit StAR after binding inside the cavity. 
Removal of the sait bridge results in a unified hydrophobie cavity, which is more 
stable than when the sait bridge is present, since burying a charged pair in a hydrophobie 
enviroment costs energetically. Our results show that replacement of a single amino acid 
of the charged pair is sufficient to stop ail StAR activity (Chapter 2.1. Fig. 5). Although 
stabilization of the cavity by the replacement of a single charged amino acid cannot be as 
grand as the destabilization by the water inside the cavity, it seems that removing half of 
the change in the cavity is sufficient to reduce the population of open unfolded StAR. 
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Thus cholesterol will bind at much reduced rates. Also, the remaining charged amino acid 
might not be restrained in proper position to orient cholesterol suitably inside the cavity. 
If however cholesterol still manages to bind inside the StAR cavity, albeit at largely 
reduced rates, it is unlikely that cholesterol is released efficiently from StAR. As a matter 
of fact, it is envisionable that replacement of the water molecules by the hydrophobie 
cholesterol results is a stable complex. The combination of these two possibilities 
probably dictates the unoticable StAR-dependent cholesterol transfer inside mitochondria 
for the mutant StAR, as compared to StAR-independent cholesterol transfer (Bose et al., 
1996). Under stimulatory conditions (cAMP), it is possible that the phosphorylation of 
the mutant StAR conveys structural changes that may allow some cholesterol to bind 
StAR and be transferred into mitochondria as observed. 
4.1.2. Phosphorylation: Undeniably, pbosphorylation of StAR is important to convey 
structural changes that augment StAR's capacity to transfer cholesterol. As a matter of 
fact, phospborylated species responding to ACTH were discovered before StAR was 
identified (Alberta et al., 1989; Clark et al., 1994; Epstein and Orme-Johnson, 1991a; 
Epstein and Orme-Johnson, 199lb; Pon et al., 1986; Pon and Orme-Johnson, 1986; Pon 
and Orme-Johnson, 1988). Since the discovery of StAR, it bas been demonstrated that the 
buman StAR is phosphorylated on S57 and S 195 (Arakane et al., 1997), but that only the 
removal of the 8195 phosphorylation site (S19SA mutation - relatively S194 in the 
hamster) resulted in loss of StAR activity. As ofyet, no systematic investigation bas been 
undertaken to explore ail putative phosphorylation control sites on StAR activity. 
We have identified conserved StAR putative phosphorylation sites of thirteen 
vertebrate species (Chapter 2.2. Table 1), and as such, have developped a strategy to test 
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phosphorylation control of the hamster StAR. Our initial screening was based on the 
altered StAR activity when the phosphoryaltion site is removed by replacing the 
phosphorylable serine by an alanine. Effectively, alanine and serine have a similar 
volume, but the functional y-hydroxyl group of serine is absent in alanine. Of the eleven 
putative phosphorylation sites tested, only three mutants altered StAR activity: Sl3A, .. 
Sl85A, and Sl94A. Ail three mutants decreased StAR activity; Sl3A decreased StAR 
activity the least, and Sl94A decreased StAR activity the most (Chapter 2.2. Fig. 2). 
In agreement with previous studies of the human StAR (Arakane et al., 1997), the 
hamster Sl94A dramatically decreased StAR function, resulting ftom a direct decrease in 
StAR phosphorylation (Chapter 2.2. Fig. 3). Yet, Sl94A decreased to a greater extent 
StAR function when expressed as the full length StAR versus the N-terminal 46 amino 
acid cleaved (N46) StAR lacking the mitochondrial import sequence (Chapter 2.2. Fig. 
4). This suggests that although we show that the wild type N46-StAR is as functional as 
the full-length wild type StAR, 8194 seems to be implicated in both the control of StAR 
function in the acute stimulatory responses and in the control of the mitochondrial 
targeting sequence processing. Since there is no need for processing of the N46-Sl94-
StAR, S 194 now only diminishes part of StAR fonction resulting in Jess decreased StAR 
function as compared to the full-length StAR. This is in agreement with previous studies 
showing that 8195 phosphorylation is important for the acute response of the human 
StAR (Arakane et al., 1997), and that phosphorylation and processing of the human StAR 
is rapid (Artemenko et al., 2001). 
S 13A decreased basal StAR activity by 30% indicating that this amino acid is also 
important for StAR function (Chapter 2.2. Fig. 3). On the other band, stimulated StAR 
223 
activity was not affected by tbis mutation showing that it is not important for the acute 
increased steroidogenesis response under stimulation. Moreover, when the double mutant 
Sl3A/Sl94A was tested, 813A decreased both the basal and stimulated 8194A-StAR 
activities similarly (Chapter 2.2. Fig. 3). Therefore unlike 8194, 813A seems only to be 
implicated in the control of the mitochondrial trageting sequence processing. This is also 
supported by the 2D-SD8-P AGE analyses where most of the clifferent StAR bands of 
Sl3A versus wild type under cAMP stimulation, are located in higher molecular weights 
where the mitochondrial import sequence is present (Chapter 2.2. Fig. 6). In addition, 
comparison of the 813A and Sl94A 2D-8D8-PAGE results under cAMP stimulation 
supports the fact that there is synergy between the mitochondrial targeting sequence S13 
with 8194, as the bands that disappear for Sl3 also disappear for 8194 (Chapter 2.2. Fig. 
6). 
Interestingly, 818SA decreased StAR fonction for both full-length and N46, although 
only the full-length-Sl85A-StAR was stimulatable by cAMP (Chapter 2.2. Fig. S). This 
suggests that Sl8SA causes gross conformational changes in 8tAR when the 
mitochondrial targeting sequence is absent, insinuating that the mitochondrial targeting 
sequence might be important to maintain StAR conformation. This is also in accordance 
with the recent discovery that phosphorylation and mitochondrial targeting sequence 
processing are rapid (Artemenko et al., 2001); the mitochondrial targeting sequence may 
only be important to maintain StAR conformation until 8tAR is phosphorylated. 
Surprisingly, S 18SA had practically no effect on the 2D-8DS-PAGE pattem (Chapter 2.2. 
Fig. 6 and 7), malring its implication in StAR fonction control practically inexplicable at 
the time. Fortunately, we completed the hamster StAR model during the progress of this 
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analysis and the model showed that the hamster S 185 was not accessible to solvent 
making it impossibe to be phosphorylated (Chapter 2.2. Fig. 10). Unlike Sl8S, 8194 is 
directly accessible to solvent and bas been shown to be phosphorylated by 32P 
incorporation in the human counterpart Sl9S (Arakane et al., 1997). We therefore 
hypothesized that the activity alterations of S l 8SA were due to alterations in protein 
geometry intrinsic to the amino acid properties instead of the possibility of 
phosphorylation. 
As mentioned previously, serine and alanine have similar volumes, but they have 
different cbemical properties: serine is non-charged polar and alanine is hydrophobie. To 
test the hypothesis that activity alterations of Sl8SA were due to amino acid properties 
rather than its capacity to be phosphorylated, we mutated 8185 to mimic a constitutive 
phosphorylated amino acid (negatively charged) and to a polar residue that cannot be 
phosphorylated. In order to mimic phosphorylation, we have cbanged S 185 into and 
aspartate and glutamate (8185D and 8185E, respectively) as both of these are charged 
negatively at physiological pH, and they have at least an additional atom at position .S 
mimicking the additional phosphate group when the amino acid is phosphorylated. 
Cysteine on the other band, is identical to serine except that the hydroxyl oxygen in 
serine is replaced by sulfur in cysteine. Effectively, this maintains the non-charged polar 
nature of the residue although it cannot be phosphorylated (818SC). Therefore if8tAR is 
phosphorylated at Sl8S, Sl8SD and/or Sl85E should be extremely active yet would not 
respond to stimulation. Also, 818SC should be exactly the same as Sl8SA. The activity 
profiles show that 818SD and 818SE result in a greater loss of StAR activity than S 18SA, 
white Sl8SC partially recuperates Sl8SA StAR fonction (Chapter 2.2. Fig. 9). Moreover, 
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S185C is stimulatable by cAMP, while S185D and S185D are not. This clearly suggests 
that S 185 is not phosphorylated and its altered activity profile is a result of altered protein 
conformation. Furthermore, further examination of S185's spacial location revealed that 
it is located immediately ''undemeath" the E168-R187 salt bridge, helping to anchor the 
salt bridge through hydrogen bonding. Therefore, increasing the length of the S 185 by 
aspartate and glutamate probably disturbed the orientation of the salt bridge resulting in 
the ablation of StAR function similarly to our E 168L and Rl 87M mutants. This also 
supports the importance of the salt bridge integrity in the hydrophobie cavity for proper 
StAR function. Since Sl85A probably caused distortion of this key feature of StAR 
functionality, it probably caused the gross conformational changes in StAR suggested 
when the mitochondrial targeting sequence is absent. 
4.1.3. StAR-Dependent Cho/esterol Transfer Mechanism: The next natural step with 
the StAR model is to shed light on the StAR mechanism for cholesterol transfer inside 
mitochondria. Unfortunately, the crystalized human MLN64 comprised only the START 
domain from 230-443 (Tsujishita and Hurley, 2000) corresponding to amino acids 66-279 
of the hamster StAR (Chapter 2.1. Fig. 1). Modeling of the rest of the residues of the 
hamster StAR at this point would only be speculation. In addition to using modeling, it is 
possible to calculate the theoretical free energy of any protein with respect to the solvent 
accessible surface, so long as structural datais available in si/ico. From these structure-
based thermodynamic calculations (Freire, 1993;Hilser and Freire, 1997), it is also 
possible to identify partially folded (unfolded) states of proteins in equihbrium with tbeir 
native state and calculate theoretical binding constants of their ligands (Baker and 
Murphy, 1998; Hilser and Freire, 1997; Lavigne et al., 2000). Conveniently, Pierre 
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Lavigne and collaborators have implemented the structure-based thermodynamic 
calculations in a computer program named STC. 
Three mechanisms are presenlty proposed for StAR action: 1) desorption, 2) molten 
globule, and 3) intermembrane shuttle. Unfortunately, not one of these models can 
explain all experimental evidence collected to date. Desorption states that as StAR enters 
mitochondria via its mitochondrial targeting sequence, contact sites are created between 
the outer and inner mitochondrial membranes thus allowing for large quantities of 
cholesterol to diftùse from the cholesterol-rich outer mitochondrial membrane to the 
inner mitochondrial membrane where P450scc resides (Kallen et al., 1998b). This can 
account for the rapid cholesterol transfer into mitochondria necessitating little StAR 
(Artemenko et al., 2001), that StAR is located at "contact sites" of the inner and outer 
mitochondrial membranes (Pon et al., 1989; Schwaiger et al., 1987; Stocco and Clark, 
1996), and the fact that StAR is quickly degraded by mitochondria (Clark et al., 1994; 
Stocco and Clark, 1996). The greatest argument against this mechanism is the fact that 
StAR can still function without the mitochondrial targeting sequence as presented here 
and also previously (Arakane et al., 1996; Arakane et al., 1998), since the desorption 
mechanism is entirely dependent on the action of the mitochondrial targeting sequence's 
capacity to mediate StAR's entry inside mitochondria. The molten globule hypothesis is 
based on the observation that StAR looses tertiary structure white retaining secondary 
structure at low pH (Bose et al., 1999; Christensen et al., 2001). Through molten globular 
species, StAR can interact preferentially to membranes (Christensen et al., 2001), acting 
on the cytosolic side of the outer mitochondrial membrane. Unfortunately, an acidic 
environment of pH 3.5-4.0 locally at the mitochondrial membrane bas yet to be proven 
227 
and does not account for the fact that StAR was observed to be located in the 
intermembrane space of mitochondria (King et al., 1995). Finally, the intermembrane 
shuttle mechanism is the child of the crystalized human MLN64 structure {Tsujishita and 
Hurley, 2000). The authors suggest that the hydrophobie tunnel discovered in the crystal 
is responsible for binding cholesterol inside StAR and thus shuttles from the outer 
mitochondrial membrane to the inner mitochondrial membrane, much like the mechanism 
of sterol carriers. They also suggest that the transfer mechanism necessitates 
conformational changes of the loops and or the C-terminal a-helix to allow cholesterol 
access to the hydrophobie tunnel since the openings are not large enough to let 
cholesterol pass. The greatest downfalls of this mechanism are the fact that the crystal 
does not account for the N-terminal region of StAR comprising the mitochondrial 
targeting sequence, and that shuttling of cholesterol from one membrane to the next 
would be fast enough as observed. These authors also suggest that StAR can enter into 
the mitochondrial intermembrane space without the mitochondrial targeting sequence 
based on the work of others (Derman et al., 1993), although this bas not been proven for 
StARyet. 
Since the StAR. mechanism still remains a mystery, mostly due to the hydrophobie 
nature of StAR not allowing proper analysis of the protein, and contradicting 
experimental evidence exist, the notion of an amalgamated mechanism representing all 
these observations is growing. Recently, such a mechanism was presented (Stocco, 
2000); StAR-mediated cholesterol transfer inside the mitochondria would be some sort of 
a ''pore", which while interacting with both mitochondrial membranes, would change 
conformations through a molten globular fonn to expand the hydrophobie tunnel 
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extremities allowing cholesterol to pass. However, this is not supported by any new 
experimental evidence. This ''pore" mechanism therefore merges the desorption and 
molten globular mechanisms, using the sterol carrier structure of l'dLN64. Unfortunately, 
this ''pore" model is still dependent on the presence of the N-terminal mitochondrial 
targeting sequence and does not account for the observation that StAR can be located in 
the intermembrane space, other than at "contact sites". In addition, no protein interactions 
were successfully obtained for StAR as of yet (Kallen et al., 1998a; Kallen et al., 1998b). 
Simultaneously, we present another vision. Following the key observations that the C-
terminal region StAR is believed to conformationally change transiently for cholesterol 
binding (Tsujishita and Hurley, 2000), that upon binding of a cholesterol analogue causes 
StAR to loose a-helical structure (Petrescu et al., 2001), that molten globular states of 
StAR are possible although artificially at low pH values (Bose et al., 1999;Christensen et 
al., 2001), and that the C-terminal a.-helix entirely covers the cholesterol binding site and 
should be free for movement, we conceptualized that StAR function is mediated through 
various conformational states of the C-terminal a-helix (Chapter 2.1. Fig. 6 and 8). In 
order to test this hypothesis, we used theoretical structure-based thermodynamic 
calculations to determine the possibility of the existence of such species under normal 
physiological conditions. We show that an unfolded C-terminal a-helix StAR is 
theoretically plausible in a significant popoulation and should be important for StAR-
mediated cholesterol transfer inside mitochondria. 
Severa! key components come to mind for our novel "flipping StAR" mechanism. 
First of ail, our model bas a hydrophobie cavity instead of a hydrophobie tunnel as for the 
MLN64 crystal. Therefore StAR absolutely bas to open to allow cholesterol access to the 
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binding site as suggested (Tsujishita and Hurley, 2000). Second, discovery of water 
molecules inside the MLN64 crystal is crucial as the driving force allowing StAR to open 
(Tsujishita and Hurley, 2000). Destabilization of StAR by the hydration of the 
hydrophobie cavity (by approximately 12 kcal/mol) makes a significant population of 
unfolded StAR (approximately 2%) available for cholesterol binding and transfer inside 
mitochondria, as calculated by structure-based thermodynamics (Freire, 1993; Lavigne et 
al., 2000). Third, StAR activity is govemed by the equilibrium of conformational states 
of StAR, along with the cholesterol gradient between mitochondrial membranes, resulting 
in the observed rapid adaptation of StAR to acute stimulation and inactivation (Clark et 
al., 1994; Stocco and Clark, 1996). Fourth, due to our modeling and STC calculations, 
StAR is not limited by the presence of the mitochondrial targeting sequence and can be 
localized pratically anywhere solution, including in the intennitochondrial space or in 
proximity of the mitochondrial outer membrane in the cytosol. This allows for a rapid 
cholesterol transfer inside mitochondria as observed (King et al., 1995) for the case of the 
intermembrane space shuttle mechanism, but does not exclude the possibility that StAR 
functions outside mitochondria. And fifth, our theoretical dissociation constant reflects a 
mechanism in which cholesterol will be released rapidly (Artemenko et al., 2001). 
On the other hand, one can argue that: 1) no experimental evidence shows that the C-
terminal a-helix is the only structure that changes conformation for cholesterol binding 
and that anyhow, it refolds ontop of cholesterol between "trips", and 2) our modeling 
does not take into account phosphorylation and the N-terminal mitochondrial targeting 
sequence in the StAR mechanism. Here, we supply new in silico experimental data 
demonstrating that the StAR C-terminal a-helix can unfold to produce a significant 
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population molten globular species of StAR. We only simulated the movement of the C-
terminal a-helix for simplicity and because it has been shown to be critical for StAR 
function (Bose et al., 1996; Lin et al., 1995). Moreover, the C-terminal a-helix is the 
only helix in proximity of StAR' s cholesterol binding site, which can lead to the observed 
loss of a-helical content upon the ligation of the cholesterol ~ogue (Petrescu et al., 
2001). It is entirely possible that other structures, such as loop Cll, simultaneously move 
with the C-tenninal a-helix as previously suggested by Tsujishita et al. (Tsujishita and 
Hurley, 2000); STC calculations ofthis movement demonstrate that these conformational 
changes are beneficial to StAR molten globular populations, aiding to bind cbolesterol. It 
is also possible that the C-terminal a-helix refolds ontop of cholesterol after it has bound 
to StAR, although this could significantly reduce the transfer rate as an additional step is 
required for effective cholesterol transfer. In addition, it bas already been demonstrated 
that StAR looses much a-helical cbaracter wben a cholesterol analogue binds (Petrescu et 
al., 2001), and the C-terminal a-helix will only refold ontop of cholesterol if it can be 
shown that it's refolding is faster than cholesterol release from the binding site. 
Finally, it is impossible to model the first 65 amino acids of StAR since the equivalent 
amino acids of MLN64 have not been crystalized. On the other band, it seems that 
phosphorylation and N-terminal processing of StAR are rapidly obtained after StAR 
transcription, and are necessary for conveying StAR activity (Artemenko et al., 2001). 
These authors conclude that wild type StAR is rapidly phosphorylated in the cytosol after 
transcription of the StAR mRNA, followed by import into the mitochondrial 
intermembrane space where the N-terminal mitochondrial targeting sequence is rapidly 
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cleaved. Therefore, what is the linlc between phosphorylation, N-terminal processing, and 
StAR function? 
First of ail, StAR phosphorylation seems to serve two fonctions. First, it interacts with 
the N-terminal mitochondrial targeting sequence. This would be especially important 
outside mitochondria where the mitochondrial targeting seqeunce is important to localize 
StAR in proximity of the outer mitochondrial membrane. Second, StAR phosphorylation 
would somehow increase StAR reactivity inside mitochondria, after the mitochondrial 
targeting sequence is rapidly cleaved (Artemenko et al., 2001). Overall, phosphorylation 
may perform these tasks by simply augmenting StAR stability as suggested elsewhere 
(Clark et al., 2000). On the other band, it seems that the major function of the 
mitochondrial targeting sequence is to localize StAR in proximity of the outer 
mitochondrial membrane since no direct protein-protein interactions have been found for 
StAR, StAR is functional without the N-terminal mitochondrial targeting sequence, and 
the mitochondrial targeting sequence is rapidly removed after StAR import into 
mitochondria. Yet here, we show that there seems to be a possible interaction between the 
mitochondrial targeting sequence and phosphorylation suggesting that outside 
mitochondria, the mitochondrial targeting sequence may also be implicated in StAR 
stability. 
4.2. P450cl 7: 
4.2.J. Site-Directed Mutagenesis: In order to understand substrate selectivity of the 
P450cl 7, we mutated the hamster P4SOcl 7 at precise amino acids in the desire to change 
the hamster P450cl 7 into a more ''buman" type. Basically, we compared the amino acid 
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sequences of several species to rationaly choose residues that might be implicated in 
substrate selection and/or activity control the P450cl 7 (Chapter 3.2.). Since the hamster 
P450cl 7 produces both DHEA and androstenedione is relatively large amounts, it is 
conceivable that the primary amino acid sequence of the hamster resembles both the 
DHEA and androstenedione producing P450cl 7s, such as the human and rat P450cl 7s 
respectively. Therefore, this enables us to target specific amino acid that might convey 
human P450cl 7 specificity and/or activity profile. 
Of ail the possible hot spots, three key amino acids stood out: T202N, D240N, D407H. 
lnterestingly, these three amino acids resulted in different patterns of the hamster 
P450c 17 activity alterations. Three distinct patterns were obtained: 1) a general effector 
for all P450cl 7 activities, T202N; and 2) a particular P450cl 7 activity, D240N; and 3) a 
particular P450cl 7 activity for a specific pathway, D407H (Chapter 3.2. Table 2). 
Unfortunately, only the D407H mutant resulted in making the hamster P450cl 7 a bit 
more ''human" as predicted. 
Unlike the R200N guinea pig P450cl7 mutant (Beaudoin et al., 1998), the hamster 
T202 seem to be implicated in the overall reactivity of the hamster P450cl 7 since both 
the l 7a-hydroxylase and 17,20-lyase activities were decreased for both pathways (DHEA 
and androstenedione pathways - Chapter 3.2. Table 2). On the other band, the guinea pig 
mutant R200N specifically increased l 7a-hydroxylation of pregenenolone and decreased 
17,20-lyase of l 7a-hydroxyprogesterone; this effectively makes the guinea pig P450cl 7 
activities resemble more like the human P450cl 7 activity profile. Regrettably, the double 
mutant R200Nm02N did not result in further activity alteration. 
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Interestingly, the D240N mutation seemed to have perturbed the hamster P450cl 7 in 
such a way as to specifically decrease 17,20-lyase activity for both l 7cx-pregnenolone 
and 17cx-hydroxyprogesterone (Chapter 3.2. Table 2). Yet, this mutation decreased the 
17,20-lyase activity more for the DHEA pathway more than for the androstenedione 
pathway, suggesting that this mutation bas a greater effect on the binding interactions of 
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the l 7cx-hydroxylpregnenolone 31}-hydroxyl group than on the 3-keto group of l 7cx-
hydroxyprogesterone; this is the only structural difference between these substrates. 
Finally, D407H specifically reduced the l 7cx-hydroxylase activity for the 
androstenedione pathway for the hamster P450cl 7 (Chapter 3.2. Table 2). This is rather 
interesting since similar mutations in the human P450cl 7 resulted in decreased l 7cx-
hydroxylase. Of particular interest, it was recently reported that the mutation P409R 
(Lam et al., 2001) caused complete loss of 17cx-hydroxylation in a patient harbouring this 
mutation. On the other band, it was initially reported that the mutation F417C caused 
specific loss of 17,20-lyase activity (Biason-Lauber et al., 2000b) although investigation 
of this mutation by others showed that it resulted in outright abolition of ail P450cl 7 
reactivity (Gupta et al., 2001). The only way that the hamster P450cl 7 D407H mutation 
resembles more like the human P450c 17 is in the fact that now, the hamster P450cl 7 
harboring this mutation relatively produces more DHEA than androstenedione when each 
pathway is compared individually. 
To our dismay, we were unable to convey complete human P450c17 activity to the 
hamster P450c17. To obtain this, we would have had to obtain an increased 
DHEA/androstenedione production ratio due to an elevated 17,20-lyase activity for the 
DHEA pathway as compared to the androstenedione pathway; the l 7a-hydroxylase 
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activity should not have been altered. Then again, obtaining our present results enabled us 
to classify the fonction of amino acids in the substrate selection and P450c 17 activity. But 
in order to obtain a complete understanding of their implication in these P450c 17 
characteristics, we opted for a molecular model of the hamster P450cl 7. 
4.2.2. Modeling of the Hamster P450cl 7: Alignment of the hamster and human 
P450c 17 was unambiguous and therefore made it relatively simple to model the hamster 
P450cl 7 by homology to the human coordinate data (Chapter 3.2. Fig. 2). In order to be 
able to compare discreet structural differences between these two models, it is necessary 
to perform the same energy mjnimizations and molecular dynamic calculculations when 
modeling. In effect, this is to reduce possible differences due to human manipulation. 
Upon completion of the hamster model, we first compared the overall structures and the 
active sites of the hamster and human P450cl 7 models, followed by modeling of the 
hamster mutants to visualize the effect of altering these amino acids on the 
conformational states of the hamster P450cl 7. Finally, we docked ail the possible 
P450cl 7 substrates in the hamster P450cl 7 model to try to understand the P450cl 7 
substrate specificity. 
Overall, the hamster and human P450cl 7 structures resembled each other to great 
extend as we predicted. Yet, structural differences were evident. Three dissimilarities 
were discovered: 1) consolidation of the hydrophobie domain consisting of the a-helices 
A, F, and G, and the (3-strands 1.1-1.3 and 2.1-2.2; 2) positioning of the J' a-helix; and 3) 
the structural environment of the active site (Chapter 3.2. Fig. 4A and 4B). The 
implication of these structural changes is not ail clear, although it is certain that these 
ultimately change the conformation of the hamster P450cl 7 conveying the observed 
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activity profile. Specifically, it is imaginable that ail these "global" structural changes 
outside the active site are responsible for the active site conformation. For example, when 
the active sites of the hamster and human structures are compared, the catalytically 
important T306, believed to be responsible for the homolysis of oxygen (Lee-Robichaud 
et al., 1998), is kinked upwards from the tloor of the active site composed of the heme. 
Moreover, this ''kinkjng" positions the hamster P450cl 7 H-1 loop closer to the putative 
substrate entrance than in the human structure, implying that this loop may be important 
for substrate recognition upon binding (Chapter 3.2. Fig. 4C and 40). 
Molecular modeling of the hamster P450cl 7 mutants shed light on their implication 
for P450cl 7 reactivity. Indeed, the mutant T202N is located in the F-helix (Chapter 3.2. 
Fig. S), and interacts with V483 forming the roof of the active site. Even though 
asparagine ·bas more volume than threonine (two 8-atoms vs one y-atom, respectively), 
the T202N-V483 interaction still exists. Yet, T202N causes the roof of the P450c17 
acitve site to drop, lowering the active site's ''headroom". Since ail the P4SOcl 7 
substrates are ·virtually identical on the P-side of the steroids [formed by predominately 
by the methyl groups at position 18 and 19 for the interaction of the steroid and the roof 
of the active site (Auchus and Miller, 1999)], it is easily understandable that the mutation 
T202N reduces ail of the hamster P450cl 7 activities. In addition, the T202N mutation 
caused Il 12 to move out of place; Il 12 seems a great deal implicated in substrate binding 
for reactivity. 
D240N is located halfway in the G-helix at the junction of the G-, I- and B '-helices 
adjacent to the H-I loop (Chapter 3.2. Fig. 5). This mutation caused the I-helix to kink, 
raising T306 away from the heme plane, and lowering 1112 closer to the heme. Yet the 
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most important alteration seems to be the stuffing of R96 and R440 towards the active 
site; these amino acids seem implicated in the initial substrate recognition upon substrate 
uptake into the active site. It is conceivable that alteration of these amino acids by the 
D240N mutation, results in the reduction of l 7a-hydroxylation at two discrete levels. 
First, movement of Il 12, R96 and R440 towards the inside of the hamster P450cl 7 active 
site twists and shrinks the active site probably making it more difficult for the l 7a-
hydroxylated products to enter the active site. And second, it seems that the l 7a-
hydroxyl group of 17a-hydropregenenolone and l 7a-hydroxyprogesterone interact with 
R96 and/or R440 as they enter to the active site. The fact that the only difference between 
the substrates for the l 7a-hydroxylase and 17 ,20-lyase activities is the presence of the 
l 7a-hydroxyl group for the 17,20-lyase substrates and the l 7a-hydroxylase activity did 
not change with the mutation D240N, suggests that an interaction of the l 7a-hydroxyl 
group with R96 and/or R440 is more important than the actual alteration in the hamster 
P450cl 7 active site conformation for this mutation. This is supported by other 
experimental results; recently, it was demonstrated that in cellular systems, the P4SOcl 7 
steroid metabolism consists of two steps (Soucy and Luu-The, 2000). The first step is the 
production of 17a-hydroxylated products after which they are released from the P450c 17. 
When enough l 7a-hydroxyl products accumulate, they seem to compete for the P4SOcl 7 
and thus shift reactivity. This suggests that although the KM's for the human P4SOcl 7 
activities are similar for ail the substrates except l 7a-hydroxyprogesterone (which is 
about 5-10 times higher than the others (Auchus et al., 1998; Lee-Robichaud et al., 
1995)). In addition, as we determined the concentration of pregnenolone or progesterone 
necessary to have a linear correlation between 17a-hydroxylation and 17,20-lyase 
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activity, we discovered that there seemed to be a 17a-hydroxylated product/initial 
substrate concentration ratio (for example: 17a-hydroxyprogesterone/progesterone}, 
where the 17a-hydroxyl product effectively competed for the P450cl 7 shifting the 
activities of the hamster P450c 17 towards 17 ,20-lyase (unpublished results ). Therefore, 
this suggests that although the rate of both P450cl 7 activities ~ similar (as dictated by 
the KM's}, differences in the binding affinities of the substrates influences P450cl 7 
activity. Unfortunately, no binding assays are as yet performed for all P450cl7 substrates 
but should be close at hand (personal communication with R.J. Auchus). 
At tirst glance, it is less obvious why the mutation D407H specitically reduced 17a-
hydroxylation for the androstenedione pathway. D407H is most remotely located mutant 
from the active site, positioned in the meander loop (Chapter 3.2. Fig. 5). Since loops are 
generally believed to move ail about, it is unclear how this mutation can affect anything, 
yet it does. Upon a closer examination, 0407 is located upstream of the heme binding 
C442 and during modeling, results in a shift in heme positioning and· active site volume 
reduction. At this moment, we cannot explain how this active site conformational change 
leads to a specitic reduction in either 17a-hydroxylase activity and/or progesterone 
binding. Yet, it is possible that if the hamster P450c 17 is phosphorylated similarly to the 
human P450cl 7, this mutation could affect hamster P450cl 7 phosphorylation much like 
the F417C mutation in the human P450cl 7; in the case of the hamster, this alteration in 
P4SOcl 7 phosphorylation results in the reduction of 17a-hydroxylase activity specitically 
for porgesterone. 
Due to the lack of time, we did not model the substrates in ail of the modeled hamster 
P4SOcl 7 mutants. According to our substrate binding models, a total of 12 models would 
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have to be analyzed. Therefore, we cannot absolutely account for the effects of these 
mutants on substrate binding. 
4.2.3. Substrate Uptalce Mechanism for the Hamster P450cl7: Before we can 
conclude about the effects of the mutants on the binding of the substrates, we must first 
have an understanding of the mechanism involved in the uptake of these substrates in the 
hamster P450cl 7. To be able to compare these results with the human P450cl 7 (Auchus 
and Miller, 1999), we docked the substrates in similar positions in the hamster modelas 
in the human structure. Contrary to the human docked models, we obtained two sets of 
hamster P450cl 7 models for each docked substrate (Chapter 3.3. Fig. 1 and 2). Since 
similar patterns for the models were obtained, a molecular mechanism for substrate 
selectivity and uptake into the hamster P450c 17 becomes apparent, a result not foreseable 
with the human docked models. 
As the substrates were docked in the human P450cl 7 structure (Auchus and Miller, 
1999), it was discovered that the active site was not large enough to allow a bi-lobal 
binding of the substrates conveying the two activities of P450c 17 as previously described 
(Burke et al., 1997; Laughton et al., 1990; Lin et al., 1994). Our results show that 
although a bi-lobal active site is not present in the hamster P450cl 7, but the substrates 
rotate in the active site in order to obtain optimal positioning for reactivity. Interestingly, 
similar patterns for the all the substrates were obtained except for the binding of 
pregnenolone. 
Indeed, amino acids seemingly important for the binding and proper entry of the 
substrates in the hamster P450cl 7 active site were identifed. Brietly, two sets of amino 
acids were recognized as important for either directing the substrates as they enter the 
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P450cl 7, or placing them appropriately for reaction (Cbapter 3.3. Fig. 2). The tirst set is 
composed mainly of residues surrounding T306 and R96; two residues directly opposite 
each other in the active site, and lined up with the volume of the empty acitve site. This 
set includes amino acids Kl 10, G303, T306, and V366, along with S94, R96, and R440. 
The amino acids responsible for the proper binding of the substrates for reactivity are 
A302-G303, Kll0-1112, and R440 atone end, and P321 with A367-L370 for the other 
end; the only substrate functional groups capable of interacting strongly enough with 
P450cl 7 to maintain substrate positioning in the active site are the polar "oxygens" at 
either ends. lt is not surprising that some residues are members ofboth these sets, as these 
are located in a position much like the corner where two walls meet, in the active site 
three-dimensional space. 
These findings are supported by previous discoveries of human P450cl 7 mutants 
reported to change P450cl 7 reactivity due to supposed active site formation alterations. 
Most significantly, the R96W mutant (Laflamme et al., 1996) and the duplication of Il 12 
(lmai et al., 1993) have been reported to abolish P450cl 7 activity. Moreover, our 
modeled hamster mutants also alter the positioning of these key amino acids supporting 
their implication in the mechanism of substrate uptake. 
S. Conclusions 
A tremendous amount of structural information is obtained from molecular modeling. 
This information can explain previously obtained data, such as site-directed mutagenesis, 
and open new exciting testable opportunities targeting specific objectives. Here, we used 
molecular modeling to shed light on the elusive mechanism of the StAR function and to 
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explain our structure/function analyses of the P450cl 7 in hamsters. Overall, we bave 
successfully combined modem molecular modeling witb more traditional 
structure/fonction analyses to develop testable models, assisting us to refine our 
understanding of these systems. 
5.1. StAR: 
According to our results presented here, we perceive StAR as baving two distinct steps 
for reactivity after its transcription from mRNA: 1) cytosolic modification and 
localization to mitochondrial membranes, and 2) import into mitochondria for full 
reactivity. Of major importance, we propose a novel testable mechanism for StAR 
fonction, which can account for most of the StAR's observed characteristics. Together 
with the proposition of a "pore-like" StAR, we engage in new exciting experimentation to 
discover the true nature of StAR fonction. 
Taken together, we have achieved our objectives in: i) obtaining a realistic model of 
StAR capable of ii) explaining our rational site-directed mutagenesis results for the 
putative phosphorylation sites, and used to identify important amino acids responsible for 
StAR function (i.e.: sait bridge) to iii) clarify current contradicting experimental results. 
Our work opens new exciting areas of research including the systematic identification of 
StAR phosphorylation sites and their implication in StAR function in ail the species 
studied to date, and the elucidation of the actual StAR mechanism with respect to our 
proposed mechanism. Nuclear magnetic resonance and more classical thermodynamic 
studies will play a major part in the revelation of the actual StAR mechanism. 
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5.2. P450c17: 
Although our research on the str:ucture/function relationship of the hamster P450cl 7 
was stunted by the attractive opportunity to elucidate the StAR mechanism of action, we 
have obtained an enormous amount of information on the selectivity and activity profiles 
of the hamster P450cl7 versus the buman P450cl7. We conceptualize that the P450cl7 
mechanism is dependent on three key steps: 1) substrate recognition at the putative 
substrate entrance, mediated by residues R96 and D 116; 2) admission of the substrates in 
a temporary orientation, directed by amino acids R96 and T306; and 3) rotational 
modification of the substrates position such that they are in optimal orientation for proper 
reactivity. lmportantly, ail the P450cl 7 residues play an essential role in this mechanism, 
either to: 1) maintain structural integrity of enzyme, 2) participate in heme binding, redox 
partner interactions, and catalysis, and/or 3) influence active site geometry and hence 
substrate selection. 
Again, we met our objectives. We have: 
i. Identified amino acids responsible for hamster P450cl 7 
substrate for selectivity and have classified them accourding to 
functionality and degree of effect on overall substrate 
selection; 
ü. Obtained a useful model of the hamster P450cl 7 capable of 
explaining our rational site-directed mutagenesis, as well as 
clarifying the human and hamster activity profile differences; 
and, 
iii. Proposed a plausible P450cl 7 mechanism responsible for 
substrate uptake selectivity conferring the observed activity 
profiles. 
As for any structure-function analyses, the increasing power of nuclear magnetic 
resonance and thermodynamic instruments will play a major rote in the validation 
of any proposed mechanism. lt can be thus envisioned that such experimental 
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APPENDIX A: Enlarged Figures. 
Chapter 2.1. Fig. 1 O. Proposed StAR mechanism in the mitochondrial intermembrane 
space (see page 98 for legend). 
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Chapter 2.1: Fig. 11. Proposed StAR mechanism in the cytosol (see page 99 for legend). 
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ABSTRACT We have studied the eff'ect of the adrenocorticotropin hormone 
(ACTH) on the expression of the Steroidogenic Acute Regulatory protein (StAR) in 
vivo in rat and hamster adrenals, also in transfeC'tion experiments using COS-1 cells. 
ln vivo, ACTH increased the level of StAR mRNA within 30-60 minutes, and also 
increased the quantity of StAR but with a 2-3 hour delay. ACm induced the 
formation of many acidic StAR species as analyzed by two-dimensional gel 
electrophoresis and immunoblotting. In the transfection experiments, (Bu)i-cAMP 
also induced the formation of many acidic species for the hamster StAR; in COS-1 
cells, StAR is phosphorylated mainly on serine (S) residue(s). When alanine (A) was 
substituted for serine, Sl3A, S18SA and Sl94A mutants had decreased StAR 
activity compared to wild type, so determining the importance of these amino acid 
residues in StAR action. The full length WT, N46-truncated StAR lacldng its 
mitochondrial import sequence, and N46-Sl94A had similar activlties, whereas N46-
S18SA had completely lost lts activity. Our results suggest that S194, but not S18S, 
fonctions in association with the mitochondrial import sequence for the initiation of 
StAR activation. Further studies sbowed that Sl8S is impllcated in sait bridge 
stablllty, not in StAR phophorylation, suggesting its importance for StAR folding. 
Thermodynamic calculations of the hamster StAR bomology model based on 
MLN64, show that StAR can partially unfold to bind cholesterol and serve as a 
rapid transfer mechanism for eventual translocation into mitocbondria. This is 
supportive of a StAR functioning elther outside the mitocbondria or in the 
mitochodrial intermembrane space. 
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1. Pre-StAR (Steroidogenic Acute Regulatory protein) studies 
1.1 Studies that have lead to the discovery of phosphoproteins implicated in the acute 
response of ACTH stimulation. 
Early studies have shown that one action of adrenocorticotropin (ACTH) and 3', 
5' -adenosine monophosphate on adrenocortical tissues was to increase the conversion of 
cholesterol to pregnenolone by the cytochrome P450 side chain cleavage (P450scc) 
enzyme system, considered as the rate-limiting step of the steroidogenesis pathway 
(Stone and Hechter, 1954; Karaboyas and Koritz, 1965). In vitro studies on different 
adrenal preparations have shown that ACTH acutely stimulated corticosteroid production 
within approximately 3 minutes (Farese, 1971; Kloppenborg et al., 1968; Urquhart and 
Li, 1968) and that the protein synthesis inhibitor cycloheximide prevented this 
stimulation in vitro (Haynes, 1959) as well as in vivo (Garren et al., 1965). It bas also 
been established that removal of this inhibitor from incubation medium allows ACTH 
stimulation to occur again. Moreover, the rapid lost capacity of ACTH prestimulated 
adrenal cells to continue steroid production in the presence of cycloheximide indicated 
that these newly formed proteins are highly labile. Based on above results the concept of 
newly synthesized labile proteins bas been proposed to mediate the acute steroidogenic 
response upon ACTH stimulation. 
It was subsequently established that cycloheximide blocked the translocation of 
cholesterol from the outer membrane to the inner membrane (Privalle et al., 1983) where 
is located P450scc (Karaboyas and Koritz, 1965; Yago and lchii, 1969), without affecting 
P450scc activity (Arthur and Boyd, 1974). The transport of cholesterol into mitochondria, 
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and not P450scc activity, was thus considered the rate-limiting step in the metabolism of 
cholesterol to pregnenolone and isocaproaldehyde. 
A likely candidate for the postulated corticosteroid stimulatory protein (Furguson 
Ir, 1962) was pointed out by Krueger and Orme-Johnson (1983) who reported the 
discovery of a protein produced during acute ACTH stimulation in isolated rat adrenal 
cells. The synthetic time course and ACTH dose response of this protein were similar to 
those of corticosteroid production and they were concomitantly inhibited by 
cycloheximide. The subsequent work by the group of Orme-Johnson (Alberta et al., 1989; 
Epstein and Orme-Johnson, 1991; Krueger and Orme-Johnson, 1983; Pon et al., 1986b; 
Pon et al., 1986a; Pon and Orme-Johnson, 1986) covering the period of 1983-1991 
clearly established the existence of a family of 28 to 32 kDa phosphoproteins in various 
steroidogenic tissues that fulfills the requirements of the postulated labile steroidogenic 
stimulatory protein. Their studies showed that these proteins ail originated from a 
common 37 kDa precursor that was rapidly phosphorylated in response to cAMP, and 
cleaved during its import into mitochondria. These authors made the suggestion that this 
phosphoprotein could carry cholesterol inside mitochondria during its transit process 
(Epstein and Orme-Johnson, 1991). 
2. Post-StAR studies 
2.1 Cloning of the StAR gene and its identification as the factor responsible for 
the acute steroidogenic response to ACTH stimulation. 
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Phosphoproteins similar to those reported by the group of Orme-Johnson were 
analyzed by Stocco and Kilgore (1988) in MA-10 mouse Leydig tumor cells. They found 
in (Bu)2-cAMP-stimulated cells four newly synthesized 30 kDa phosphoproteins with 
different pl localized into mitochondria. These phosphoproteins were shown to be 
identical by tryptic peptide analysis (Stocco and Chen, 1991). They also reported that 
phosphorylation was responsible for the more acidic forms of two of these proteins. 
Purification of the 30 kDa proteins from MA-10 Leydig cells by Clark et al. 
(1994) followed by amino acid sequence analysis, allowed the cloning of its cDNA. 
These researchers demonstrated for the first time that expression of this protein in 
transfected MA-10 cells in the absence of hormonal stimulation was sufticient to induce 
steroid production (Clark et al., 1994). They have concluded that this novel protein is 
required in the acute regulation of steroidogenesis and they proposed to name it 
Steroidogenic Acute Regulatory protein. 
The cloning of the human StAR was reported in 1995 (Sugawara et al., 1995), and 
Lin et al. (1995) discovered a mutated and non functional StAR in three individuals with 
congenital adrenal hyperplasia (LCAH), a disorder that is characterized by impaired 
gonadal and adrenal steroidogenesis. This provided the first genetic evidence that StAR is 
essential for normal adrenal and gonadal steroidogenesis. Another strong evidence that 
StAR is essential for steroid synthesis is the lipid accumulation and impaired 
steroidogenesis in steroidogenic tissues of StAR gene nullizygous mice (Caron et al., 
1997b). 
The cloning of StAR cDNA bas been subsequently reported for other species, 
including pig (Pilon et al., 1997), hamster (Fleury et al., 1998b), rat (Ariyoshi et al., 
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1998), cow (Rust et al., 1998), horse (Kerban et al., 1999), chicken (Bauer et al., 2000), 
frog (Bauer et al., 2000), zebra tish (Bauer et al., 2000), rainbow trout {Todo et al., 2000), 
brook trout (Goetz, 2000), and sheep (West et al., 2001). A high StAR sequence 
homology exists between these animal species. For example, the hamster StAR is 91.9% 
homologous to mouse and only slightly less with rat, human and other indexed species. 
As for the rodents, the hamster StAR protein contains 284 amino acid residues, one less 
than the human, bovine and porcine. The StAR from ail the indexed species possess a 
mitochondrial recognition signal peptide. The hamster and mouse sequence signal 
cleavage site follows the consensus motif for a two-step cleavage site (Hendrick et al., 
1989) whereas only one cleavage is predicted for sequences of other species. 
In situ fluorescence hybridization placed the human StAR locus on chromosome 
8pl 1.2, whereas a StAR pseudogene was mapped on chromosome 13 (Sugawara et al., 
1995). Southern blot analyses suggest the presence of only one StAR gene in the hamster 
genome (Fleury et al., l 998b ). 
2.2 Tissue distribution of StAR mRNA. 
StAR expression was detected mainly in steroidogenic tissues. For example, the 
hamster StAR mRNA (1. 7 kb, 3.1 kb and S .3 kb in size) was revealed in adrenals, ovary 
and testis, and not in other tissues (Fig.l) (Fleury et al., 1998b). The human StAR mRNA 
(1.6 kb, 4.4 kb and 7.5 kb) was detected in adrenals, testis, kidneys, but not in placenta 
(Sugawara et al., 1995). However, human StAR mRNA was detected in kidneys where 
StARmight be involved for the hydroxylation of vitamin D. The rat StAR mRNA (1.6 kb 
and 3.5 kb) was found in adrenals (Kim et al., 1997; LeHoux et al., 1998); in situ 
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hybridization studies revealed StAR transcripts in the rat cerebral cortex, hippocampus, 
dentate gyrus, olfactory bulb, cerebellar granular layer, and Purkinje cells (Furukawa et 
al., 1998), suggesting that StAR might be involved in neurosteroids synthesis. 
2.3 Jn vivo effects of ACTH on adrenal StAR mRNA expression 
The level of StAR mRNA in the adrenal zona glomerulosa ZG and zona 
fasciculata ZF were increased within thirty minutes after ACTH administration in rats 
(LeHoux et al., 1998) (Ariyoshi et al., 1998; Fleury et al., 1998a) and hamsters (Fleury et 
al., 1998b) indicating that ACTH regulates StAR mRNA synthesis. In other steroidogenic 
tissues, StAR mRNA levels were also induced by trophic hormones producing cAMP, 
suggesting that the cAMP-dependent protein kinase A pathway may induce StAR 
transcription. In human granulosa cells for example, the increase in StAR mRNA upon 
cAMP stimulation was associated with an increased transcription of the StAR gene that 
was blocked by actinomycin D (Kiriakidou et al., 1996). Deletion analyses of the human 
(Sugawara et al., 1996), mouse (Caron et al., 1997a), rat (Sandhoff et al., 1998), porcine 
(LaVoie et al., 1999), and bovine (Sugawara et al., 2001) StAR promoters indicate the 
existence of cAMP-responsive regions within 150, 254, 362, 60, and 342 base pairs from 
the transcriptional start site, respectively. Ali these data indicate that cAMP stimulates 
StAR gene trancription activity even though no consensus cAMP responsive element 
(CRE) sequences were found in these StAR gene promoters. This also suggests that the 
CRE binding protein does not bind directly on the StAR promoter and would rather exert 
its action in association with other transcription factors. 
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DNA motifs resembling binding sites for the steroidogenic factor 1 (SF-1) were 
identified in the human (Sugawara et al., 1996), mouse (Caron et al., 1997a; Clark et al., 
1995), and rat (Sandhoff et al., 1998) gene promoters. Furthermore, the human StAR 
promoter is not active when expressed in SF-1 deficient cells. However, the introduction 
of SF-1 into these cells stimulated the promoter activity particularly in the presence of 
cAMP (Sugawara et al., 1996). This suggests that SF-1 plays a key role in controlling the 
basal and cAMP stimulated expression of the StAR gene. The activity of the rat StAR 
promoter, like that of the human, is responsive to cAMP stimulation involving SF-1 
(Sandhoff et al., 1998). In the mouse, SF-1 is also required for activation of the StAR 
promoter but may not be the factor tbat confers cAMP responsiveness in steroidogenic 
cells (Caron et al., 1997a; Clark et al., 1995). 
In SF-1 transfection experiments in a nonsteroidogenic cell line, 
CCAAT/enhancer binding protein P was reported to be involved in the basal and (Bu)2-
cAMP stimulated regulation of the mouse StAR gene transcription (Reinhart et al., 1999). 
Moreover, the transcription factor RIP 140 was recently shown to bind to SF-1 and DAX-
1, negatively modulating the cAMP enhancing effect on the human StAR promoter 
activity (Sugawara et al., 2001). In the murine StAR promoter, a series of complex 
protein-DNA interactions were reported to occur within a cAMP responsive region 
containing C/EBP(J, SF-1, and AP-1 binding sites (Tsujishita and Hurley, 2000). Taken 
together these results clearly show tbat cAMP is effectively involved in the positive 
control of the StAR gene promoter activation. However, the interaction between known 
and unknown transcription factors involved in the complete cAMP action on the StAR 
promoter is yet to be unraveled. 
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2.4 In vivo ejfects of ACTH on adrenal zonal and intracellular distributions of StAR,· 
optical and electronic microscopy. 
Indirect immunotluorescence of rat adrenal paraffin sections revealed the 
presence of StAR in the zonae glomerulosa, fasciculata and reticularis. In control 
adienals (Fig.2A), StAR was more concentrated in the thin zona glomerulosa (arrows) 
but more diffusely distributed in the zona fasciculata and zona reticularis (black bar). 
Five hours after ACTH treatment (Fig.2B), the intensity of the fluorescent signal was 
mainly increased in the zona glomerulosa (arrows) andzonafasciculata (black bar). 
Colloidal-gold electron microscopie studies on thin rat adrenal sections revealed 
that more than 98% of positive StAR labeling was located over mitochondria (Fig.3) 
(LeHoux et al., 1999). It was determined that StAR is mainly localized in the 
intermembrane space and the intermembrane space side of the mitochondrial cristae 
membrane (King et al., 1995). ACTH administration lead to a significant increase of gold 
particles over mitochondrial zona glomerulosa and zona fasciculata cells, whereas it had 
no apparent increasing effect on the number of gold particles in the cytoplasm (LeHoux 
et al., 1999). These results indicate that upon ACTH stimulation, StAR does not 
accumulate in the cytoplasm and that it is either translocated into mitochondria or 
degraded in the cytoplasm. The level of StAR mRNA was increased in hamster (Fleury et 
al., 1996; Fleury et al., 1998b) and rat adrenals (Ariyoshi et al., 1998; Fleury et al., 
1998a; LeHoux et al., 1998) within thirty to sixty minutes post in vivo ACTH 
administration. The increase in StAR protein levels was delayed compared to its mRNA 
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in rat adrenals (LeHoux et al., 1998; LeHoux et al., 1999), suggesting that the newly 
synthesized StAR mRNA was not completely translated into protein. 
2.S In vivo effects of ACTH on rat adrenal StAR processing; characterization by SDS-
PAGE and immunoblotting. 
Under ACTH stimulation the intensity of many rat adrenal specific StAR protein 
bands migrating between 29-39 kDa increased in mitochondrial and supematant 
preparations (Fig.4). The expression of a 30 kDa band was only induced in mitochondria, 
its relative intensity being one tenth that of the major 29 kDa band. A 34 kDa protein 
band only increased in the supematant of the ACTH-stimulated rats (LeHoux et al., 
1999). AU these increases were observed for the three to five hour treatments. Sucb an 
increase was not observed for the one hour treatment (not shown) even if plasma 
corticosteroid levels were already maximally elevated at that time of treatment (LeHoux 
et al., 1999). 
Furtber characterization of the rat adrenal StAR by two-dimensional gel 
electrophoresis and immunoblotting showed the presence of four StAR species in the 
contrai homogenate preparation (Fig.SA, upper panel). The quantity of StAR was not 
increased in the ACTH treated group one hour after ACTH administration, whereas one 
band present in the control (arrow) disappeared in the treated group (Fig.SA middle 
panel). In agreement with these results, Artemenko et al. (2001) also did not find any 
noticeable increases in adrenal StAR expression between control and ACTH treated rats 
thirty minutes after treatment. These results clearly show that StAR does not 
quantitatively change much within the first hour of treatment during acute stimulation by 
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ACTH. Consequently, to explain the action of StAR during this acute stimulation period, 
one should look at minute changes in StAR characteristics. 
Five hours after ACTH administration, however, many changes occurred in the 
number of StAR species as well as in StAR intensity as illustrated (Fig.SA, lower panel). 
Also, as seen in Fig.SB, two main StAR species (5.9/29 and 5.7/29) and four minor . 
species were revealed in mitochondria of control preparations (upper panel). Five hours 
after ACTH administration, ail the above mentioned species were increased in intensity 
and new mainly acidic StAR species were revealed in mitochondria. In the supernatant, 
ACTH treatment led to less apparent changes than in mitochondria. However, ACTH 
induced an increase in the 5.5/29 and 5.4/29 species and a reduction in the 5.4/28 species 
(Fig.SB lower panels). The latter species was observed only in supernatant but not in 
mitochondria. In agreement with our data Artemenko et al. (2001) reported the induction 
of many acidic StAR species in rat adrenals three hours after ACTH administration. 
Taken together these results show that ACTH enhanced the formation and 
accumulation of many acidic species during StAR processing and importation into 
mitochondria. 
3. Structure/Function of StAR 
3 .1 Mutationa/ ana/ysis of StARfunction in non-steroidogenic cells. 
The green monkey kidney COS-1 cell line was used to analyze the activity of wild 
type and mutated StAR. The assay consists of cotransfecting an expression plasmid 
harboring StAR cDNA and an F2 construct containing cytochrome P450scc-adrenodoxin 
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reductase-adrenodoxin cDNA (Harikrishna et al., 1993). The introduction of the 
cholesterol side chain system is essential since COS-1 cells are not steroidogenic. In tbis 
assay the pregnenolone secreted in incubation media retlects StAR activity. Using tbis 
system Lin et al. (1995) found that the plasmid containing normal human StAR cDNA 
synthesized 175 ng of pregnenolone per dish compared to 20 ng for the empty vector. 
Nineteen ng were secreted for the mutan~ Argl93Stop found in one LCAH patient and 25 
ng for the mutant Gln258Stop found in two other LCAH patients. The 20 ng 
pregnenolone secreted in incubation media for the empty vector corresponds to StAR. 
independent cholesterol transport into mitochondria. Using tbis assay we have studied the 
effect of increasing concentrations of the hamster wild type StAR-pcDNA3.l on 
pregnenolone synthesis in the presence or absence of the stimulating agent (Bu)l-cAMP. 
With a fixed concentration of the F2 construct, a maximum in pregnenolone secretion 
was obtained with 75 ng ofWT StAR-pcDNA3.l. 
We have thus studied the effect of (Bu)2-cAMP on the characteristics of StAR by 
2-dimensional gel analysis. Fig.6 shows that (Bu)2-cAMP increased the number of 
mitochondrial StAR immunoreactive species in transfected COS-1 cells. 
Two main immunoreactive StAR bands were revealed for control wild type (Ctr-
WT) with pl of 5.9 and 5.7 migrating in the 30 kDa area (Fig.6A). StAR immunoreactive 
bands are also observed in the right portion of the figure. When (Bu)l-cAMP was added 
in the incubation medium, the two main bands found in Ctr (panel A) were present with 
many induced additional StAR species (Fig.6, panel B). These data are in agreement with 
the in vivo long-term effects of ACTH discussed earlier, showing quantitative and 
qualitative differences in characteristics between Ctr and stimulated StAR preparations. 
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3.2 Mutation of putative phosphorylation sites in the hamster StAR and StAR activity 
Pon et al. (1986b) used 2-dimensional gel electrophoresis to monitor proteins 
synthesized in control and ACTH- or cAMP-stimulated rat adrenal cells. They have 
identified four proteins with different pl baving identical proteolytic peptide maps, now 
known as StAR. Two of these proteins were found in unstimulated cells and four after 
cell stimulation. They also found that 32P-phosphate was incorporated into two of these 
proteins and that incubation with E. coli pbosphatase caused a decrease of this 
incorporation. These authors established a correlation between the phosphorylation of 
these proteins and steroidogenesis upon ACTH stimulation in rat adrenal cells. 
By amino acid sequence alignment of StAR ftom the thirteen different species 
indexed up to now, we bave determined the presence of eleven putative phosphorylation 
sites in the hamster StAR which were conserved among most species. The eleven 
putative pbosphorylation sites of the hamster StAR that were mutated are serine (S) S 13, 
SSS, S60, S90, Sl8S, S194, S273 to alanine (A), and threonine (T) TS and T262 to valine. 
(V). The mutants S13A, S185A and S194A decreased StAR activity by 30%, 81% and 
95% respectively, whereas the others did not result in any changes (Fleury et al., 2002). 
The secretion of pregnenolone was increased for WT and ail mutants in the presence of 
(Bu)2-cAMP. However, the increase was 40% and 89% lower for the stimulated S18SA 
and Sl94A mutants compared to the stimulated WT. These results clearly show that it is 
the mutation Sl94A that affected StAR activity the most. The double S13A/Sl94A and 
Sl85A/S194A and the triple Sl3A/Sl85A/S194A mutants were thus engineered and 
tested on StAR activity. The activity of the double mutant S 13A/S 194A was further 
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decreased compared to that of the Sl94A mutant, yet still stimulated by (Bu)2-cAMP. 
The StAR activity of the double Sl8SA/Sl94A and triple Sl3A/Sl85A/S194A mutants 
were practically abolished demonstrating the importance of these three amino acid 
residues (Fleury et al., 2002). 
The change in StAR activity of the above-mentioned mutants was not due to 
differences in StAR expression. In fact, the quantity of expressed protein was the same 
for unstimulated WT and mutant transfections. However, an increase in the quantity of 
StAR occurred when (Bu)2-cAMP was added to the incubation media. This was also 
similar for WT and S185A, S194A and Sl85A/S194A mutants, although as mentioned 
above, the mutant StAR activity was considerably lower than that of WT. In the case of 
the double Sl85A/S194A mutant StAR activity was even abolished (Fleury et al., 2002). 
Given these results we conclude that altered mutants StAR activity is due to the mutation 
and not in di:fferent protein expression levels. 
When analyzed by two-dimensional gel electrophoresis, the migration pattem of 
the S194A mutant in COS-1 cells stimulated by (Bu)2-cAMP for 24 hours ditfered from 
the stimulated WT. Empty circles (Fig.6B) show the location of the main low pl StAR 
species present in WT and absent in the Sl94A mutant; many acidic StAR species 
present in WT were not revealed in the Sl94A preparation. These results are in 
agreement with those of Arakane et al. (1997) showing that the substitution of the human 
StAR amino acid residue Sl95 (equivalent to the 8194 in hamster) by alanine, decreased 
steroidogenesis activity and did not yield the more acidic StAR species detected by two-
dimensional immunoblotting. The conversion of the human S 195 amino acid residue to 
an aspartic acid residue had no decreasing effect on steroidogenic activity, which is not 
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incompatible with the idea that a negative charge at this site could modulate StAR 
function. The migration pattern of the Sl3A and Sl8SA mutant preparations stimulated 
by (Bu)2-cAMP, however, did not differ much from WT (Fleury et al., 2002). The lack of 
effect by the S 13A mutation on the migration pattem of StAR is not surprising since the 
part of the protein containing the amino acid S 13 is removed when the leader peptide is 
cleaved by a mitochondrial protease. The lack of effect of the mutation S l 8SA is more 
intriguing and is indicative that this amino acid residue might not be a phosphorylation 
site. To determine ifS185 was effectively a true phosphorylation site, we have substituted 
the amino acid S 185 by either glutamic acid or aspartic acid in order to mimic the 
presence of a negatively charged group on 8185. These substitutions resulted in no 
increases, but rather a decrease in StAR activity. Furtbennore, substitution of S 185 by a 
cysteine residue, to replace the serine OH group by a SH group having similar 
characteristics but cannot be phosphorylated, nearly fully restored basal and (Bu)2-cAMP 
stimulated activities (Fleury et al., 2002). Since the quantity of expressed StAR was 
similar between preparations, we can deduce that the hamster StAR S 185 is not a site of 
phosphorylation. 
3.3 LJN46 mutants and StAR activity. 
We have deleted the first N-terminal 46 amino acid residues of the hamster StAR 
to remove the mitochondrial import sequence. Wben coexpressed in COS-1 cells with the 
F2 construct, the truncated hamster N46-WT protein was as active as its full-length 
counterpart (Fleury et al., 2002). These data are in agreement with those of Arakane et al. 
(1996) suggesting that removal of the StAR mitochondrial import sequence does not 
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affect steroidogenesis. We took advantage of the fact that the truncated N-46 StAR was 
as active as the WT to study the effect of mutating the putative phosphorylation sites 
Sl85 and Sl94. The mutant N46-Sl85A and the double mutant Sl85AS/194A had no 
StAR activity; the pregnenolone found in the incubation media was the same as that of 
the empty vector transfection. Surprisingly however, the activity of the unstimulated 
N46-Sl94A mutant was as strong as that of the N46-WT, the quantity of StAR being 
similar for both preparations. When (Bu)2-cAMP was added to the incubation media for 
N46-WT and N46-Sl94A preparations, the StAR mass increased in quantity. In contrast 
to the unstimulated preparations, the StAR activity of the stimulated N46-WT was 
significantly more elevated than that of the N46-Sl94A mutant (Fleury et al., 2002). 
These results thus indicate that modification of the hamster StAR S 194 site affected the 
acute enhancing effect of (Bu)2-cAMP on StAR activity even in the absence of its 
mitochondrial import sequence. This stresses the importance of this amino acid residue 
for StAR full activity. 
3.4 StAR phosphorylation. 
In order to further analyze StAR phoshorylation, the hamster WT StAR 
containing a myc-tag was isolated by immunoprecipitation with a specific anti-myc 
antibody. By immunoblotting with a specific anti-phosphoserine antibody, we were able 
to reveal phosphoproteins that co-localized with StAR. When a specific anti-threonine 
anti'body was substituted to the anti-phosphoserine antl'body only a faint signal was 
observed (Fleury et al., 2002). WT StAR transected COS-1 cells were also incubated with 
[33P]orthophosphate. Following immunoprecipitation with an anti-StAR antibody, 
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analyzed by immunoblotting, we found two 33P-labeled protein bands migrating at the 
same level as StAR (Fleury et al., 2002). These bands were eut and digested with HCI 
and separated by two-dimensional thin layer chromatography in the presence of intemal 
serine, tyrosine and threonine standards. Almost all the radioactive amino acids 
comigrated with the internai serine standard, with only trace amounts with the threonine 
standard; no radioactivity was detected with the tyrosine standard. These results thus 
indicate that under conditions used, StAR was phosphorylated mainly on serine residues 
and to a much lower extent on threonine residues. Yet which serine(s) and/or threonine(s) 
are phosphorylated remains to be identified for the hamster StAR. 
4. Mechanisms of StAR-Dependent Cholesterol Transfer 
4.1 Discussion of the pre- and post-MLN64 crystal models: desorption, molten globule, 
intermembrane shuttle and PBR-associated mechanisms. 
No clear concise picture can summarize all the experimental data reported to date. 
Therefore, it is not surprising that several models of StAR function exist in literature. 
Historically, these proposed mechanisms can be separated into two eras: pre- and post-
MLN64 crystallographic data. Until the human MLN64 protein START domain was 
crystallized (Tsujishita and Hurley, 2000), no definite three-dimensional structural data 
was obtained to possibly elucidate the actual StAR mechanism. There are two key 
observations that have to be kept in mind wherever one tries to describe StAR function. 
These include: 1) the wild type StARhas a mitochondrial targeting sequence although it 
is not necessary for proper StAR activity, and 2) a minute amount of StAR is actually 
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needed to transfer large amounts of cholesterol inside mitochondria (Clark et al., 1994; 
Petrescu et al., 2001). Yet, the defining characteristic of StAR function is the fact that the 
hydrophobie cholesterol has to be translocated from the outer mitochondrial membrane, 
through the aqueous hydrophilic intermembrane space, to the inner mitochondrial 
membrane where P4S0scc resides for proper steroidogenesis. 
In the initial proposed mechanism of StAR function by Kallen et al. (1998) pre-
:MLN64 crystallographic data, cholesterol would be transferred to the inner mitochondrial 
membrane where P4S0scc resides through a desorption mechanism. As StAR enters 
mitochondria via its N-terminal targeting sequence, the two mitochondrial membranes 
would merge thus allowing cholesterol to "freely" transfer from the cholesterol-rich outer 
mitochondrial membrane to the cholesterol-deprived inner mitochondrial membrane. This 
mechanism can account for the observation that StAR does co-localize to mitochondrial 
contact sites (Pon et al., 1989; Schwaiger et al., 1987; Stocco and Clark, 1996). Since the 
cholesterol gradient essentially drives its transfer inside mitochondria, large amounts of 
cholesterol could be transferred through this mechanism in little time, necessitating little 
amounts of StAR. Once inside the mitochondria matrix, mitochondrial enzymes would 
degrade StAR explaining its rapid turnover. Unfortunately to this date, there have not 
been any protein-protein interactions discovered between StAR and the mitochondrial 
import machinery to support this mechanism. Moreover, the desorption mechanism 
cannot explain the discovery tbat StAR can function without its mitochondrial targeting 
sequence (Arakane et al., 1996; Arakane et al., 1998; Fleury et al., 2002). 
Another proposed StAR mechanism consists of molten globular states active on 
the cytosolic side of the outer mitochondrial membrane. This is due to the observation 
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that the 63-188 StAR fragment is protease resistant (Bose et al., 1999). lndeed, these 
authors have demonstrated that molten globular states of StAR are detected at low pH 
conditions (3.5-4.0), suggesting that these molten globular states are important for StAR 
function. Moreover, Christensen et al. (2001) have demonstrated that these molten 
globular states preferentially bind to cholesterol-rich membranes supporting their 
existence and their importance in StAR activity. On the other band, the existence of 
acidic conditions immediately surrounding the outer mitochondrial membrane remains to 
be revealed in order to drive the observed StAR molten globular states. 
Unfortunately, no StAR crystal bas been obtained yet due to its highly 
hydrophobie nature. The closest approximation to the actual StAR three-dimensional 
structure is the recent crystal structure of the human MLN64 protein START domain 
(Tsujishita and Hurley, 2000). MLN64 is highly homologous to StAR and is believed to 
bave a similar function to StAR in. the human placenta, brain, and n.on-steroidogenic 
tissues (Biecbe et al., 1996; Moog-Lutz et al., 1997; Watari et al., 1997). Straight from 
the crystallographic data, Tsujishita and Hurley (2000) suggest that MLN64 and thus 
StAR, function through an intermembrane shuttle mechanism. This comes from the 
observation that the MLN64 crystal is detined as a hydrophobie tunnel formed by a U-
shaped P-barrel topped by a C-terminal a-helix; the openings of the hydrophobie tunnel 
are aligned to the poles of the capping a-helix. Moreover, these authors have 
demonstrated that both MLN64 and StAR bind one molecule of cholesterol per protein. 
They suggest that in order for cholesterol to bind, conformational changes of either the C-
terminal a-helix and/or an adjacent loop have to occur since the hydrophobie tunnel' s 
openings are not large enough to allow a cholesterol molecule through. Unfortunately, the 
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crystallographic data cannot describe any structural data for the mitochondrial targeting 
sequence as this segment was removed prior crystallization. Therefore, the importance of 
the mitochondrial targeting sequence in StAR remains elusive and cannot explain how 
StAR functions without it. These authors suggest that StAR could enter into the 
mitochondrial intermembrane space without the mitochondrial targeting sequence based 
on the work of others (Derman et al., 1993). On the other band, electron microscopie 
studies of N62-StAR suggest no entry of this molecule in mitochondria (Arakane et al., 
1996). The greatest downfall of this mechanism is that it is believed to be unfeasible that 
a shuttle mechanism transferring cholesterol, migrating from one membrane to the next, 
is rapid enough to support the observed cholesterol transfer inside mitochondria. 
Recently it was shown that StAR and the peripheral-type benzodiazepine receptor 
(PBR) are localized in proximity of each other on the outer mitochondrial membrane 
(West et al., 2001). This observation, coupled to the fact that there is a reduction in 
steroidogenesis in the absence of PBR (Papadopoulos et al., 1997), suggests that these 
proteins could interact in the translocation of cholesterol inside mitochondria. This is 
supportive of the suggestion that StAR acts on or in the outer mitochondrial membrane, 
although, more studies are needed to confirm that this interaction is necessary for proper 
StAR function. 
Finally, due to the lack of a single mechanism being able to explain ail 
experimental data, the notion of "mixed mechanisms" is growing. Of particular interest, 
Stocco (2001) bas recently suggested that StAR would function somewhat like a pore 
where StAR would take the three-dimensional structure descn'bed by the MLN64 crystal, 
be anchored at mitochondrial membrane contact sites, and sustain conformational 
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changes allowing cholesterol to pass through StAR's hydrophobie tunnel. However, there 
is no additional experimental data supplied for this hypothesis; tbis model is still 
dependent on the presence of the N-tenninal mitochondrial targeting sequence and does 
not account for the observation that StAR can be located in the intermembrane space, 
other than at contact sites. 
We have thus investigated a possible mechanism for StAR function set on 
homology modeling of StAR to the MLN64 crystal structure, and through the postulation 
of possible important molten globular states of StAR. 
4.2 Proposed mechanism for StAR action based on thennodynamic calculations. 
In addition to using molecular modeling to solve a protein' s mode of action, it is 
possible to calculate the theoretical free energy of any protein with respect to the solvent 
accessible surface, so long as structural data is available in silico. From these structure-
based thermodynamic calculations (STC) (Freire, 1993; Hilser and Freire, 1997), it is also 
possible to identify partially folded (unfolded) states of proteins in equilibrium with their 
native state and calculate theoretical binding constants of their ligands (Baker and 
Murphy, 1998; Hilser and Freire, 1997; Lavigne et al., 2000). Thus, we have used these 
tools to enlighten our understanding of the StAR function. Both the hamster and the 
hwnan molecular models were obtained by homology modeling to the MLN64 
crystallographic data, while STC simulations were performed on the hamster model. Yet, 
it is not the scope of this review to describe the molecular models or the actual STC 
simulations. These results are the subject of another publication (Mathieu et al., 2002). 
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We conceptualised that StAR function is mediated througb various 
conformational states of the C-terminal a-helix following the following observations: 1) 
molten globular states of StAR are possible althougb artificially at low pH values (Bose 
et al., 1999; Christensen et al., 2001); 2) the C-tenninal region of StAR is believed to 
transiently change conformations for cholesterol binding (Tsuji~hita and Hurley, 2000); 
3) upon binding of a cholesterol analogue, StAR looses a-helical structure (Petrescu et 
al., 2001); 4) the C-terminal a-helix entirely covers the cholesterol binding site and 
should be free for movement; and 5) the StAR models had a hydrophobie cavity instead 
of a hydrophobie tunnel - the fact that a cavity is present instead of a tunnel, suggests that 
conformational changes are absolutely necessary for cholesterol binding. Througb the 
production of various models of different conformational states of StAR, matcbed by 
STC calculations, we have shown that a StAR unfolded C-terminal a-helix is 
theoretically plausible in a significant population under normal conditions. This partially 
unfolded StAR should be important for StAR-mediated cholesterol transfer inside 
mitochondria (Mathieu et al., 2002). These observations become important for describing 
any StAR mechanism. 
In the case of the intermembrane shuttle mechanism, it is believed that this 
mechanism is improbable due to the slow nature of protein diffusion in solution. STC 
calculations of the StAR models showed that the equilibrium between the folded and 
partially unfolded states (molten globular) of StAR is rapid, supporting a much faster 
intermembrane shuttle mechanism (Artemenko et al., 2001). This mechanism no longer 
necessitates StAR to unfold and refold to bind or release cholesterol. Therefore, a simple 
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rotational translation is needed to transfer cholesterol inside mitochondria at 
mitochondrial contact sites. 
The partially unfolded states of StAR can also add insight into a mechanism 
where StAR functions on the cytosolic side of the outer mitochondrial membrane. In this 
case, the molten globular states of StAR may be useful to efficiently transfer cholesterol 
:from the outer mitochondrial membrane to PBR, or another unidentified factor, which 
could transfer cholesterol inside mitochondria. Since the STC calculations were obtained 
with StAR in solution, the results are applicable to both the aqueous intermembrane space 
and the cytosol. 
4.3 Importance of the cholesterol binding site sait-bridge environment in the StAR 
mechanism. 
An interesting feature of StAR is the conserved El68-Rl87 sait-bridge pair 
(hamster StAR reference numbering) among animal species. In the StAR models, as well 
as for MLN64, this sait-bridge is located at the bottom of the U-shaped P-barrel opposite 
the movable C-terminal a-helix, indicating that it may serve an important function in 
StAR activity. In the molten globular intermembrane shuttle mechanism, this part of the 
hydrophobie cavity does not significantly change in the process of confonnational 
change, nor during cholesterol binding. This sait-bridge can be envisioned as having two 
critical functions: anchoring for cholesterol binding and maintenance of minimal 
structure for the proper binding site definition. Through our modeling, we have shown 
that this sait-bridge can be implicated in hydrogen bonding of cholesterol to the binding 
site via one water molecule (Mathieu et al., 2002). In tenns of maintaining minimal 
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structure detinition for the binding site, burial of a sait-bridge in a generally hydrophobie 
pocket obviously costs energetically. Since this sait bridge is located on adjacent strands 
in the U-shaped P-barrel, it may thus help in maintaining the U-shaped P-barrel upon 
conformational changes of the C-terminal a.-helix. Supporting this observation, the 
peptidase-resistant fragment of the human StAR is from 63-188 (Bose et al., 1999). Thus, . 
the sait bridge may be implicated in this peptidase resistance. 
Discovery of StAR sait-bridge mutations that abolish StAR activity (Mathieu et 
al., 2002) also support a critical role for this amino acid pair. In the event where only one 
amino acid of the sait-bridge is mutated for another non-charged amino acid, the 
remaining charged amino acid is too unstable in the hydrophobie environment and thus 
probably leads to improper protein folding (Bose et al., 1998). Moreover, our mutational 
analyses identified S 185 as being important for StAR function. Upon a closer look, this 
amino acid is not solvent accessible and therefore cannot be phosphorylated unless major 
conformational changes occur. Therefore bow can this amino acid alter StAR function to 
such an extent? In the hamster model, 8185 is located directly beneath the sait-bridge 
pair, actually helping in maintaining the sait-bridge in position through hydrogen 
bonding. Thus, not only is the presence of the sait-bridge important for proper StAR 
function, but its environment and 3-dimensional space are critical as well. 
4.4 Overview of ACTH stimulation and StAR expression andfimction. 
The greatest challenge in explaining StAR function resides in unifying 
phosphorylation and leader peptide modulation to StAR molecular mechanisms. 
Although contradicting results suggest that StAR tùnctions on the cytosolic side of the 
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outer mitochondrial membrane instead of the intermembrane space, our thermodynamic 
calculations support either of these models. Thus, only two steps seem necessary for 
StAR activation: 1) leader peptide modulation possibly via phosphorylation, allowing 2) 
StAR partially unfolded states for cholesterol transfer. As suggested previously 
(Christenson and Strauss m, 2001), phosphorylation could entice leader peptide 
modulation before or after actual contact to mitochondria. In either case, these are not 
inconsistent with the StAR partially unfolded states. 
In the case where StAR fonctions in the mitochondrial intermembrane space, the 
leader peptide modulation via phosphorylation leads to StAR's import into the 
intermembrane space wherc it can now fonction through the shuttle mechanism (Fig 7 A). 
On the other hand, if StAR fonctions outside mitochondria (Fig 7B), modulation of the 
leader peptide by phosphorylation should lead to StAR mitochondrial targeting for which 
StAR partially unfolded state becomes necessary for cholesterol binding, mediating 
cholesterol transfer to an undetermined factor mediating cholesterol entry into 
mitochondria. 
These mechanisms are consistent with StAR without its leader peptide since these 
experiments have ail been performed in transfection assays expressing large amounts of 
N-terminally cleaved StAR. The true test would be to verify if knock out animais would 
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Figures legends 
Fig.1 Tissue distribution of hamster StAR mRNAs. Lines l'-and 2': ovary and testis with 
a film exposure time of 72h. Lines 1-8: ovary, testis, female kidney, male kidney, female 
liver, male liver, female adrenal and male adrenal, respectively with a film exposure time 
of 24h (Fleury et al., l 998b ). 
Fig.2 Indirect immunofluorescence micrograph of paraftin sections of rat adrenals at 0 
(A) and S h (B) after ACTH stimulation. C: Capsule; ZG: zona glomeru/osa; ZF: zona 
fasciculata; ZR: zona reticularis (LeHoux et al., 1999). 
Fig.3 Colloidal-gold electron microscopie studies of thin rat adrenal sections. A, In the 
zona g/omeru/osa (ZG) of the control glands, StAR was detected over MT. A few 
particles are localized in the cytoplasm, whereas the nucleus (N) is negative (x 40,000). 
B, The number of gold particles is increased over MT in the adrenal ZG in rats S h after 
ACTH stimulation. The detection of StAR remained unchanged in the cytoplasm and 
negative in the N (x 40,000). Similar results were obtained for the zona fasciculata cells. 
C, Higher Magnification of mitochondrion (*) appearing in A and B (x 80,000) (LeHoux 
et al., 1999). 
Fig.4 Effects of ACTH on the level of StAR in rat ACTH-stimulated rats whole adrenals. 
Two groups of three male rats were injected with ACTH and were killed S b after 
treatment; two other groups served as contrais. Immunoblotting analyses were performed 
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on 40 µ.g of mitochondrial and supematant preparations, obtained by differential 
centrifugation and submitted to SDS-PAGE (LeHoux et al., 1999). 
Fig. 5 Effects of ACTH on the level of StAR. A) Male rats were injected with ACTH and 
then killed 1 h and S h after treatment, respectively; another group served as control, .. 
analyses were performed on zona glomerulosa (ZG) preparations. B) One group of male 
rats was injected with ACTH and then killed S h after treatment; another group served as 
control. Proteins from whole adrenal homogenates (HOM) panel A, mitochondria (MT) 
and supematant (SN) panel B preparations were separated by electrofocusing and 
electrophoresis, and transferred onto nitrocellulose membrane. Western blotting analysis 
was performed using a specific anti-StAR antibody. The bottom panel is a schematic that 
shows the mobility of the different StAR species. Species are expressed as pl over MW 
(in kDa) (LeHoux et al., 1999). 
Fig.6 COS-1 cells co-transfected with the F2 construct and WT StAR-pcDNA3.l 
plasmids were incubated for 24 hours. (Bu)2-cAMP (cAMP) (1 mM) was present in B 
medium. Filly µ.g mitochondrial proteins of each preparation were separated on two-
dimensional polyacrylamide gels, first by electrofocusing and then electrophoresis. 
Proteins were then transferred on membranes and revealed by an anti-StAR antibody 
(Fleury et al., 2002). 
Fig. 7 StAR partially unfolded states are necessary for StAR activity. This figure adds 
StAR partially unfolded states either to the intermembrane shuttle mechanism (A) or in 
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the case where StAR functions outside mitochondria (B). In both cases, StAR mRNA is 
transcribed from the genome, translated into StAR protein, which is rapidly 
phosphorylated to modulate leader peptide activity (adapted from Christenson and 
Strauss m (2001); encircled + signs denote steps which can be stimulated by cAMP. A) 
The intennembrane shuttle mechanism. Once StAR is phosphorylated, the leader peptide 
is activated, leading to a protein-dependent or -independent import pathway (1 - grey 
pentagon). The exact nature of the StAR mitochondrial import mechanism remains to be 
elucidated. Once inside mitocbondria, StAR can fonction through the intermembrane 
shuttle mechanism where conformational changes through partially unfolded states 
become important for proper StAR fonction. B) StAR fonctions outside mitochondria. 
Again, StAR protein is produced and phosphorylated rapidly, allowing the leader peptide 
to interact with the outer mitochondrial membrane ( either lipid- or protein-dependent) to 
target StAR near a fonctional mitochondrial cholesterol transporter system (T - grey 
hexagon); a possible candidate is PBR (West et al., 2001). Near the outer mitochondrial 
membrane, StAR can function through partially unfolded states allowing either 
cytoplasmic (Niswender, 2002) or OMM cholesterol to bind, and transferring cholesterol 
to T. In either mechanism, StAR can function without its leader peptide so long as: 1) 
StAR can enter the mitochondria without its leader peptide in the intermembrane shuttle 
mechanism (leader peptide-independent import), or 2) N-truncated StAR associatcs to 
mitochondrial cholesterol rich membranes (Christensen et al., 2001). OMM, outer 
mitochondrial membrane; IMM, inner mitochondrial membrane; I, unidentified 
mitochondrial import mechanism for StAR; T, unidentified mitochondrial cholesterol 
transport mechanism (ie: PBR); grey circles, cholesterol. 
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